Panic Disorder, a specific clinical entity? An exploration into psychological and biochemical aspects by Timmerman, L. (Leo)
Panic Disorder, a specific clinical entity? 
an exploration into psychological and biochemical aspects. 
Paniekstoornis, een speciflcke ziekte eenheid'! 
cell verkcnning naar psychologischc- en biochemische aspecten. 
Proefschrift 
tel' verkrijging van de graad van doctor 
aan de Erasmus Universiteit Rotterdam 
op gezag van de Rector Magnificus: 
Prof. Dr. P.W.C.Akkermalls, M.A. 
en volgcns besluit van het College voor Promoties. 
De opcnbarc verdediging zal plaatsvintlcn op: 
wocnsdag 29 november 1995 om I 1.45 lim. 
door 
Leo Timmerman 
geboren te Rotterdam. 
Chapter 1 has been adapted from: 
Timmerman L, Pepplinkhuizen L (1993) 
Panic disorder an update; State Art Clin Psychiatry 4: 4-13 
Chapter 2 has been adapted from: 
Timmerman L (1994) 
Biologische aspecten van de paniekstoornis; Acta Neuropsychiatrica 6;1:6-11 
Errata: 
The following references should be added to references chapter 3-14: 
Bond MP, Vaillant JS (1986) 
An emperical study of the relationship between diagnosis 
and defense style; Arch Gen Psychiatry 43;285-288 
Lapiere YD, Hamilton DM (1993) 
Anxiety and depression: Distinct or Continuum; Focus on Depression and Anxiety 4:76-81 
Praag HM van (1991) 
De biologische psychiatrie op weg naar de toekomst en de gevaren van vooruitgang 
Acta Neuropsychiatrica 3:36-41 
• 
Tyrer P, Seivewright N, Ferguson B, Tyrer J (1992) 
The general neurotic syndrom: a coaxial diagnosis of anxiety, depression and personality disorder 
Acta Psychiatr Scand 85: 201-206 

Promotiecommissie 
Promotorell: 
Ovel'ige ledeu: 
Paranimfen: 
Prof. dr. L. Pcpplinkhuizen 
Prof. dr. J. Pas schier 
Prof. dr. W.J. Schudel 
Prof. dr. M.J.M. van S011 
Prof. dr. Ee. Verhulst 
Paul de Beurs 
Jcan-Luc Klompenhouwcr 
Ht\1any lamentable effects this fear causeth in men, as to be red, pale, tremble, sweat; 
it makes sudden cold and heat to come over all the body, papitations of the heart, 
syncope & c." 
From: The anatomy of melancholy by Robert Burton 1651 
Voor: Anja, Eeico, mijn ouders en Jans. 
Copyright 1995, by L. Timmerman 
All rights reserved. No parts of this thesis may be reproduced in any form without 
permission from the author 
Drukkerij Van Es, Spijkenisse 
Frontpagc: "Face of anxiety and depression", Judica Berkelaar 1995 
ISBN: 9090089 61 6 
I 
I 

Contents 
paXe 
INTRODUCTION 4 
CHAPTER 1 PANIC DISORDER, AN UPDATE 7 
CHAPTER 2 BIOLOG1CALASPECTS OF PANIC 25 
DISORDER 
CH;IPTER3 CO-MORBIDITY BETWEEN PANIC 45 
DISORDER AND MAJOR DEPRESSION: 
MODELS AND CONCEPTS OF THE 
PRESENT INVESTIGATION. 
CHAPTER 4 DESIGN OF THE STUDY 59 
CHAPTER 5 BASELINE CHARACTERISTICS 67 
5.1 Introduction 68 
5.2 Subjects, biographical aud psychopathological 
data 68 
5.3 Drop-outs 70 
5.4 Discussion 71 
CHAPTER 6 PSYCHIATRIC PATIENTS: PROFILE AT 73 
BASELINE 
6.1 Introduction 74 
6.2 Method of statistical analysis 74 
6.3 Results 75 
6.4 Discussion 8S 
CHAPTER 7 DISTINCTION BETWEEN THE GROUPS 91 
OF PATENTS WITH DEPRESSION 
AND/OR PANIC DISORDER 
7.1 Introduction 92 
7.2 Method of statistical analysis 93 
7.3 Results 93 
7.4 Discussion 105 
CHAPTERS IN1'ERDEPRENDENCE OF SOME 107 
PSYCHOLOGICAL CHARAC-TERISTICS 
8.1 Introduction 108 
8.2 Method of statistical analysis 108 
8.3 Results 108 
8.4 Discussion 109 
COURSE AFTER SIX AND NINE MONTHS 
CHAPTER 9. ASSESSMENT OF THE COURSE IN 117 
PSYCHIATRIC PATIENTS 
9.1 Introduction 118 
9.2 Method of statistical analysis 118 
9.3 Results 119 
9.4 Discussion 121 
DISCUSSION ON THE GROUP OF PATIENTS 
NOT ON MEDICATION AT INCLUSION 
CHAPTER 10. BASELlNE DISTINCTION BETWEEN 123 
GROUPS OF PATIENTS WITH AND 
lVlTHOUT MEDICATION 
10.1 Introduction 124 
10.2 Method of statistical analysis 124 
10.3 Results 124 
10.4 Discussion 126 
CHAPTER ll. INTERDEPENDENCE OF SOME 129 
PSYCHOLOGICAL AND BIOCHEMICAL 
PARAMETERS: AN EXPLORATION 
11.1 Introduction 130 
11.2 Method of statistical analysis 130 
11.3 Results 130 
11.4 Discussion 132 
CHAPTERI2. COURSE AFTER SIX MONTHS OF 147 
TREATMENT AND ON FOLLOW UP IN 
THE PATIENT GROUP NOT ON 
MEDICATION AT BASELlNE 
12.1 Introduction 148 
12.2 Method of statistical analysis 148 
12.3 Results 148 
12.4 Discussion 155 
CH/\PTER 13. CONCLUDING REMARKS 157 
CHAPTER 14. CONCLUSIES EN MNBEVELlNGEN 163 
2 
COlltellts 
Summary 180 
Samenvatting 188 
Verantwoording 196 
Curriculum Vitae 197 
Publicatics 198 
3 
INTRODUCTION 
The prevalence of panic disorder with or without avoidance behavior during life is 
2%. The percentage of people who suffer from panic attacks without satisfying the crite-
ria fur panic disorder is much higher and has a prevalence of 10% during life. There is a 
great deal of similarity between panic disorder and another frequently Dcellning psychiatrk: 
disorder namely major depression. Not only do patients with panic disorder have a nineteen 
times higher risk of developing a depression during life then may be expected by chance 
alone, but the relationship between the two aftlktions also appears from a certain degree 
of similarity in association with response to provocation tests such as the lactate infusion 
test, the C02 inhalation tcst and from a considerable level of similar response to treatment 
with psycho-pharmaceutical dmgs such as various tricyclic antidepressants and inhibitors 
of serotonin uptake. 
There are a number of hypotheses for explaining the co-morbidity between panic dis-
order and depression. Some of these explanation models nrc: 
1. There is a symptomatic overlap between two etiologically different afflictions. 
2. One can speak of a continuum between panic disorder and depression. 
This continuum may be of etiological-, chronological- andlor psychopathological 
nature. 
In other words: Panic disorder not only has its own eliology, but may also be an 
etiological fnctor in the development of depression. 
3. Panic disorder and depression are in essence one and the same psychiatric disorder 
but one can speak of multiple presentation forms. Clusters with a profile composed 
of more symptoms of panic disorder or more symptoms of depression may arise 
from a large number of possible symptoms. 
Multi-dimensional investigations into panic disorder are described in this thesis. 
The principal question was whether there was a single central biologically determined 
disorder in patients suffering from panic disorder andlor depression. Differences in 
psychological defense organization and coping strategies would then possibly determine 
whether a patient either develops panic disorder or depression. 
In our investigations, in addition to psychological aspects such as defense organization 
and indicated coping strategies, several biochemical parameters including serotonergic, 
amino acids and the /3-carboline norhannan and the inter-correlationship between 
biochemistry and psychology were also investigated in groups of patients and a reference 
group. 
Following the fjrst part of this investigation, treatment of the 3 groups of patients 
(with depression, panic disorder and depression with panic disorder) with antidepressants 
and cognitive therapy according to protocol was undertaken. 
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ll1fruductioll 
The effects of this treatment on the complaints of the patients, on the psychological 
characteristics such as defense organization & coping strategies and on a number of 
biochemical parameters were all assessed after treatment for six months. Three months 
after the termination of the treatment and discontinuation of the antidepressant, a follow-
up investigation was undertaken in a limited number of patients in order to assess the 
eventual remaining therapy-associated changes in the personality characteristics and 
biochemical parameters 
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CHAPTER 1. PANIC DISORDER, AN UPDATE 
Introductio1l 
The modern division of anxiety syndromes or anxiety disorders has a history of more 
than a hundred years. The current classification and insights arose from investigations 
and assumptions from clinical presentations and syndromes slich as neurasthenia, heart 
neurosis, anxiety neurosis, Da Costa's syndrome, effort-syndrome, inltable heart, nervous 
exhaustion, neurocit'culatory asthenia, vaso-motor neurosis, psycho-vegetative syndrome 
and so forth [Kelder 1989]. 
Most of the above mentioned diagnostic entities indicate that a particular aspect of 
what we until today refer to as anxiety disorders stood central as heart neurosis or "sol-
dier's heart" for the investigators and clinicians of that period. 
In 1871, Da Costa described the irritable heart. He observed that during the American 
civil war, not only sudden pain in the heart region accompanied by severe hemt palpitations, 
but also impaired vision and dizziness occurred in otherwise healthy young men. 
Interestingly enough, fear was not mentioned. Da Costa attributed one and the other to 
hyperaesthesia in the nervc centres of the heart. 
This syndrome was latcr rcnamed as "effort syndrome", considering the limited 
tolerance for physical cffort. 
Later, the term neurocirculatory asthenia and even later the concept of heart neurosis 
appeared. 
Soon after the description by Da Costa, Beard introduced the term neurasthenia, also 
known as "American nervousness" in which he postulated that a deficiency in nervous 
energy was the cause of many of these symptoms. Many solid anxiety illnesses and 
phobias are come across in his description. Beard attributed the syndrome to the stressed 
and exhaustive American way of living. 
In the DSM-IV, anxiety disorders are divided into phobias and anxiety states which 
include panic disorder and generalized anxiety disorder, obsessive-compulsive disorder 
and post-traumatic and acute stress disorder. 
Panic disorders are subdivided into those with and those without avoidance behaviour 
and a quantitative norm conccrning the frequency of panic attacks and duration of 
complaints has been added to the definition of panic disorders [DSM-IV 1994]. 
Agoraphobia is now classified under panic disorder with avoidance behaviour. 
Agoraphobia \vithout panic attacks is considered separately. 
The assumption that panic attacks are connected with agoraphobia is almost a hundred 
years old. In 1895, Freud commented that" in the case of agoraphobia, we frequently 
find the reminder of an anxiety attack and what the patient fears most in reality is the 
occurrence of sllch an attack under particular situations which he considers to be 
unavoidable" IFreud 1961]. 
The symptomatology of panic disorders consists of psychic and somatic symptoms 
(sec table 1). 
8 
Chapter I 
The somatic symptomatology includes dizziness, tachycardia, increased sweating, 
dyspnea, flushes,polyuria, nausea, lump in the throat (choking) and paraesthesia, 
The psychic symptomatology includes feelings of unrest, fear of dying, fear of going 
crazy or doing something impulsive, tcndency to t:lint, distorted perception and feelings 
of depersonalization and derealization, 
Table 1. SYIl1I)tolllatology of' I)""ic disorders 
1. Acute anxiety/panic. occurring spontaneously or in particular situations in which 
the patient without the trusted companion feels lost in busy crowds, open spaces, 
public transport etc. 
2. Fear, often converting to fear of dying. fear of going crazy or losing control of 
oneself. 
3. Vegetative complaints such as dyspnea, choking, dizziness, feeling faint, 
palpitations, tachycardia, chest pain or discomfort, trembling, shivering, sweating, 
cold and/or hot flushes, nausea, paraesthesia. 
4. Depersona1ization and derealization, sometimes also distorted perception of 
environment and own body. 
Source: The Practitioner 9, 2 February 1992, p. 2. L. Pepplinkhuizcn. 
There is a definite sequence in which the symptolll(ltology of the phenomena in panic 
attack develops. The early symptoms are dyspnea, flushes, pain in the chest and 
palpitations. Dizziness, increased sweating, feelings of derealization and tendency to 
faint all occur later. The psychic anxiety feelings mostly occur late. This may indicate 
that psychic anxiety depends on a response to the somatic phenomena [Katerndal 19X81. 
The experience from the cognitive therapy is that panic attacks are mostly accompanied 
by hyperventilation, evoking physical sensations which are misinterpreted by the patient 
as "catastrophic" and which induce psychogenic anxiety. 
Hyperventilation probably callses distress in those who have a predilection to fear and 
misinterpret their bodily responses to lowered C02 [Chambless 1990). 
Epidemiology 
From investigations in different parts of the world, it appeared that the prevalence of 
anxiety disorders was rather uniform. A prevalence of 2.9% to 8.4% was observed in 
population studies [Marks 1986]. 
Recent investigations into the epidemiology of panic disorders showed a 6- months 
prevalence of 0.6% to 1.5% (USA, Zurich, Munich, Kangwha Islands, Korea) IHumble 
1987]. It was noteworthy that more women than men suffered from panic disorders. The 
difference between men and women varied from 50% to 200% in various studies. 
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Tahle 2. Prevalence of llllnic disorder at different sites 
Community survey 
Prevalence periud 
New Havena 
BaHimore~ 
St. Louisa 
Zurichl:l 
Munichc 
Kangwha Islandsd 
Stockholm countye 
6 months 
6 months 
6 months 
1 year 
6 months 
lifetime 
I year 
Prevalence period 
Prevalence (%) 
Total 
0.6 
1.0 
0.9 
1.5 
l.l 
1.4 
0.8 
men 
0.3 
0.8 
0.7 
0.7 
0.5 
Source: M. Humble. Acta Psychiat Scand 1987; 76: 22. 
wOlllen 
0.9 
1.2 
1.0 
2.2 
1.2 
The prevalence of anxiety disorder during the lifetime varied from 10% in men to 
almost 20% in women, 3.8 % being contributed by panic disorder [Rorseman et a11987J. 
In a large study in 18000 adults in America, Robins observed that during their lifetime, 
24% of the investigated adults had the feeling of nervousness, 9% had isolated panic 
attacks, 3,6% had relapsing panic attacks which did not completely satisfy the criteria for 
panic disorder with regards to insufficient symptoms, duration or frequency of attacks 
and 1.5% satisfied the DS.M-ITI-R criteria for panic disorder during their lifetime IRobins 
1990]. 
The same prevalence in panic disorder was observed in Edmonton, Puerto Rico, New 
Zealand, Munich, Florence and Seoul [Weissman 1992}. 
Panic attacks mostly occurred for the first time in the second decennium of life. The 
average age at which panic disorder began was 26 years [Crowe 1983J. OCCUlTence after 
the age of 40 years is rare, but panic attacks in children are relatively frequent and may 
be diagnosed as separation anxiety disorder and school phobia. 
Genetic aspects of pallic disorder 
During more than a hundred years, investigators observed that anxiety disorder was 
frequently "in the family". 
Long before our modern specific diagnostic categories for anxiety disorders were 
established, it was known that neurasthenia, soldier's heart and other anxiety disorders 
occurred more frequently in family members of patients with anxiety disorder than in 
family members of healthy individuals. In older studies, the incidence of anxiety dis-
orders in the first degree relatives of patients with anxiety disorder was observed to be 
about 15% [Carry 1981], 
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In a morc recent study in family members of patients with panic disorder or generalized 
anxiety disorder, the incidence of panic disorder in the first degree relatives was observed 
to be 24.7%. In a control population, this figure was 2.3%. 
A similar difference was not observed for generalized anxiety disorder. The chances 
of occurrence of panic disorder in female family members was twice that in male family 
members of patients with panic disorder [Crowe 1983 J, 
Although family studies indicate a genetic basis for psychiatric disorders, environmental 
innucnces should also be investigated because they may be the cause oft~unilial occurrence 
of such disorders. Studies in twins offcr a way to investigate \vhether genetic factors are 
really important for familial occurrence. The principle behind such studies in twins is 
that the percentage of afilicted patients of each genetically determined disorder would be 
higher in monozygotic than in dizygotic twins. Concordance for each pail' of twins can 
be determined. If the concordance in the monozygotic twins is higher than that in the 
dizygotic twins, it is likely that genetic influences predominate over environmental 
influences. For panic disorder, this concordance was observed to be five times as fre-
quent in monozygotic compared to dizygotic twins, but no difference was observed for 
generalized anxiety disorder [Slater 1979; Parkinson 19831. 
KendleI' et a1. [1993] found in a population based twin study that the familial aggregation 
of panic disorder was due largely to genetic factors. 
They estimated that the heritability of liability ranged from 30 to 40%. 
From a familial perspective, panic disorder with phobic avoidance appeared to represent 
a more severe form of the syndrome than panic disorder without avoidance. 
Prevalence of panic disorder in the first degree relatives of patients with panic disorder 
varied between 7% and 20% [Weissman 1990J. 
Life el'ellts alld pallie disorder 
Although for the patient, the first panic attack occurs as a most unpleasant "spontaneous" 
surprise, it seems that frequently, some important event has occlllTed in the life of that 
patient in the month preceding the first panic attack. It is not uncomlllon that the first 
panic attack occurs during a serious illness, after an accident, after loss of an important 
individual (separation trauma), but it can also occur in the period post-partlls or after use 
of alcohol, marijuana, cocaine or amphetamines [Blaser et a11987; Fagaval et al 1989J. 
A disrupting factor in the sense of a life event was demonstrated in 40% of the cases 
(see table 3) and 52% of the patients sufi'ered from prodromal depression or from 
generalized fear before the first panic attack [Lelliot! e! al 1989J. 
II 
Table 3. Precipitating factors in the first panic attack 
Quarrels in family or marriage 11 % 
Illness in the family 8% 
(Pending) divorce 6% 
Pregnancy and birth 4% 
Death of a friend or a family member 4% 
Physical illness 2% 
Financial problems 2% 
Other events 6% 
Total with direct causes 43% 
Source: Lelliott ct a!. AGP 1989; 46; 1000-4. 
Attempts to type personality disorders in patients suffering from panic disorder 
progress with great difficulty. Dependant. avoiding as well as hysterical characteristics 
have been described, in addition to borderline personality disorders and patients with 
underlying eating disorder [Class et al 1989; Mavissakalian et a11988; Reich et a119871. 
The association between personality disorder and panic disorder in general can be 
regarded as weak. 
Similar personality profiles were obtained in a heterogeneous population of psychiatric 
outpatients or patients with social phobia, obsessive-compulsive disorder and major 
depression, 
At the same time, it should be remembered that personality disorder may be secondary 
to panic disorder, 
A number of patients mentioned that prior to panic attacks and complaints of phobia 
they led an independent life with a certain amount of confidence, This was in sharp 
contrast to their frightful clinging to their partners in the period when panic"disorder first 
:o;truck, 
However, personality pathology does predict a poorer response to treatment in patients 
with panic disorder [Reich 1991]. 
There is a link between :o;eparation anxiety and separation trauma in early life and 
symptoms of panic in adulthood, This is possible due to a endogenous neurophysiological 
vulnerability expres:o;ed as a heightened sensitivity to separation, There is a tendem::y for 
separation anxiety to aggregate in families [Klein 1980,Silove & Manicavasagar 1993], 
Co-morbidity: pauie disorder and depression 
The distinction between panic disorder and depression has caused much scientific 
controversy and clinical confusion, Some investigators speculated that panic disorder 
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may be a form of depression, This speculation was supported by the observation that 
patients with panic disorder and agoraphobia demoralized quickly. Life with recurring 
panic attacks arextensive phobic avoidance eventually leads to despair and hopelessness. 
Others regarded panic disorder and depression as different entities, Marks suggested that 
treatment of panic disorder with antidepressants was only effective if the patient was 
also depressive [Marks 1983]. 
Meanwhile, there is substantial evidence that this theory is incorrect [Klein et al 1989]. 
Indeed, the co-diagnosis of depression in patients suffering from panic disorder is 
frequently made and those suffering from depression have frequent panic attacks, 
particularly jf the patient also suffers from social phobia [Angst et al 1985; Stein 1990]. 
In a narrower sense, the prevalence of depression in patients with panic disorder is 
30%-70%, whereas 20%-30% of the patients with major depression develop panic dis-
order during their life [Pel icier 1992]. 
It has been suggested that anxiety disorders and depressions have common diathesis 
and shared vulnerability (see also chapter 3), This hypothesis implies that anxiety dis-
orders and depressions are expressions of the same aftliction [Coryell cl a1 19921. 
Genetic studies, however, tcnd to indicate that depression and anxiety disorders co-
exist rather than being casually related, Less often, it represents an associated independent 
entity [Cassano 1989]. Goldstein et al [1994] examined in a family study of 1047 adult 
first degree relatives of 193 probands in four diagnostic groups:panic disorder, panic 
disorder with major depression, early onset major depression and screened normal controls. 
They concluded that panic disorder is a specific familial entity that is not associated with 
a broad range of other anxiety or other psychiatric disorders, with the possible exception 
of social phobia. Depression seen in the course of panic disorder most commonly 
represents symptomatic elaboration or complication of panic disorder. 
Apart from the risk of developing depression, there is a high risk of parasuicide and 
successful suicide in patients suffering from panic disorder {Coryell et a119911. There is 
a 40% chance that during his life, a patient suffering from panic disorder will make a 
(para)suicidal act. 
The development of alcohol andlor medication dependence is another important risk 
in patients suffering from panic disorder. About 30% of sllch patients run the risk of 
developing secondary abuses of alcohol [Reich et al 1987; Helser et al 1988J. There is 
also a 30% chance of bellzodiazepine "addiction" {Cox 1989]. 
Outcome studies 
The most important methods for treating panic disorder are psychotherapy, namely 
cognitive/behaviour therapy, treatment with tricyclic antidepressants, monoamine oxidase 
inhibitors (MAOI) or benzodiazepines. Often, a combination of treatments is used. 
In a study published in 19HI, a fo11ow-up for 5-10 years in 54 outpatients who were 
treated for anxiety neurosis was reported. Thirty-two of these patients suffered from 
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primary panic disorder. Most of the patients (28 of the 32) reported that already as a child 
they were nervous or had phobias. In later life, 24 of the 32 patients developed depression 
which was serious enough to warrant professional treatment [Cloninger et al 1981]. 
Sixty patients with panic disorder and agoraphobia were interviewed 2 to 4 years after 
completing a 4 months treatment with medication and behaviour therapy. During the 
follow-up interview, 18 patients had stopped the medication, 36 patients lIsed a Iow-
dose, 3 patients used the originally prescribed dose and 3 patients used an increased dose 
of medication. During the initial phase of the investigations, the number of panic attacks 
was 4-5 per \veek, but during the follow-up the number of panic attacks was 1-2 per 
week. As far as the behaviour variables were concerned, an improvement was noted in 
all patients. Patients who had been depressive tended to relapse inspite of continued 
medicationlNagy et al 1989]. 
Personality disorders are quite common and are of predictive value. Medication for 
treating panic disorder was less effective in a group of patients with personality disorders 
than in a group without personality disorders [Mavissakalian et aI 1988; Reich 19881. 
The oldest studies on the treatment of panic disorder with medication arc with 
imipramine and MAO! [Klein 1964; Klein et al 1978]. 
The average dose of imipramine that was required to completely block panic attacks 
was 150-200 mg/day [Zitrin et al 1983]. 
From the group of MAOI, fenc1zine was investigated, In one study, fenelzine was 
observed to be superior to imipramine [Sheehan et al1980J. The disadvantage offenelzine 
was that the patients had to be put on a diet without tyramine to avoid hypertension 
crisis. Some patients Oil this medication also suffered from serious orthostatic hypotension 
and sleeplessness, At present, clomipramine is usually selected when treating panic dis-
orders with tricyclic antidepressants ICassano et a119881. 
New serotonin-uptake inhibitors were also effective for treating panic disorders [Den 
Boer et al 1987, 1988]. It seems likely that the drugs which prominently affect the 
serotonergic system are more effective in panic disorders than those drugs which affect 
the noradrenergic system. The selective, reversible, .Monoamine-A inhibitors, 
moclobemide and brofaromine also appeared to be effective for treating panic disorders 
and were without the side-effects of the classical, non-selective MAOI, [Garcia-
Doregnardo et al 1991; Berger et al 1991]. 
In the last few years, it has become evident that benzodiazepines, namely alprazolam, 
may be effective in blocking panic attacks and anticipatory anxiety [DeItito 1991; 
Balestrieri 19891. 
There arc still very limited data available on the intermediate- and long-term secondary 
pharmacological treatment of panic disorders. Astudy in which imipramine and alprazolam 
were used indicated that during treatment for X months, the therapeutic effect was 
maintained without development any seriolls side-effects or a need for any increase in 
the dose [Curtis 19911. 
It is advisable to recommend treatment for a minimum of 12 months to limit the chances 
of a relapse. Mavissakalian & Peril 11992] reported that 75% of patients with panic 
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disorder and agoraphobia who had shown marked and stable response to 6 months of 
acute treatment with imipramine relapsed within 6 months of discontinuing the drug. 
One year maintenance treatment with the antidepressant proved to have protective effects 
against relapse. 
Long-term treatment is especially indicated in patients in whom there is a poor Jang-
term prognosis based on for example, co-morbidity in the sense of mood disorder, 
personality disorder, extreme avoidance behaviour and/or serious social limitations. These 
patients may benefit from a flexible integration of pharmacological and cognitive-
behaviourial treatment [Katschnig 1991; Pollack 1990]. 
Investigations into prevention of relapse in unipolar depressions have provided data 
\'lhich may also he successfully lIsed to treat patients \'lith panic disorders. 
It seems likely that the best way to either prevent or to lower the frequency of relapse 
is to maintain the same dose of medication on which the patients initially improved. In 
depressive patients, the prognosis was improved further with psychotherapy [Kupfer et 
al1991]. 
\Vhen a potent benzodiazepine is used in the treatment of panic disorder, it is 
recolllmended to slm'lly taper-off this medication in 3-6 months and every symptom 
that arises during the tapering-off should be carefully evaluated because not only could 
the initial symptoms of panic disorder recur, but there may be a case for withdrawal 
symptomatology which may require a different approach. There is some evidence that 
slow, partial tapering-off of medication, namely benzodiazepine, helps to prevent relapse 
and to maintain the therapeutic benefit [Ballinger 1991]. 
Cognitive-behavior therapy was also effective in the treatment of panic disorders 
with agoraphobia [Klosko et al 1990]. 
Uncontrolled studies showed that cognitive therapy was valuable in the treatment of 
panic disorder. 
In three controlled studies, cognitive therapy was shown to be more effective than 
supportive therapy and relaxation training, but was as effective as alprazolam. 
In Oxford (UK), in a clinical trial in patients with panic disorder, cognitive therapy 
was compared with imipramine, with intensive relaxation and with a group of patients 
on waiting list. Patients in the cognitive therapy group showed more improvement than 
others after 3 months, at the end of the psychotherapeutic treatment and after 15 1110nths. 
The group of patients on waiting list did not improve significantly [Gelder et al 19911. 
One session per week of exposure therapy appeared to be sufficient to obtain good 
results in panic disorder with agoraphobia [Chambless 1990J. For well-motivated patients 
who can practise self-exposure on their O\vn, it is often sufficient to provide adequate 
explanation of the disorder and to prescribe medication. Cognitive therapy alone is 
sometimes insufficient to totally suppress panic attacks. In patients in whom anticipatory 
anxiety prevents self-exposure, a combinaton of medication and behaviour therapy are 
necessary [Klein et aI1987]. 
IS 
In general, the prognosis for patients suffering from panic disorder is not entirely 
favourable. In a recent long-term follow-up study of2-6 years in 423 patients who were 
treated with medication, it appeared that 31 % of the patients remained convalescent after 
the medication period had expired. The remainder of the patients developed episodic or 
mildly chronic course, whereas 18.6% of the patients continued to suffer from serious 
chronic panic disorder 1 Katschnig et al 19911. 
COllclusion 
The biological, genetic, personality and life events studies indicate that panic disorder 
is caused by a combination of biological predisposition, life events and psychological 
maintaining factors. The results of outcome studies indicate that the advocates of both a 
poor and of a bad outcome in panic disorder are correct since the outcome of panic 
disorder depends from a number of variables. An important prognostic factors is among 
others: Comorbidity with personality-, and other psychiatric disorders namely depression 
(see also chapter 3). 
Tn general, more than half of the patients suffering from panic attacks and agoraphobia 
maintained substantial improvement, 10%-20% showed full recovery at follow-up and 
up to 20% remained seriously ill [Hirschfeld 19911. 
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CHAPTER 2. BJOLOGICALASPECTS OF PANIC DISORDER 
lutroduction 
Panic disorder with or without agoraphobia is a condition determined by multiple 
causes with a prevalence of 1.2% to 3.H% during life. The disorder dearly occurs more 
frequently in women than in men, This, onen invalidating disease, also has a high risk of 
other psychiatric disorders such as abuse of alcohol and benzodiazcpine, depression and 
suicide l , 
In the etiology of panic disorder, as we have discussed in chapter I, the following, 
among others, play an important role: 
1. Genetic and biological [aclorsl,2 2. Separations in the early youth3, .. 3. Personality 
charactcristks5 4. Psychosocial factors6 5. Recent events7 
In this chapter, the biological-psychiatrical theories concerning the origin(s) of panic 
disorder are presented. 
The biological aspects of panic disorder involve the participation of the noradrenergic, 
the serotonergic and the gamma-aminobutyric add (GABA) systems, in addition to the 
role of peptides and neuro-anatomical factors. 
In recent years, serotonin (5-hydroxytryptamine, 5-HT) has been at the center of re-
search into the role of ncurotransmi-tters in psychiatric disorders. There are strong 
indications that 5-HT is involved in scveral diverse psychiatric disorders including, 
aggression, suicide, Alzhcimer's dementia, anorexia nervosa, alcoholism, depressions 
and anxicty disordersR. 
The function of the noradrenergic (NA) ~ystem was extensively investigated previously. 
The findings established the importance of the foremost nucleus ofNA: the locus coerulells 
in panic disorders. The discovery of the bezodiazepine/GABA receptor complex provided 
additional information on the role of the GABA system in anxiety disorders",5.41i • 
The importance of some peptides in panic disorders has only come to light in the last 
few years and besidcs ctiological research, also offers possibilities for new provocation 
tests for panic attacks. 
The possibilities offunclional neuro-anatomical investigations in psychiatric disorders 
by means of single photon emission tomography (SPECT)- and positron emission 
tomography (PET)- scans have increased enormously. This lead to correlations between 
regional brain function and psychiatric disorder. 
The following biological topics arc dealt with in succession: The serotonergic-, 
noradrenergic- and GABA-theory on the origin(s) of panic disorder, the role of peptides 
and finally neum-anatomical hypotheses on panic disorder. 
The serotollergic hypothesis 
The most important serotonergic nuclei in the brain are the dorsal and median raphe 
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nuclei situated in the brainstem, They have afferent and efferent connections to many 
parts of the brain slich as the cortex, hypothalamus, thalamus, hippocampus, septum and 
substantia nigra (see Figure I), 
Figure 1. l"Iajor serotonin and norepinephrine neural tracts in rat brain 
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Note: Serotonin tracts color: red Norepinephrine tracts color: black (After Young lA., 
Cohen D.l: "The molecular biology of development", in: Basic Handbook of Child 
Psychiatry. New York Basic Books, 1979). 
There is a close association between the serotonergic system, the dorsal raphe nuclei 
and the noradrenergic system, the locus coeruleus being the most important9• Animal 
studies showed that lowering of the 5-HT function resulted in decreased anxiety, whereas 
stimulation of the 5-HT function induced anxietylO. The finding that inhibitors of serotonin 
uptake had a therapeutic effect in patients with panic disorders strongly indicated that 5-
HT also played an important role in decreasing anxiety in hUlnansl!, 
The anxiolytic effect of antidepressants is probably brought about via the down-
regulation of the hypersensitive 5-HT receptors, Kahn & Van Praag postulated that over-
sensitivity of some of the serotonin receptors Illay be a pathogenetic mechanism in panic 
disorder I2•13, The down-regulation which develops upon chronic administration of 
antidepressants probably occurs in order to compensate the increase in S-HT caused by 
these antidepressants in the synapse cleft. A short-term effect of this increase may be 
27 
responsible for the temporary worsening of the disorder during the initial weeks of 
treatment l4, However, other investigators attributed the actual effect of antidepressants 
to an increase in the function of 5_HTL'i, There are various 5-HT receptors, Each one of 
these receptors has a specific pre- or post-synaptic location in the brain, The 5-HT1A 
receptor is particularly important in panic disorder's, 
Pharmaceutical drugs such as ritanserine and buspirone (BusparR) which act on receptors 
other than the 5-HT1A receptor, appeared not to be effective in the treatment of panic 
disorders1s.17, The exact function of the 5-HT1A receptor is unclear. Hypothetically, it can 
be stated that an inhihitory effect on the 5-HT system via the 5-HT1A receptor probably 
leads to anxiolytic effect, whereas over-activity in the 5-HT pathways, namely of the 
ascending dorsal raphe system may cause pathologic anxiety8, Although there is still 
discussion on whether there is a specific 'serotonergic disorder' which accompanies 
panic attacks and on the nature of this disorder (hypo- or hyper-activity), there is consen-
sus on the fact that a number of drugs which act on the system are effective in the treatment 
of panic disorders. In a double-blind study in which the serotonergic-acting fluvoxamine 
(FevarinR) was compared with the noradrenergic-acting maprotiline (LudiomilR), Den 
Boer observed that maprotiline was considerably less effective in the treatment of panic 
disorderS, However, no differences in the affectivity for treating panic disorders were 
observed in a recent study in which a prominently noradrenergic-acting desipramine 
(PertofranR) and largely serotonergic-acting clomipramine (AnafraniIR) were comparedl8• 
The selectivity of these drugs and their metabolites at the levels of neurotransmitter 
and receptors is, however, not very high, Therefore, it is highly desirable that the 
investigations reported by Den BoerR should be repeated with drugs that have a higher 
selectivity for serotonergic- and noradrenergic-action. 
The different hypothesis concerning the role of the serotollergic system in panic disorder 
have been given in table 1. 
The lIora({rellergic hypothesis 
The most important center of the central noradrenergic (NA) neurones is on the locus 
coemleus (LC) which is situated at the bottom of the 4'" ventricle (Figure I), The LC 
receives input via many different neurotransmitter systems including serotonin, opiates, 
gamma-aminobutyric acid, dopamine and glycine, These modulating neurotransmitter 
systems probably have an inhibitory effect on the LC. In contrast, corticotrophin-releasing 
hormone (CRH), glutamate, purine nucleic acids, substance P and muscarinergic and 
cholinergic systems have an excitory effect. On the basis of these findings, besides the 
serotonergic system 19, the noradrellergic system also plays an important role in the 
integration of the adaptive reactions of the central nervous system (CNS) to stimuli from 
the surroundings, behavior, or physiology-attributed dysfunction of the LC may lead to 
the development of panic disorder2o,21, 
The simplest noradrenergic theory on the origin of panic attacks goes out from an 
over-activity of the LC22,2J, The theory is based on the following findings: 
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Electrical stimulation of the LC in experimental animals induced behavior which could 
be interpreted as panic attack, whereas lesions in the LC of monkeys prevented panic 
attacks after electro-stimulationB , 
The concentration of3-methoxy-4-hydroxy-phenylglycol (MHPG), the most important 
metabolite of cerebral NA, correlated positively with the level of anxiety in patients 
with panic disorder24,25, 
Drugs such as yohimbine, a pre-synaptical-acting Ci1-receptor antagonist which increase 
the activity of NA cells in the LC appeared to have an anxiogenic effect. 
Administration of yohimbine led to an increase in the level ofMHPG in the blood26 , 
Drugs such as clonidine (DixaritR), an (X2-receptor antagonist with an inhibitory effect 
on the LC via pre- or post-synaptic <x 2-receptors appeared to be able to partially block 
panic attacks20• Clonidine decreased the secretion ofMHPG more in patients suffering 
from panic disorder than those in a control group. 
Chronic administration of drugs. tricyclic antidepressants and inhibitors of monoaminc 
oxidase, led to a reduction in the central noradrcnergic turnover and a decrease in the 
activity of the LC2~. Both tricyclic antidepressants and monoamine oxidase inhibitors 
appeared to be effective in the treatment of panic disorder29 ,3n. 
The noradrencrgic theory is not \vithout controversies. Gorman et apt have summarized 
the points of criticism: 
The etTect of yohimbine was not specifically examined in a population of patients 
with panic disorder, but in a population of psychiatric patients with diverse disorders:'.l. 
Il was reported that the findings by Redmond et aF] in monkeys were not panic attacks, 
but concemed arousal.H. 
The investigation by Charney et aP5 in which they observed differences in response 
to yohimbine administered in a group of patients with panic disorder and to a group of 
controls was criticized because only a sub-group of patients with more than two panic 
attacks per week showed a significantly higher increase in the level of MHPG after 
yohimbine than in the control group. It also appeared that the investigation was not 
reproducible. 
Imipramine blocked panic attacks. But imipramine had no effect on yohimbine-induced 
anxiety and only made it worseD • 
Buspirone stimulated the LC, but did not have any panic attack-provocating properties. 
It can, however, increase anxiety if given at high doses)·")..j, 
Increase in the level of MHPG was not observed in patients \vith panic attacks which 
were induced by infusion of lactate]..j and inhalation or exposure to carbon dioxide 
(CO) in vivo for phobic stimuli. 
Electrical stimulation of the LC in humans did not produce panic reactions36, 
Den Boer37 mentioned the following additional points of criticism on the noradrenergic 
hypothesis: 
The values for the levels of catecholamines in the plasma, the urine and the liquor in 
the groups of patients with panic disorder were no different to those in the control 
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group in most of the studies. The value for the level of ¥HPG in the liquor of these 
patients was also nonnaP8. 
Yohimbine did not only appear to be a noradrenergic-acting (Y2-antagonist, but also 
acted on the serotonergic system as a 5-HT agonist of pre-synaptic receptors and on 
the dopaminergic system39,40. The anxiogenic effect of yohimbine, therefore, could 
not be exclusively attributed to its antagonistic action on the Ci1-receptor, but could 
also have been due to its action on the 5-HT system. 
In addition, it was also confusing that in individuals who were pretreated with alprazolam 
(XanaxR), yohimbine overload led to less anxiety, but pretreatment with imipramine offered 
no protection. 
Kahn & Van Praag l2 discussed the problem of the noradrenergic post-synaptic 
(Yl-receptor function as follows: 
- The response of growth hormone to clonidine was reduced in patients with panic 
disorder which indicated a decreased post-synaptic (Y2-receptor sensitivity in these patients. 
The marked decrease in blood pressure after clonidine administration, however, actually 
indicated an increased sensitivity of the post-synaptic (Y2-receptor. 
The 'simple' hypothesis of over-activity of the LC via, for example, lowered pre-synaptic 
Ci1-receptor activity43, therefore, surely does not explain all the findings. It is more likely 
that there is a sub-group of patients with panic disorder in whom the regulation of their 
NA function is abnormaF. Possibly, CO2 also plays a role in the development of a panic 
attack: there is a group of patients whose reaction to inhalation of CO2 is a panic attack. 
The brain of these patients may be over~sensitive to CO2 or that the LC is extra stimulated 
by carbon dioxide4-t.45. 
Tlte GAllA Itypotltesis 
The neurotransmitter gamma-aminobutyric acid (GAB A) also plays an important 
inhibitory role in anxiety disorders~6. Important centers of GAB A-neurons are spinal 
cord, cerebellar cortex, nucleus caudatus, cerebral cortex, substantia nigra and the locus 
coeruleus. Besides noradrenergic receptors, the locus coeruleus also has a high 
concentration of GAB A receptors. Gamma-aminobutyric acid (GABA) has inhibitory 
effects on among others, the loclls coeruleus and on the serotonergic celIs of the raphe 
nuclei47• This is an example of the manner in which the different neurotransmitter systems 
call affect each other. 
Specific populations of benzodiazapine~binding sites have been discovered. These 
sites are linked with certain GABA receptors. It is likely that the action ofbenzodiazapines 
on the GABA system is executed selectively via the GABAA receptors
45
.46• 
Drugs such as benzodiazapine which are agonists of the GABA function have anxiolytic 
effect. Drugs such as pentylenetetrazol and flumazenil (AnexateR) which are antago-
nists of the GAB A function can cause anxiety. The agonistic effect of benzodiazapines 
on GABA-effect is to open the chlorine ion channels via the so-called benzodiazapinel 
GAB A receptor complex. This causes hyperpolarization of the post-synaptic membrane 
of the neuron and the neural stimulation is inhibited. 
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The GABA hypothesis of panic disorder states that there is an abnormal benzodiazapinel 
GABA complex in patients suffering from panic disorder46, 
Some investigators were of the opinion that henzodiazapines indeed decreased the 
anticipation anxiety in patients with panic disorder, but were 110t effective in blocking 
panic attacks48,49, However, at present, there is clinical proof that potent benzodiazepines 
such as diazepam (VaIiUlnR), Lorazepam (TemestaR), alprazolam (XanaxR) and clonazepam 
(RivtrilR) are effective in the treatment of patients with panic disorder50-54 • 
Gamma-aminobutyric acid (GABA) is not the only naturally produced substance in 
the body with a high affinity for benzodiazepine receptors: 
l3-carboline-3-carboxylic acid (G-CAM) derivatives are a group of compounds with an 
aLTay of biochemical and pharmacological activity. Among others, these compounds 
demonstrate a high affinity for centrally located benzodiazepine receptors and can act as 
agonists, antagonists or reverse agonists with regard to benzodiazepine receptor55,56. 
Most of the I3-CAM derivatives have an antagonistic effect on benzodiazepines. 
Antagonistically acting 13-CAIVI produced anxiety and stress reactions in rhesus 
monkeys55,57. 
In humans, administration of carboline monomethylamide which is closely related to 
1l-CAM led to panic-like reactions", 
Schouten59 was the first to demonstrate a B-carboline, norharman in human plasma. 
Investigations on the occurrence of B-carbolines in groups of patients with panic dis-
order, in view of these data, appear to be interesting and are currently being conducted by 
us, 
In summary it can be concluded that the neurotransmittor GABA plays an important 
role in panic disorder. There are however other naturally produced substances like B 
carbo lines, though less well investigated than GABA, who also have affinity for the 
benzodiazepine receptor. 
The /'ole of lIeIlJ'O-ac/;"e peptide (Cholecystokillill) ill pallic disorder 
Cholecystokinin (CCK) is a neuro-active peptide which occurs in several forms and 
has both central and peripheral action. In the brain, CCK is present in various areas such 
as the brainstem, the amygdala and the cortex; the hippocampus is an important center 
where CCl( possibly interacts with the GA BA system, Different types of CCl( receptors 
have been described. Stimulation gives an excitory effect on the pyramidal neurons of 
the hippocampus. This effect call be completely eliminated by benzodiazepines37. 
Cholecystoklllinoctapeptide (CCKs) appears to be the most common form of CCK in 
the central nervou~ systcm60,61. 
A difference in the number of CCKs receptors bet\veen patients with panic disorder 
and control individuals was demonstrated in clinical investigations. Panic disorder patients 
have fewer receptors than. controls. It was also observed that intravenous administration 
of CCK4 (a tetrapeptide neurotransmitter) and the commercially available pentagastrin 
(a pentapeptide) induced panic-like reactions in healthy volunteers and in a significantly 
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higher percentage in patients with panic disorder62 • Neural pathways and receptors of 
CCK4 have been identified. Intravenous use of CCK4 for provocation test in panic dis-
order was observed to be safe for experiments in humans. Its effect was dose-dependent 
and appeared to be reliable as far as the reproducibility was concerned. 
It seems likely that CCK is also important in the etiology of panic disorder. LydiaI'd et 
a163 observed that patients with panic disorder had significantly lower concentrations of 
CCK, in cerebrospinal tluid (CSF) than a control group. They proposed the following 
hypotheses as an explanation: 
- The sensitivity of cholecystokinin receptor is increased in patients with panic disorder. 
The cholecystokinin activity is lowered in order to compensate this. 
- Patients with panic disorder have a decreased number of cholecystokinin receptors 
which is accompanied by a decreased activity of CCK~r 
- The activity of CCKl{ is decreased as compensation because of a (theoretical) increase 
in the activity of CCK4• 
The third hypothesis is most appealing on the basis of the provocation tests with CCK4, 
but a concluding theory on how the compensation then progresses is, however, lacking. 
Neuro-anatomkal theories concerning panic disorder The limbic system plays a central 
role in human emotions including anger, excitement and anxiety. This system consists of 
amygdala, hippocampus, uncus, nuclei of septum and thalamus, hypothalamus and 
rhinencephalon wherein, among others, the gyrus para-hippocampus and gyrus cingula. 
The various parts of the limbic system are linked to each other (see Figure 2). 
Figure 2. Limbic connections with relevance for panic disorder 
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Abbreviations: fx - fornix, mtt - manlluillothalamic pathways. (after Mesulam: 'Neural 
substrates of behavior: the effects of Brain Lesions npoll1l1entai state' , in: Th New harvard 
Guide to Psychiatry. Cambridge, Massachusetts, and London, England; Harvard 
University Press 1988), 
A central role is set aside for the hippocampus and gyrus cingula in dealing with 
emotions which come from the cortex. Lesions in gyrus cingUla, with links from the 
brainstem to frontal cortex and from the frontal cortex to the gyrus para-hippocampus, 
cause a decrease in the ability to experience anxiety in humans. In recent years, 
investigations on the imaging of brain with the aid of SPECT- and PET-scans have become 
possible. In such investigations, radioactive agents are injected in the body and their 
distribution after a certain period in the brain is mapped on the basis of the emitted 
radiation. These investigation techniques provide functional information on the regional 
activity in the brain. Patients who develop panic attacks upon infusion of lactate, showed 
an abnormal (increased) brain activity for consumption of blood oxygen in the para-
hippocampus region, as can be shown on the PET-scan68• 
Anticipation anxiety for an electric shock in healthy volunteers increased the bilateral 
temporal blood flow as measured by the PET-scanM • 
Tn patients with panic disorder, an abnormal asymmetrical blood tlow and an altered 
metabolism were observed in the para-hippocampal gyrus during periods without panic67 • 
Gorman ct UPI classified the cerebral location corresponding with panic attacks, 
anticipation anxiety and avoidance behavior on the basis of neuro-anatomic findings. As 
a neuro-anatomical hypothesis, they proposed that panic attacks could be attributed to 
the stimulation of one of the three brainstem nuclei: The chemo-receptors in the extended 
marrow, the locus coeruleus in the pons and/or the dorsal raphe nuclei in the rostral part 
of the formatio dorsalis. The raphe nuclei and the chemo-receptors directly innervate the 
LC. According to Gorman et aPI, anticipation anxiety is rooted via the brainstem to the 
limbic system. Possible inhibition of the hippocampal region by the LC causes feelings 
of anxiety. Phobic avoidance behavior often continues to persist for a prolonged period 
after the stimuli have ceased. Cognitive functions are essential for this: 
There are links between reticular formation-LC-limbic lobe and prefrontal cortex, via 
which this cognitive process may proceed. The pre-frontal cortex is that part of the brain 
which is most involved in learning and in dealing with complex emotions. 
Associations between the autonomous presentations of panic attack with the surrounding 
factors and the cognitions which occur during the attack are established in the prefrontal 
cortex. The limbic system also modulates the emotional experiences. According to Gray 
et a169•70, the information from this system, received via the thalamus or the cingUla cor-
tex is stored in the temporal horns of the brain. 
In connection with this theory, it is of significant meaning that the noradrenergic system 
and the serotonergic system both project to the septo-hippocampal systemflS • 
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Gray et a169.70 meant that the ascending noracirenergic projections to the septo-
hippocampal system amplified arousal. The serotonergic system with afferents from the 
raphe nuclei to the septo-hippocampal system probably played the same role with regards 
to displayed behavior. Gray et al 69 stated that dmgs which reduce anxiety act on the most 
important noradrenergic afferents of the LC and on the scrotonergic afferents of the raphe 
nuclei to the septo-hippocampal system (see Figure 1). 
The association between the noradrenergic system and the serotonergic system was 
also stressed in the study by Asnai et aF'. They tested the serotonergic system and the 
adrenergic system of patients with panic disorder and depression and of control individuals 
by overloading them with m-chlorophen-ylpiperzine (a 5-HT agonist), desipramine and 
a noradrenergic agonist. These authors concluded that the noradrenergic system and 
serotonergic system did not funetion independently of each other, but that there may be 
a common noradrenergic and serotunergic disorder in patients with panic attacks and 
those suffering from depression. 
COllclusiOilS 
None of the theories discussed in this article or those mentioned in Table I can provide 
a single clear and sufficient explanation for the origin of panic disorder. 
Table I Biological explanations for panic disorder 
1. Hypersensitivity 5-HT receptors 13 
2. Decreased serotonergic transmission!5 
3. Over-activity of noradrenergic system, namely the loclls coeruleus because of 
decreased pre-synaptic a1-receptor activity4.l 
4. Sub-groups of patients with panic disorder as a result of an abnormal regulation of 
their NA fUilction2 
5. Abnormal henzodiazepine/GABA complex~6 
6. Abnormal concentration of B-carboline59 
7. Over-sensitivity for carbon dioxide~5 
8. Abnormal cholecystokinin activity63 
9. Cornmun noradrenergic/serotonergic disorder71 
10. Dysfunctional septo-hippocampal system2! 
Its biological pathogenesis remains unknown. As behavior and cognitions may dep-
end on several functional brain regions it is likely that psychiatric disorders can be caused 
by different brain abnormalities. By no means have all neuJ'O-transmitter systems yet 
been investigated. The development of new selective receptor agonists and antagonists 
may possibly accelerate the elucidation of the process(es) which underlie the biological 
abnormalities in patients with panic disorder2. 
As mentioned in the introduction, besides the biological factors, there are many other 
factors that are important in the development of panic disorder. It is not unlikely that an 
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integrated bio-psychosocial model of cause will qualify as an important model for 
explanation. Alf et aP2 provide an example: According to him an inborn predisposition 
[Of an accelerated triggering of the Locus coendeus and/or an (for example, through 
experience of separation in early childhood) increased susceptibility caused by events in 
life would decrease the threshold for the occurrence of paroxysmal anxiety states. 
In these panic disorder patients, rapid vegetative physical complaints develop as a 
result of psychological and/or biological factors. These complaints may be misinterpreted 
as catastrophic which then may lead to panic attacks. 
Inborn predisposition! susceptibility + stress ->- anxiety ->-- somatic complaints + 
misinterpretation ->- panic attack 
According to Alf et al 72 , the further development of avoidance behavior, 
hypochondriasis, addiction or anticipation anxiety would depend for a major part on the 
personality stmcture of the involved individual. 
In a more elaborate psychophysiological model (Ehlers & MargrafJ) panic anxiety is 
described as an outcome of a positive feedback loop. In this model multitude of factors 
are integrated and bodily and/of cognitive changes may serve to trigger panic attacks. 
At this moment we do not have a biological marker, nor a psychological profile, to 
characterize the patients with panic disordel: 
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CHAPTER 3. COMORBIDITY BETWEEN PANIC DISORDER 
AND MAJOR DEPRESSION: 
MODELS AND CONCEPTS OF THE PRESENT 
INVESTIGATION 
This chapter focusses on the comorbidity of panic disorder with depression, its 
prevalence, hypothesized causes and relevant factors. As we have seen in the previolls 
chapters panic disorder with or without avoidance behavior is a fairly frequently occurring 
psychiatric disorder. It has a prevalence of 2% to 4% during life and often follows a 
chronic recurrent course [Katherndahl & Realini, 1993], This percentage is clearly lower 
than that for depression (6% to 8%) and represents only a relatively small percentage of 
all the anxiety disorders wich has a 15 % prevalence during life [Pasnau & Bystritsky, 
1994] (see table D. 
Table 1. Prevalence of anxiety and depression during life 
Mood disorders % Anxiety disorders % 
Major depressieve episode Panic disorder 2 
Any episode 6 Panic symptoms 10 
Unipolar only 5 Phobias 13 
Bipolar Any anxiety disorder 15 
Dysthymia 
\Vithout major 
depression 2 
Any affective disorder 8 
Source: Pasnau & Bystritsky, 1994. 
The concept of co-morbidity stands for every other clinical diagnosis which was made, 
or may occur during the clinical course of a patient with the index diagnosis under 
investigation [Feinsein, 1970j. 
A number of recent clinical studies have drawn attention to co-morbidity between 
panic disorder and major depression. 
Aronson [1986] cited the figures ranging from 39% to 75% from different studies in 
his discussion on the co-morbidity percentages between panic disorder and depression. 
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Stein et al [1990'] reported a figure of 63% for lifetime depression in patients with 
panic disorder. 
Breier et al [1986] observed that 68% of their patients with panic disorder and 
agoraphobia satisfied the criteria for either suffering. or for having suffered from major 
dcpres-sion. However, 35% of the patients had depressive episodes which could be 
regarded as secondary to the agoraphobia, 
The risk of an existing panic disorder in patients with major depression is 18.8 times 
higher than that which may be expected on the basis of chance alone [Boyd et aI, 1984 J. 
Wetzler & Katz [1989] and Huyser [1993] reported that the percentage of anxiety 
symptomatology in patients with major depression was higher than the percentage of 
depressive symptoms in patients with panic disorder. 
Psychiatric disorders including panic disorder and depression disorders also occur in 
positive association with other frequently occurring psychiatric disorders such as 
generalized anxiety disorder, social phobia, obsessive-compulsive disorder, somatic dis-
orders and substance abuse [Maser & Cloninger, 1990 J. 
Co-morbidity of panic disorder with rare psychiatric disorders such as winter depression 
[Halle & Dilsaver, 1993] and alexithymia [Parker et aI, 19931 have also been reported. 
However, negative associations such as that between anxiety disorders and anti-social 
personality disorders also do occur. 
In epidemiological and clinical studies, the relationship between panic disorder and 
depression can be investigated in t\VO ways: 
I. As the concomitant occurrence of well-defined diseases such as panic disorder or 
major depression according to DSM-IV criteria; a categorical classification. 
2. As the correlation and co-variance of depression and panic disorder on dimensional 
rating scales such as the Symptom Check-List (SCL-90). 
Hiller et al [1989] compared the extent of overlap between the anxiety and depressive 
disorders at symptom-, syndrome-, and diagnostic levels. 
The degree of overlap was observed to be the highest at symptom level, whereas it 
was the lowest at the diagnostic level. The diagnostic process is based on symptoms and 
syndromes wich are usually combined for a diagnosis. If symptoms tend to be correlated 
they are said to form a common syndrom. Different from the diagnostic classification, 
wich also has other criteria as prognosis or severity characteristics, a syndrome 
classification provides a quantitative approach to a number of symptoms. 
Hiller et al [1989J stated that the investigator must decide all the psychopathologic 
level at which the investigated groups would be differentiated: 
If diagnosis is chosen as a criterium for classification, a part of the overlap between 
the disorders at symptom level is certainly lost, but the chance of demonstrating a signi-
ficant difference between clinical presentations with differing psychopathology is 
increased. 
47 
Whether specific symptoms can be used as predictors of the diagnostic andlor syndrome 
overlap between panic- and depressive disorders has not yet been adequately investigated. 
It is clinically observed, on the one hand, that daily variations in the mood, early 
awakening and psychomotor retardation occur very rarely in anxiety disorders, whereas 
on the other hand, severe agoraphobia, depersonalization, derealization and distortions 
of sensory perception occur frequently in panic disorders but not in depressions [Pasnau 
& Bystritsky 19941. 
Factors of cOlllorbidity between pallic disorder and depression 
Several factors are important in the etiology of the co-morbidity between panic dis-
order and depressions. These are: 
1. Gender of the patient 
Scheibe & Albus [1992J reported that co-morbidity between panic disorder and 
depression was much higher in women (79.5%) than in men (20,5%). In addition, 
women had a higher tendency for avoidance behavior and showed more generalized 
anxiety. 
2. The duration of the illness 
The chance of developing a secondary depression in patients suffering from panic 
disorder correlated positively with the length of the period during which the patient 
suffered from panic disorder [Lesser et aI, 1988; Argyle & Roth, 19891. 
It is possible that having panic attacks for prolonged periods which is often 
accompanied by the development of avoidance behavior and demoralization may 
lead to depression !Sheehan & Sheehan, 1982j. However, in a recent study [Stein et 
ai, 1990al. it appeared that severity, duration and degree of avoidance behavior were 
not significant predictors for the development of major depression in patients suffering 
from panic disorder, 
3. Genetic bUl'den 
Genetic studies have indicated that panic disorders and depression shmv a partial 
etiological overlap [Torgensen, 1990J. 
Children of depressive parents are both "at high risk" for depression as well as for 
anxiety disorders, Children of parents with anxiety disorder also have a higher risk 
for anxiety disorders and for depression I \Veissman, 1990 j, 
On the basis of a recent large study of the genetic factors in panic disorder and major 
depression, Weissman et al [1993] stated that panic disorder and major depression 
were distinguishable disorders which occurred together in relatives of patients in 
both groups more often than was to be expected on the basis of chance alone and that 
panic disorder accompanied by major depression was not a separate independent 
disorder) but was a genetically heterogeneous patientgroup. 
4. Co~mol'bidity with social phobia and genel'aliz~d anxiety disorder 
The incidence of major depression is significantly higher in patients suffering from 
panic disorder accompanied by social phobia or generalized anxiety than in patients 
without social phobia or generalized anxiety disorder I Stein et al 1990h]. 
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Tileol'eticll/mode/s 
A number of theoretical models have been constructed which can explain the 
simultaneous occurrence of panic- and depressive complaints. 
Francis [1992] described five models: 
1. A continuum model 
Anxiety and depression must be localized on the same continuulll and be based on a 
common pathogenesis. According to this hypothesis, co-morbidity merely retlects an 
artificial separation of a complex syndrome into different components. 
This hypothesis is similar with the 'variant hypothesis' of Aronson [1987] and the 
unitary model of Stravrakani & Vargo [1986J. 
2. The model of separate well defined concomitant syndromes 
This co-morbidity hypothesis does recognize that there is overlap between anxiety 
disorders including panic disorder and depression. The categorical differences which 
are lost in a continuum model are preserved. Anxiety- and depression disorders are 
regarded as occUlTing so frequently that the t\VO concomitant diagnoses coincide merely 
on the basis of change. 
3. Predisposition mudel 
Anxiety and in particular panic disorders mostly preceded depressive disorders 
indicating that anxiety disorder may be a predisposing factor in the development of 
depression. This predisposition may proceed for example via a psychological pathway, 
such as secondary depression in patients with panic disorder wich results from 
demoralization [Sheehan & Sheehan, 1982]. 
It is also conceivable that a biological abnormality responsible for panic disorder 
(e.g., high level of a neurotransmittor) might evolve into another biological 
abnormality (e.g., down-regulation of receptors in the same system) that might be 
responsible for depressive disorder. 
4. Overlap due to definition 
The correlation between panic and depression may be partially artificial because of 
the overlap between the items that are llsed to detine panic disorder and depression. It 
is possible that in the DSM IV, complex syndromes have been classified in very 
narrowly described categories which are so closely related that they often occur at 
the same time. 
5. A combined model 
Tn this model, in addition to diagnostic categories for depression and panic disorders, 
the generalized mood disorders are also included for patients presenting with mixed 
features of both anxiety and depression. This agrees with the 'general neurotic 
syndrome' ofTyer 11984J. Tyer pleaded t,)r the presence of this syndrome in individuals 
with chronic symptoms of anxiety and depression and specific personality 
characteristics such as excessive timidity, low self-confidence, dependence on others 
and tendency to avoid anxiety-inducing situations. This group of patients had 
alternating exacerbations of complaints which at one time fitted in with anxiety 
disorder and then again with depression. Tyer [1984] spoke of this group of patients as: 
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"In reality they may represent the same person wearing different clothes". 
This concept also called "mixed anxiety and depressive disorder" is supported among 
others by the findings of Clay ten et al [1991 J, Angst & Dobler-Mikolan [1985) and 
Barlow et al [1986). 
Janet [1909] too, in his concept of the psychasthenia in which there is partial 
dissociation ("abaissement du niveau mental"),loss of the highest integrative functions 
and reduced awareness of the reality described a model that showed similarities with 
the "General Neurotic Syndrome" as formulated by Tyree 
The psychasthenia described by Janet encompassed patients with, among others, 
phobias, other anxiety disorders and obsessive-compulsive complaints r for review 
see: Gray, 1978). 
6. Another explanation model for the occurrence of panic disorder and depressive 
complaints at the same time is partial development of mUltiple psychopathology. 
A high percentage of adult patients with panic disorder and agoraphobia appeared to 
have school phobias and separation anxiety as a child. Later in life, beginning in 
adolescence, they often suffered from social phobia and their panic attacks appeared 
to have been frequently preceded by mono-symptomatic autonomous disorders such 
as hyperventilation, palpitations and trembling. Panic attacks in turn were preceded 
by anticipation anxiety and avoidance behavior, whereas depression and 
demoralization were seen as the end phases in the development of the psychopathology 
[Deltito et aI, 1991]. This model may be seen as a variation of the predisposition 
model as described under 3. 
Introduction to 0111' 011'11 im'estigations 
In these investigations, a multi-dimensional approach at the similarities and the 
differences between patients with panic disorder, patients with major depression, patients 
with major depression and panic disorder and a reference group of healthy individuals 
was undertaken. 
This was done on the basis of the model of an unitary hypothesis of comorbidity in 
wich panic disorder and major depression result from a cOlllmon biological substrate and 
in wich psychological factors as defense organisation or coping strategies determine 
whether a panic disorder or depression occurs. 
The three diagnostic groups were compared and the patient group as a whole was also 
compared with the hcaHhy reference group concerning the following: 
- Symptoms - Defense mechanisms - Coping mechanisms - Biochemical parameters 
Response to adequate psychiatric treatment was determined in the three patient groups, 
and the influece of psychiatric treatment on defense mechanisms, coping strategies and 
biochemical parameters. These variables and its relationship with the patientgroup under 
study will be shortly described below. 
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Symptoms 
Symptoms of the patients with major depression and with panic disorder show a cel1ain 
amount of overlap as mentioned in the introduction of this chapter on co-morbidity of 
panic disorder with major depression. This overlap was confirmed recently once again 
by Huyser r 1993] in the investigations on symptomatology of depression disorder and 
anxiety disorder and in our own study on symptomatology of in-patients suffering from 
major depression or panic disorder [Timmerman et al. 1994]. From a recent study 
[Timmerman et a1. 1995] it could be concluded that panic attacks shmv a characteristic 
symptomatology which may be regarded as reproducible as indicated also by the results 
of various studies in which diverse groups of patients with panic disorder were evaluated 
for symptomatology at different moments using different evaluation tools. 
This symptomatology occurs in addition to the feeling of panic, and encompasses 
somatic anxiety equivalents such as dizziness, chest discomfort, tachycardia, s\veating 
and trembling. 
Defeuse mechanisms 
The use of defense mechanisms is an involuntmy adaptation to intra-psychological 
and/or external stress directed at diminishing this stress. 
Use of defense mechanisms mostly alters the perception on the internal and external 
reality and is an integrated psychodynamic process. 
Historically, the defense mechanisms were first described by Sigmund Freud [1894J. 
He described 5 important properties of defense mechanisms. These were: 1. Defense is 
an important way to deal with feelings and instincts. 2. Defence is unconscious. 3. Defense 
mechanisms can be distinguished from each other. 4. Although often characteristic for 
serious psychiatric disorders, defense me<.:hanis111s are reversible. 5. Defense may be 
adaptive as well as pathologic. 
Freud's daughter Anna elaborated the concept of defense mechanisms in her standard 
work 'The Ego and Mechanisms of Defense' [1937J. Later, she pointed out the imp0l1ance 
of the chronology in the development of the defense organization. Some defense 
mechanisms such as denial and projection arc normal in childhood, but may lead to 
psychopathology at an advanced age. Vaillant [1988] divided defense mechanisms into 
psychotic defense, immature defense, nClIrotk defense and adult defense. (Table I) 
Table 1. Structure of the defense organization l 
PSYCHOTIC DEFENSE: 
IMMATURE DEFENSE: 
Denial 
Distortion 
Passive aggression 
Acting out 
Dissociation 
Projcction 
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NEUROTIC DEFENSE: 
MATURE DEFENSE: 
Autistic phantasies 
Devaluation 
Splitting 
Intellectualization 
Repression 
Reaction formation 
Postponement 
Somatization 
Undoing 
Rationalization 
Oppression 
Altruism 
Sublimation 
Humor 
IAfter Vaillant GE: Defense Mechanisms in: The New Harvard Guide of Psychiatry 
Cambridge: Harvard University Press [1988]. 
His division in psychotic and neurotic defenses is suggestive for a correlation between 
defense mechanism and psychopathology. 
Remarkably, very little is known on the relationship between defense organization 
and psychiatric illnesses such as panic disorder and major depression. 
Tn an investigation into defense organization, Bond & Vaillant [1986] observed that 
there was no correlation between symptom disorders and defense organization in any of 
the 74 clinical and ambulant psychiatric patients with various diagnoses as rated with the 
Bond Defense Style Questionnaire (DSQ). Patients \vith major depression in this 
investigation appeared to be very similar to the control group as far defense organization 
was concerned. The other groups of patients showed more immature defense organization 
than the control individuals. Bond & Vaillant [1986] stated that defense organization and 
psychiatric diagnoses were two independent variables and pleaded for a separate axis in 
the DSM in which defense orga-nization was to be classified. 
Pollock & Andrews [1989] observed that ambulant psychiatric patients with anxiety 
disorder appeared to use other more immature defense mechanisms as rated with the 
DSQ than a control group. It appeared that within the group of patients with anxiety 
disorder distinction according to diagnosis and apparent use of defense mechanisms was 
possible: 
Patients .with panic disorder with or \vithout agoraphobia appeared to use displacement, 
somatization and reaction formation as the main defense mechanisms, whereas patients 
with obsessive-compulsive complaints as a whole did not usc "humor", but instead used 
undoing. projection and acting out as the most apparent defense mechanisms. Similar to 
the obsessive-compulsive group of patients, patients with social phobia did not use 
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humor as defense mechanism, but did use displacement and devaluation. Pollock & 
Andrews [1989] investigated only patients suffering from anxiety disorder. They did not 
study patients with major depression, 
Bloch et alll993Jused the Defeuse Mechanism Ratiug Scale to compare the defense 
mechanism organization in a group of patients with panic disorder with that in a group of 
patients suffering from an carly primary dysthymic disorder - a milder form of depression 
compared to major depression. The patients with dysthymic disorder made lllorC use of 
defense mechanisms: "projection, acting Ollt, passive aggression, hypochondriasis, 
devaluation and projective identification." The patients with panic disorder apparently 
used neurotic defense mechanisms: "reaction formation and undoing" more often. 
No comparison between the patient populations and a control group of reasonable size 
was either reported by Akkerman et al [1992J or by Bloch et al [1993]. However, this 
was done by Andrews et al [1989]. They compared a group ofpatients with panic disorder 
with a control group, but observed no differences in the defense organization. 
An extensivc emperical study using the Defense .Mechanism Inventory (DMI) was 
undertaken in diverse groups of healthy volunteers, howcver only to a very limited extent 
in psychiatric patients Jlhilevich & Gieser, 1986]. 
Application oflhe DMI in patients with "anxiety complaints", anxiety appeared to be 
possitively correlated to neurotic defenses as" denial, repression, reaction formation and 
intellectualization" . 
To date, only a single study has been reported in which a group of (clinical) patients 
suffering from depression was directly compared with a group of control individuals 
using the DMT. In that study, it appeared that depressive men were more inclined to use 
internalized defense, whereas depressive women were inclined to use more externalized 
defense than controls JMargo et ai, 1993]. 
In another investigation of depressive patients, it appeared that these patients very 
often made use of the defense me-challism: Turning aggression against self [lhilevich & 
Gieser 1986]. This was in agreement with that to be expected on grounds of 
psychoanalytical theory [Freud 1894]. 
In an earlier pilot study by our O\VI1 research group in patients suffering from panic 
disorder, it became evident that patients with panic disorder apparently llsed defense 
mechanis-m~ such as denial, reaction formation and turning aggression against self in a 
larger extent than a control group of volunteers (Timmerman et ai, 1994]. 
The results of the relationship between symptom disorder and defense organization 
are summarized in Table 2 and show that no finn conclusion about the relationship between 
defense mechanisms and psychiatric diseases as panic disorder and major depression 
can be drawn. Studys of patients with panic disorder-major depression co morbidity are 
lacking. 
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Table 2. Symptom disorder and defense mechanisms 
Aut/wI's 
-Pollock et al 
[1989] 
-Akkerman et al 
[19921 
-Bloch et al 
[1993 J 
-Andrews et al 
[19891 
-.Margo et al 
[ 1993J 
-lhilcvich et al 
[19861 
-Timmerman et al 
[1994] 
S)'1llptom disorder 
Anxiety disorder 
Major depression 
Panic disorder 
Panic disorder 
.Major depression 
Major depression 
Panic disorder 
iJejellsellleC/WII is/lis 
Postponement, 
somatization reaction 
formation 
Tmmature defense 
Reaction 
formation undoing 
No difference as 
compared to controls 
Less intellectualization 
as compared to controls 
.More tllrning aggression 
against self as compared 
to controls 
More denial, reaction 
formation and turning 
aggression against self as 
compared to controls 
The course of defense mechanisms during treatment remains unknown, with the 
exception of the investigations by Akkcrman et al [1992]. Akkerman et al investigated 
the course of defense mechanisms during the therapy of patient with major depression 
using the Defcnse Style Questionnaire. There was no change in the use of neurotic or 
adult defense mechanisms during therapy, whereas the use of immature defense 
mechanisms was decreased. 
In other studies, a control group was often lacking or non-validated rating scales had 
been used. 
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Coping 
According to Lazarus' transactional model of stress, an event is regarded as stressful 
if an individual's psychological well-being is threatened [Lazams & Folkman, 1984]. 
The concept of coping is defined as a form of problem-solving whereby the individual's 
well-being is at stake and the individual is unable to fall back onto existing routine skills 
and possibilities. 
Coping is then also seen as 'personality in action under stress' [Troop, 1994]. Two 
important ways of coping can be distinguished: 
1. Problem-focused coping via altering the disturbed relationship between individual 
and surrounding. Problem-solving and seeking help from others belong to this strategy. 
2. Emotion-focused coping by regulating the disturbed relation without dealing with 
the CHu:;;e, but through intra-psychological processes for example, denial and use of 
other reactions such as passively hoping that things will change, blaming oneself and 
avoiding social contact [Kleber & Brom, 1992]. Palliations via, for example, excessive 
smoking, alcohol usage and drugs abuse are also included here [Schreurs 19841. 
Traditionally, coping is seen as a personality trait [Troop, 1994]. Other authors view 
coping as determined by the situation [Bifulco & Brown, 1994]. 
Andrews [1991] stated in a theoretical model that general vulnerability for anxiety 
disorders and depressions was determined by a high level of 'trait' anxiety with poor 
coping and that spec((ic susceptibility for certain psychiatric disorders was related to 
psychodynamic factors. Trait anxiety is seen as the strongest determinant for the 
development of psychiatric symptoms within these two factor theory of neurosis. Similar 
to Andrews [1991], Rosenbaum [1980] stated that effective coping can protect the 
individual against enviromental-, cognitive- and biological threats whk:h may otherwise 
lead to depression and anxiety. The 'vulnerability' model assumes that coping style is a 
relatively stable aspect of one's personality. 
Roy-Byrne et al [1992] investigated the differences in the coping mechanisms that 
were used by three groups of patients with panic disorder with or without avoidance 
behavior. In this study there were panic disorder patients with comorbidity with major 
depression and personality disorders. The shift from problem-targeted to emotion-targeted 
coping \vas strongly correlated with the degree of severity of the symptomatology which 
was observed but not to the psychiatric diagnoses of the patients. Coping strategy appeared 
to be state dependent. The severity of underlying stress appeared in this investigation to 
be a more important predictor for the way of indicated coping than the psychiatric dia-
gnoses. This stress-dependence of coping-strategy was in contrast to the theory by 
Rosenbaum [1980] \vho viewed coping as a stable personality-related (trait) aspect. 
In the investigations by Roy-Byrne et al [19921 the diagnosis: panic disorder, depression 
and panic disorder with depression had no correlation to specific coping mechanisms. 
\\'hether the-re were also correlations between copingstrategy and defense organization 
was investigated by Schreurs [1987J. He found no clear correlations between defense 
organization and coping-strategy that was used. Ihilevich & Gieser [1991] did observe 
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correlations between defense organization and coping-strategy. It appears that individu-
als with a high tendency for repression, denial and reaction formation inclined towards 
avoidance, with those individuals whose main defense mechanism is prillcipalization 
(intel1ectualisation) used in particular calming thoughts as coping-strategy, whereas those 
who turned aggression against self incline towards pessimism. Ihilevich & GIeser suggest 
that defense organisation and coping strategy add to each other. 
Biochemicallel'els alld psychopathology 
Recent studies have shown that lowered serotonergic function is characteristic 
for some forms of depression, suicides and panic disorder [BaH & WhybrO\v, 1993; 
Timmerman, 19841 
Serotonin is derived from the amino acid tryptophan via 5-hydroxytryptophan (5-HT). 
Serotonin is mainly stored in thrombocytes. 
Tryptophan is for the largest part bound to plasma albumin. In addition, there are free 
fractions of serotonin and tryptophan in the blood. The concentrations of these agents in 
thrombocytcs and blood give an indication on the functioning of the serotonergic system. 
Only free tryptophan can cross the bloodlbrain barrier. The transport occurs via a carrier 
protein. However, for the binding to this carrier, there is competition with other large 
neutral amino acids (LNAA) and tyrosine. 
The ratio of tryptophan and other amino acids in the plasma rellects the amount of 
tryptophan available for serotonin synthesis in the central nervous system [Timmerman, 
19841. 
Tyrosine is the precursor of noradrenaline and dopamine. Just like serotonin, these 
two monol1mines are also thought to be important in the pathology of depression and 
panic disorder [Green & Costain, 19X 11 (see also chapter 2). Tyrosinc is also for a major 
part bound to plasma protein and has to compctc with other LNAA and tryptophan for 
transport through thc bloodlbrain barrier to the brain. 
In previous investigations in a group of patients with depression, we observed 
significantly lowered ratios of tryptophan/LNAA and tyrosine/LNAA in the plasma 
[M¢ller et ai, 19861. The neurotransmitter serotonin is involved in a large number of 
diverse psychiatric disorders including anxiety disorders and depression [Den Boer et 1.11, 
19871. At the same time, there appears to be a link between thc serotoncrgic system on 
the one hand and disorders of the impulse control in the sense of suicidal and aggressive 
impulse breakthroughs on the other hand. The functioning of the serotonergic system 
can be measured among others via its metabolite 5-hydroxyindoleacetic acid (5-HTAA), 
the level of which correlated negatively with suicide and with aggression [Asberg et aI, 
1976; Brown et ai, 1979]. Further, in a study of our own group [Timmerman et ai, 1994], 
it appeared that serotonin (5-HT) in blood platelets was positively correlated with 
subjectively experienced anxiety which fitted in with the theory which states that 
stimulation of the serotonergic fUllction can induce anxiety [Kahn et ai, 1992]. 
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On the basis of the observed correlations between the scrotonergic system with 
aggression and suicide one Illay speculate that this system is coupled to "aggression". 
The freudian hypothesis of suicide implies that aggression is targeted at the self instead 
of at the outside world, by lIsing other psychological defense mechanisms. 
Not only serotonin might he associated with psychological entities as e.g. defense 
mechanisms, agression and anxiety: f) carholines or harmala alkaloids are of special inte-
rest since they show a spectrum ofhiochcmical and pharmacological activities including 
inhibition of MAO-A, competitive inhibition of serotonin uptake, binding to 
benzodiazepine and opiate receptors and very likely action on dopamine receptors in 
preclinical studies. The· carbolines have been recognized as aromatic alkaloids of wkh 
norhanllan can be detected in very low concentrations in human plasma and in several 
organs of the rat '-for review see: van Gelderen et ai, 1994]. 
Most of the known B carbolines are anxiogenic, though some of the J3 carboJines have 
anxiolytic properties. Tn a previous pilot study [Timmerman et ai, 1994] in patients suffe-
ring from pank disorder, it was noted that their norhanllan, a J3 carboline \vith similar 
activity as a henzodiazepine in rats, was negatively correlated with the defense mechanisms 
of principalization and repression and was positively correlated with coping-strategie 
palliation. Norharman was not a trait marker for anxiety: no correlation was observed 
between plasma norharman and level of anxiety. 
Resp0Jl.ve to therapy, copiug aud de/elise organizatioll 
The most frequently used therapies for treating depression and panic disorder are: 
psycho-pharmaceutical drugs and psychotherapy [Timmerman & Pepplinkhuizen, 1993]. 
There are a large number of psycho-pharmaceutical drugs which are effective in the 
treatment of pank disorder and depression. However clomipramine is the only drug that 
has been officially registered in 1991 in the Netherlands for treating depression as well 
as panic disorder [Modigh et 1.11, 1992 [. Therefore clomipramine was chosen for the 
treatment of each of the patients in our study. Another advantage of choosing clomipramine 
was the possibility of determining the plasma concentrations of clomipramine and its 
active metabolite which offered the possibility to assess the therapy compliance of the 
patients. 
Very little is known about the course of coping and defense mechanisms in patients 
with major depression andlor panic disorder after adequate treatment. Hoffart & Mal1insen 
[1993] observed in their study that problem-focused coping and wishful thinking as 
measured on a "wishful thinking scale" in clinical psychiatric patients with agoraphobia 
and with major depression disminished and mainly behaved as a state phenomenon after 
treatment for 1 year. The agoraphobic patients, with or without depression, had before 
treatment a lower level of seeking social support than purely major depressed patients. 
This difference was not reducible to differences in the level of psychopathology before 
treatment. The seeking social support scores increased after treatment with the remission 
of symptoms and correlated well across assessments. Akkerman et al [1992], using the 
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Defense Style Questionnaire, investigated the course of immature defence mechanisms 
during the treatment of patients with major depression. During treatment, there was no 
change in the lIse of neurotic or adult defense mechanisms, whereas the use of immature 
defense mechanisms decreased. 
Aim of file currell! i11l'estigah'olls 
Comorbidity between panic disorder and depression is, sofar, an unexplained 
phenomenon in psychiatry. 
We studied this question from the standpoint of the unitairy hypothesis of panic disorder 
and depression in wich these disorders may share a common biological substrate and in 
wich other factors, in general conceptualized as psychological factors, determine and 
shape pathology. 
Secondly, the inter-correlations between the different psychological and biochemical 
parameters were studied and finally the effect of combined drugs- and psychotherapy on 
symptomatology, defense organization, coping-strategy and biochemical parameters in 
the group of patients was investigated. 
S8 
Chapter 4 
59 
CHAPTER 4. DESIGN OF THE STUDY 
Patients 
The patient investigation was conducted at the out-patient psychiatry department of a 
general hospital "Het Drechtsteden-ziekenhuis, locatie Ref~ia". At the out-patient dep-
artment of psychiatry, in the period 1991-l993, 30 new patients suffering from a single 
episode or recurrent episodes of major depression (DSM-III-R 296.2,296.3) were selected 
on time of rcfcral. A minimum of 30 patients suffering from panic disorder with or with-
out avoidance behavior (DSM-III-R 300.21, 300.00) were also recruited. In the DSM-
ITT-R it is possible to establish the diagnosis of panic disorder as second axis I diagnosis 
in the group of patients primarily suffering frol11l11ajor depression and major depression 
as the second diagnosis in the group of patients suffering from panic disorder. 
Exclusioll criteria 
Psychiatric disorders, including dysthymia, other than major depression or panic dis-
order. Depression with severe agitation, serious tendency for suicide, or psychotic 
symptomatology, severe sleep disorders, epilepsy, organic mental disorders, alcoholism 
or drug abuse during the last 5 years, thyroid diseases, liver diseases, bone-marrow 
suppression. allergy or hypersensitivity for clomipramine. glaucoma, urine retention, 
hypertension, hypotension, clinically relevant cardiovascular complaints. significant 
abnormalities in ECG and EEG, abnormal clinically relevant chemical/biochemical 
laboratory findings, clinically relevant kidney disease and pregnancy & lactation. Patients 
had to be free of somatic medication. 
In addition, a reference group consisting of 54 healthy volunteers aged 18-65 years 
from the hospital personnel was formed. This reference group was screened for 
psychopathology using the SCL-90. Individuals from the reference group had a SCL-90 
total score (NEU) which was similar to or lower than the average score of the standardized 
groups for men and women from the Dutch population. 
Procedure 
Psychiatric diagnosis were made by three experienced psychiatrists using to Munich 
Diagnostic Checklist. 
Prior to treatment, the following questionnaires had to be completed in connection 
with psychiatric diagnostic, symptomatology, coping and defense (see for details under 
Questionnaires). 
Munich Diagnostic Check-List (MDCL) 
Hamilton Rating Scalc for Depression (HRSD) 
Symptom Check-List (SCL-90) 
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Utrechtse Coping-List (UCL) 
Defense Mechanism Inventory (DMI) 
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Previous history on the total duration of the illness and of the current episodes was 
registered. Three groups of patients were formed on the basis of Munich Diagnostic 
Checklist (MDCL) (see also Questionnaires): 
1. Panic disorder with or without avoidance behavior 
2. :Major depression with or without melancholia 
3. Major depression and panic disorder 
Informed consent 
Patients were only enrolled into this study after written informed consent had been 
obtained, Both the patients and their general practitioners were informed in writing as to 
the aim and the method of the investigation. 
Prior to participation in this study, a wash-out period of 10 days, applied in as many 
patients as possible, during which no psycho-pharmaceutical drugs were used was 
preferred. Before starting the study, blood from the patients was screened for thc lise of 
trk:yclic antidepressants. 
Both the groups of patients suffering from major depression and from panic disorder 
were treated with t:iomipramine. Their clomipramine blood levels were also monitored. 
It was intented to treat every patient with a 150 mg dose of clomipramine. 
The questionnaires mentioned above were repeated 6 months after starting treatment 
and at the eventual follow-up. The UCL, DMI and SCL-90 were self-rating scales which 
were filled in by the patients at 9.00 a.m. at the out-patient department of psychiatry. The 
completed questionnaires were checked by a trained secretary at the out-patient depart-
ment of psychiatry. 
Thereafter, a semi-structured interview took place during which the MDCL and HRSD 
were filled in by one of the three psychiatrists, to confirm diagnosis and severity of 
illness. 
Previous history on the total duration of the illness and of the current episodes was 
registered by the investigator. 
Biochemical assesmelll 
Blood was investigated with particular regards to the previously mentioncd parame-
ters: serotonin in platelets, serotonin in blood, serotonin in plasma, norharman, tryptophan, 
tyrosi-nc-tryptophan ratio and tyrosine ratio. Thirty (3 x 10) ml blood was taken from 
each patient for determining the levcls of serotonin in blood, plasma and thrombocytes, 
amino acids, norhannan and clomipramine. Blood was taken at 8.00 a.m. and repeated 6 
and 9 months after starting treatment. The blood analyses were conducted at the Erasmus 
University of Rotterdam laboratory of the Section Pathophysiology of Behavior. The 
biochemical methods for analyses that were used are published elsewhere [Fekkes & 
Bode 1993]. 
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The treatment with clomipramine was conducted according to an increasing dose 
schedule, whereby a dose of 150 mg clomipramine was reached within 3 weeks of 
treatment. Blood levels of elomipramine were determined to check therapy compliance 
by the patients. 
Treatmellt 
In addition to treatment with clomipramine [Modigh et ai, 1992], patients suffering 
from depression as well as those suffering from panic disorder were also given 
psychothera-peutic counselling in the form of cognitive therapy [Sokol et aI, 1989]. In 
the first 6 months of treatment, patients participated in at least 10 sessions of cognitive 
therapy. 
In patients with panic disorder, attention was given to incorrect cognitions mostly 
cognitions of catastrophic nature. Irrational beliefs concerning self-image, future and 
feelings of guilt were also dealt \vith in patients with depression. In cases of avoidance 
behavior, the patient was encouraged to exposure themself to threatening situations. 
Quesh'ollllail'es 
In this investigation the patients \vere examined by the scores on the Symptom Check-
list 90 (SCL-90) - a dimensional self-rating scale. 
The clinical psychiatric diagnosis was established with the Munich Diagnostic Check-
List (MDCL) - an operationalization of the DSM-I1I-R criteria. 
The defense organization of the patients and references \vere measured using the 
Defense Mechanisms Inventory (DMD [GIeser & Jhilevich, 1969; Jhilevich & GIeser, 
19861. 
The coping strategies in patients and reference group were determined with the Utrechtse 
Coping-List (UCL), [Schreurs, 1987] that is a satisfactorily validated scale in the 
Netherlands for compiling an inventory of coping. 
Details of the instruments are presented below. 
The MUI/ich Diagl/osric Check· list (MDCL) 
The Munich Diagnostic Check-list (MDCL) [Hiller et aI, 1987] was used in order to 
operationalize the diagnostics in patients with major depression andlor panic disorder. 
The MDCL is an extensive tool which contains 33 of the most occurring DSM-II1-R-
diagnoses and was developed as a check-list version from the structured clinical inter-
view (SClD) compiled by Spitzer & William [19871. 
In panic disorder, among others, symptoms which occur during the panic attack, 
avoidance behavior in certain situations, and the severity of the panic attacks and of the 
avoidance behavior are scored on the .MDCL. Thus, besides a qualitative function, the 
MDCL also has qnantitative aspects. 
In major depression the following are distinguished: 1 ,I episode, recurrence, severity 
and satisfying or not satisfying the criteria for melancholia. 
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Symptomatology 
The SYlllptom Check-list (SCL-90) is a multi-dimensional complaints list based on 
self-evaluation by the patient. The check-list was developed by Derogatis et al r 1973] 
and has 8 sub-scales: 
1. Agoraphobia (AGO) 
2. Anxiety (ANG) 
3. Depression (DEP) 
4 Somatic complaints (SOM) 
5. Inadequacy to think and act (IN) 
6. Distrust and inter-personal sensitivity (SEN) 
7. Hostility (HOS) 
8. Sleep problems (SLA) 
The total score of the SCL-90 'psycho-neuroticism' can be regarded as a measure for 
psychological and physical (un) well-being. The SCL-90 can be used in 3 ways: 
1. As screening tool (e.g in order to assess the type and the level of psychopathology in 
a population). 
2. As an overall measure of the severity of a psychiatric disorder. 
3. As a l11uHi-dimensional measure for specific psychopathology. 
In general, the SCL-90 provides a valid measure for overall severity of symptomatology, 
has a satisfactory convergent validity (a high correlation with other measuring tools which 
measured the same construct) and a relatively high divergent validity (a low correlation 
with assesment instruments which measure a different construct). This was valid both 
for the anxiety- as weU as the depression-scales IBeck et aI, 19921. In the Netherlands, 
the original factor structure of the SCL-90 could not be established. The distribution of 
items over the scales in the Dutch version was, therefore, changed with respect to the 
American version I ArrindeB & Ettema, 19861. The anxiety and phobia anxiety sub-scales 
were identical, but the depression scale had in addition, items 3,19,50 and 51, whereas 
item 79 in the depression scale was omitted. However, Koeter 119921 used both the 
Dutch as well as the original version of the SCL-90 and observed that there were no 
differences in the outcome on the depression scale. Kaeter 11992] in a study in 134 
psychiatric out-patients observed that patients with depression (according to DSM-IIf) 
on the average scored higher on the SCL-90 depression scale than patients with DSrvl-III 
anxiety disorder or those without a DSM-III diagnosis. There was no difference between 
the average scores of patients with DSM-ITT depression disorder and those with co-mor-
bid depression and anxiety. Patients with anxiety disorder (according to DSM-IlI) had 
significantly higher SCL-90 phobic anxiety and anxiety scale scores as compared with 
patients without DSM-ITT diagnosis or a DSM-TTT depression disorder. 
Koeter [1992] reported that the SCL-90 depression, anxiety and phobic anxiety scales 
were both categorical and dimensional measures of specific psychopathology. 
It can be concluded that the SCL-90 was intended for use in ambulant psychiatric 
patients. The SCL-90 has a high sensitivity, but caution is recommended with regards to 
its specificity, especially for individual diagnostics [Arrindell et aI, 1986]. 
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Defense mechanisms 
The defense organization of the patients and healthy volunteers was investigated using 
the D~tense Mechanisllls [nven/of)' (DMI), [Gieser & Ihilevich, 1969; Ihilevich & GIeser 
1986]. 
The DMT provides those under investigation with ten short descriptions of possible 
cantlict situations. Each description is followed by four multiple choice questions. 
A validated Dutch translation version was lIsed [Pas schier & Verhage, 1986]. Those 
under investigation were asked to cross the answer which fitted in the best with their 
actual behavior, with the behavior they displayed in fantasy, their thoughts and feelings 
and the answer which was least applicable. The five possible answers after each queslion 
correspondcd with five important groups of defense mechanisms, These groups were 
designed on theoretical and practical grounds: 
L Turning against object (TAO). It involves: 'Attack on an object that caused real or 
supposed external frustration, 
Identification with the aggressor and postponement fall in this category, 
2, Projection (PRO). Projection means the justification of aggression by attributing the 
hostile intentions or customs to an external object. 
3, Principalizatian (PRN). Principalizing copes with the reality by explaining it with 
rational or pseudo-rational constructions so as to avoid the personal meaning of the 
encountered threat in this manner, This category includes, among others, isolation 
and intellectualization. 
4. Turning against self (TAS). This defense consists of targeting aggression to oneself, 
punish oneself and blame oneself. 
5, Reversal (REV). Present oneself in an unsuited neutral manner, or to react in a positive 
manner to a frustration or a threat. This includes the classic defense mcchanisms: 
repression, denial and reaction formation. 
Following June et al [1983], we used a sixth scale for repression (REP). This scale is 
made up by the subtraction of (TAO + PRO) from (PRN + REV) in order to obtain a 
continuum in which externally targeted defense is balanced by an internally targeted 
focus. 
The reliability and the validity of the DMI in a Dutch translation version was investigated 
by Passchier & Verhage [1986]. They stated that psychometric characteristics of the 
Dutch DMI version were satisfactory for investigational purposes, although the reliability 
and validity in males is less then in women. 
Copillg 
Coping of patients and healthy volunteers was investigated using the Ulrechtse Coping 
Lis/ (UCL), [Schreurs et ai, 1984]. The UCL lVas compiled to quantify concrete behavior 
patterns and mental attitudes in confronting problems or unpleasant events. The DeL 
has 47 short descriptions of ways to deal with problems or unpleasant events. 
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For every item, those under investigation were asked to indicate in which manner they 
seldom or never, often or very often reacted. The psychometric qualitys as validity and 
reliability are sufficient [Schreurs, 1987]. The ueL has 7 sub-scales: 
I. A; aeli ve problem solving: to take lime to investigate the situation, go to work 
purposefully, solve the problem confidently. 
2. P; palliative coping: seek distractions, feel better by smoking, drinking or relaxation, 
3. V; postpone and avoid. 
4. S; seek social support: seck help, discuss the prohlem with someone. 
5. D; depressive syndrome: overwhelmed by the situation and unable to tum the tide. 
self-withdrawal. 
6. E; expression of emotions. 
7. C; reassuring cognitions: such as "everyone has an off day once", "after rain comes 
sunshine", self-encouraging. 
In the next chapters we will discuss the results of the investigations. 
Each chapter consists of an introduction in relation to the aims of the study. statistics, 
results and discussion. 
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CHAPTER S. BASELINE CHARACTERISTICS 
5.1 Introduction 
In the following chapters the groups of psychiatric patients with panic disorder, 
depression and panic disorder & depression arc compared with the reference group 
(volunteers from the huspital personnel) and standard groups. The setup of the investigation 
is discussed in details in chapter 4. The central question in this investigation was whether 
there is a central biologically determined disorder in patients suffering from panic dis-
order and/or depression. whereby differences in defense organization and coping strategies 
possibly determine whether a patient develops panic disorder or depression. 
A description of the biographical and the psychopathological details and drop outs is 
presented in this chapter. In the following chapters, differences between the patient groups 
as a whole, reference group, standard groups and the three patient groups mutually were 
investigated using the Symptom Check-List-90 (SCL-90). Utrechtse Coping List (UCL). 
Defense Mechanism Inventory (DMI) and biochemical variables. (See chapter 4 for a 
description of the psychological rating scales with their standard groups). 
The biochemical values were separated at entry into those in blood samples from 
patients not on medication and those from patients under medication. The biochemical 
concentrations of serotonin in blood platelets (thrombocytes), in blood, in plasma and 
tryptophan, tyrosine and norharman as well as the ,so called tryptophan and tyrosine 
ratios in groups of patients and the reference group arc presented. 
5.2 Subjects, biographical and psychopathological characteristics 
The group of patients consisted of a total of74 patients of which 27 (16 women and II 
men) suffered from panic disorder, 36 (20 women and 16 men) suffered from depression 
and 11 (S \vomen and 3 men) suffered from panic disorder and depression. The average 
age of the patients was 41.S years \vith a standard deviation of 11.7 years. 
The reference group consisted of 54 (22 women and 32 men) healthy volunteers 
recruited from the hospital personnel. Their average age was 32.7 years with a standard 
deviation of S.3 years. 
For the composition of the standard groups of the SCL-90. UCL and DMI see chapter 
3 and 4; in our study we made use of transformed (T) scores (see chapter 6) for comparison 
of patient-, and reference groups with standard groups. 
A description on the differences between the diagnostic categories of the patients 
according to the duration of their illness is given in Table I. 
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Table 1. Total duration of psychiatric disorder (years) 
Diagnosis mean std.dev. median 
Panic disorder 12.3 10.9 8.5 
Depression 8.0 9.2 4.0 
Panic + Depr. 6.4 7.0 4.0 
The patients with panic disorder had a much longer total duration of their illness than 
patients with panic disorder and depression or those suffering from depression only. In 
Table 2, the duration of the current episode of the i1lness in the patients in the three 
diagnostic groups is given. It was noticed that the duration of complaints in the group of 
patients with co-morbid depression and panic disorder was much longer than in the other 
two patient groups. 
Table 2. Number of patients (percentage) classified according to duration 
of the present episode 
Duration 
Diagnosis: 
Panic disorder 
Depression 
Panic + Depr. 
0-3 
30.4 
41.2 
45.5 
3-12 
30.4 
29.4 
9.1 
12-36 
30.4 
29.4 
18.2 
>36 months 
8.7 
27.3 
The most important results obtained lIoing the MUNICH DIAGNOSTIC CHECK-
LIST (MDCL), a DSM lli-R checklist on diagnosis [Hiller et aI, 1989], are shown in 
Table 3. 
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Table 3. Munich Diagnostic Checklist 
Diagnosis: Panic disorder 
(n=27) 
Severity of Panic attacks: 
- mild / moderate 70.4% 
- severe 29.6% 
Melancholia 
Severity of Agoraphobia: 
- mild / moderate 62.9% 
- severe 14.8% 
Depression 
(n=36) 
25% 
Panic+ Depression 
(n=ll) 
54.6% 
45.5% 
20% 
80% 
20% 
In the PANIC DISORDER patients a first time panic disorder was suffered by 41 % of 
the patients. Eighty percent of the panic disorder patients suffered from agoraphobia, 
30 % from severe panic attacks. 
In the group of patients with DEPRESSION, 25% of the patients satisfied the criteria 
of Melancholia, 47 % of the patients in this group suffered fro111 a first episode of 
depression. 
In the group of patients with DEPRESSION & PANIC DISORDER, 20% of the patients 
satisfied the criteria of Melancholia and 46 % of the patients suffered from severe panic 
attacks. In this patient group with depression and panic disorder, all patients were 
agoraphobic. 
A tlrst episode of panic attacks was suffered by 63% of the patients and one could 
speak of a first episode of depression in 36% of the patients. 
5.3 Drop·outs 
Patients (N::::7) who dropped out within the first 4 weeks of the treatment were 
distinguished from those patients (N:::: 16) who dropped out after 4 weeks or treatment 
since an effect of the therapy can be expected after such a period. 
A total of 13 patients (17.5%) discontinued therapy due to adverse side-effects of 
clomipramine. In the other patients the main reason for di:-;continuation of the therapy 
was lack of succes of the treatment [Timmerman et ai, 19952]. 
In the group of patients with PANIC DISORDER & DEPRESSION, two patients 
dropped out after more than 4 weeks of treatment. In one case it was due to adverse side-
effects of clomipramine and in the other case it was because of a lack of consensus with 
the treating physician. 
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In the group of patients with PANIC DISORDER, one patient dropped out within 4 
weeks of treatment (after additional inquiry, it appeared that this patient refused 
medication) and five patients dropped out aftcr 4 weeks of treatment. Three dropped out 
because of adverse side-effects and lack of response, one because of adverse side-effects 
only and one because of hepatological disturbances. 
In the group of patients with DEPRESSION, six patieuts dropped out within 4 weeks 
of treatment. Nine patients dropped out between 4 weeks and 6 months of treatment. One 
patient refused medication, five because of adverse side-effects, two because of adverse 
side-effects and lack of response, five because of lack of response and in two patients 
treatment could not be evaluated because they had moved away during the period of 
therapy. 
It appeared that there was no differcllc:e between the severity of the psychiatric dis-
order in the group of patients who discontinued therapy as compared with the group of 
patients who continued therapy expressed as total SCL-90 score psycho-neuroticism 
(SCL NEU) before starting therapy. In the group of patients continning therapy, the total 
SCL score was 231 ± 58 before cOlllmencing therapy. In the group of drop-outs, the total 
SCL score was 231 ± 69 (the difference was not significant, P= .99 two tailed). 
Drop-outs arc discussed further elsewhere [Timmerman ct aI, 19952]. 
5.4 DisclIssion 
The percentage of co-morbid panic disorder and major depression was reported to 
vary between 25% and 40% in different studies [reviewed by Pasnau & Bytrisky, 1994]. 
This percentage was lower in our study (15%), This could have been because our study 
focussed on ambulant patients, In general, the complaints in these patients were less 
severe than those in a clinical popUlation, Co-morbidity was observed, however, in those 
patients in whom the complaints were severe [Fawcett, 198M}, 
In our study, a subgroup of patients (27%) with co-morbidity had a very prolonged 
duration of their current episode of complaints; longer than 3 years, This is in agreement 
with the findings reported by Argyle et al [19~9J who noted that patients with a prolonged 
duration of illness showed more co-morbidity, Moreover, all patients with co-morbid 
panic disorder/major depression had agoraphobic complaints, This was not the case in 
groups of patients without co-morbidity, 
Notably patients with panic disorder came later into psychiatric treatment than depressed 
patients. It is not clear whether this is because of agoraphobia of the panic disorder 
patients, or because of other reasons, 
The drop-out rate of 31 % in this study was slightly higher than 23% reported in a 
previous double-blind study [Timmerman et ai, 19942] in which tVI'D serotonin uptake 
inhibitors were investigated in the same setting in ambulant patients suffering from 
depression. However, 31 % drop-out in our study was much lower than the 56% drop-out 
that lVas reported by Johnston et al (1988) in a double-blind study for 8 weeks in which 
clomipramine was investigated in women suffering from agoraphobia. It is possible that 
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the percentage of drop-outs in our study was lower, because the patients were offered 
open treatment which reduced their uncertainty and because of the combination with 
psychotherapy. Johnston et all19881 in their study also im::reased the dose of clomipramine 
to a higher maximum (300 mg/day) which may have led to adverse side-effects in more 
patients and more drop-outs. However, the average daily dose used by them was 82.8 mg 
which was lower than that used in our study. 
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CHAPTER 6. PSYCHIATRIC PATIENTS: PROFILE AT BASELINE 
6.1 Introduction 
The central question of the studies described in this chapter was \vhether defense 
organization, coping strategies and biochemical parameters of the patient group consisting 
of patients with panic disorder and/or depression differ from a reference group (see also 
chapter 3 and 4). 
In the investigations on baseline values, it had to be initially established whether the 
reference group and the patient group could be distinguished from each other at the level 
of psychological complaints, using the SCL-90. The scores of the SCL-90 were then 
compared with those from a norm group from the Dutch population. The genders were 
separated in doing so. 
With the Utrechtse Coping-list (DCL), it was investigated whether the use of the coping 
strategies in the patient group as a whole was different from that in the reference and 
standard groups. 
The defense organization in the patient group and in the reference group were mutually 
compared and compared with that of a standard group using the Defense Mechanism 
InventOlY (DMI). More detailed descriptions of SCL-90, UCL and DMI are presented in 
chapter 4. 
It was subsequently investigated whether there were any biochemical differences bet-
\veen the patient group and the reference group. The levels of norhannan, levels of 
serotonin in the blood, plasma and in thrombocytes, concentrations of amino acids: 
tryptophan, tyrosine and the ratios of tryptophan and tyrosine as compared \vith other 
amino acids were all investigated. 
Relations of tyrosine and tryptophan will be analysed as compared with other large 
neutral amino acids in the patient group and in the reference group. The levels of norhanllan 
and serotonin will be correlated to the psychiatric disorder (see also chapter 4). For 
biochemical evaluations, the patients were divided into those using psychopharmaceutical 
drugs such as tricyclic antidepressants and patients not on such medication. 
6.2 Method of statistical allalysis 
The mean and the 95% confidence interval (C.L) of the raw scores of SCL-90, UCL 
and DMI of the reference group and the patient group as a total at baseline and after 
therapy for six and nine months are shown in Table 4. (Appendix) 
First for comparability, especially to visual presentation, the SCL-90 scores of the 
standard group were transformed into a T score with a mean of 50 and a standard deviation 
of 10. The SCL-90, UCL and DMI scores of the patient group and the reference group 
were transformed and compared with the in the above mentioned manner transformed 
scores of the standard group. 
The results are shown in the Tables and the Graphs. 
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The T scores of SCL~90, ueL and DMI arc given with 95% confidence intervals. 
Likewise the biochemical values arc presented as means with 95 % confidence intervals 
in the different patient groups and the reference group. (table 6) 
In the subsequent step, Fisher's linear discriminant analysis for independent samples 
was lIsed to identify psychological and biochemical variables \"hich were relevant in 
contributing towards distinguishing the patient group from the reference group. Signifi-
cant discriminant functions at 0,05 level only were maintained in the mode1. For testing 
Xl was used. In addition the correlations of the individual predictive variables and the 
linear discriminant function were presented. After discriminant analysis, to test for stability, 
a cross-validation was performed on a changing one-fifth of the cases. The results were 
presented in the form of 'pooled' results of the classifications of the 5 cross-validations. 
As a measure of performance of the analysis the percentage correctly classified was 
calculated. 
6.3 Results 
The mean and the 95% confidence interval of the raw scores of DMI, DCL and 
SCL-90 of the reference group and the patient group as a total at baseline are shown in 
Table 4 (sec appendix). 
In Table 5 the transformed scores as 95% confidence intervals of SCL-90, UeL and 
DMI in the patient group and in the reference group are shown. 
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Table 5. Baseline values in patients and reference 
(T scores compared with normgroupes) 
Reference Patients 
(11=54) (11=74) 
mean CP mean CP 
SCL subseale 
-----
ANX 46.2 44.9; 47.5 89.4 84.6; 94.2 
AGO 46.3 44.9; 46.9 94.2 85.7; 102.7 
DEP 47.3 45.8; 48.9 94.5 88.9; 100.1 
SOM 45.9 44.7; 47.1 73.3 69.6; 77.1 
IN 46.1 44.7; 47.5 77.2 73.1; 81.2 
SEN 47.3 45.3; 48.3 72.6 67.7; 77.7 
HOS 47.1 45.9; 48.3 64.0 59.6; 68.4 
SLA 46.2 45.0; 47.6 71.2 67.4; 75.0 
NEU 46.0 44.5; 47.6 91.7 86.5; 96.8 
UCL subsea Ie 
-----
A 49.0 46.4; 51.7 39.5 37.1; 41.8 
P 54.4 51.4; 57.2 56.9 54.4; 59.3 
V 47.8 46.2; 49.5 60.6 57.8; 63.4 
UCL-S 59.0 56.0; 62.0 55.3 52.0; 58.5 
D 48.0 46.0; 50.1 78.9 69.9; 75.9 
E 51.0 48.7; 53.4 48.0 44.7; 51.4 
G 49.8 47.1; 52.4 48.9 46.8; 51.0 
DMI subseale 
-----
TAO 54.5 51.8; 57.1 48.9 46.3; 51.5 
PRO 52.7 50.3; 55.1 52.1 49.8; 54.3 
INT 53.4 50.9; 55.8 46.3 43.9; 48.7 
TAS 42.8 39.8; 45.8 56.0 53.1; 59.0 
REV 46.2 44.1; 48.4 48.1 45.6; 50.5 
I) CI:::: 95% confidence interval of the mean 
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The scores in the reference group appeared to be lower than those in the patient group 
on all scales of SCL-90. In Figure 1, a graphic presentation of the transformed scores of 
SCL-90 in the patient group as a whole and those in the reference group is given. 
This was done separately for men and women. 
Figure 1. Transformed baseline values in the patientgroup and the referencegroup 
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There were differences between the scores in men and women, whereby the women 
had higher scores on all sub-scales of the SCL-90 with the exception of inadequacy to 
think and act (IN) and hostility (HOS). 
The differences between the genders were the highest on the scales: anxiety (ANX), 
agoraphobia (AGO), depression (DEP) and the total score psycho-neuroticism (NEU). 
In Table 5, it can also be seen that the mean and 95% confidence interval of VeL 
scores in the patient group were higher than those ill the reference group on the fonowing 
scales: avoidance (UCL-V) and depressive reaction pattern (UCL-D). 
In comparison with the standard group, the patient group had an increased tendency 
towards palliative coping (UeL-p), The patients had lower scores on active problem 
solving (DeL-A) as compared with the standard group and the reference group, 
A graphic presentation of the transformed veL scores in the patient group and the 
reference group as compared with the standard group is given in Figure 2, It is clear from 
this Figure that there were no important differences between the DeL scores of men and 
women in the patient group and the man and women in the reference group, 
Figure 2, Transformed baseline values in the patientgroup and the referencegroup 
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In the VeL, the reference group had a similar score profile to that in the standard 
group with the exception of a higher score on the sub-scale secking social support 
(UCL-S), 
Table 5 shows the results of the patient group as a whole and the reference group on 
the DMI. The patient group scored higher on turning aggression against self (TAS) and 
lower on turning aggression against others (TAO) and intellectualization (INT) than the 
reference group. 
A graphic subdivision of the DMI scores for both men and women and the scores of 
the reference group are presented in Figure 3, 
Figure 3. Transformed baseline values in the patientgroup and the referencegroup 
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Males scored higher on turning aggression against self than \vomen. Gender had no 
other important influence on the D.MI scores, The scores in the reference group were not 
different from those in the standard group with the exception of turning aggression against 
self (TAS) which was lower in the reference group, 
The biochemical values in the reference group, in the medication free patient group 
and in the patient group as a whole at baseline are given in Table 6. 
Table 6. Baseline biochemical "alues in patients and l'efel'ence 
Reference Medication Patients All 
free with patients 
patients medication 
(n~27) (n~30) (n~36) (n~66) 
Ser l ) in mean 14.2 15.5 7.6 11.2 
plasma Ci" 7.8; 20.7 10.4 ; 20.6 5.1; 10.1 8.4 ; 14.0 
(10.9 molll) 
Serin mean 3.6 3.5 1.1 2.9 
platelets Cl 3.2; 4.0 3.1; 4.0 0.2; 2.0 2.4; 3.4 
(l0·9moll 
IOE' pi) 
Ser in blood mean 957.7 K20.5 131.4 547.7 
(10-9 molll) Cl 815.9; 1099.6 682.4; 958.6 26.3; 236.5 414.2; 681.2 
Norhannan mean 0.45 0.49 0.53 0.51 
(10-12 molll) Cl 0.37; 0.53 0.31; 0.59 0.40; 0.65 0.42; 0.60 
Tyrosin mean 67.1 63.9 60.4 61.9 
(10-6 molll) Cl 59.0; 75.3 55.4; 72.4 55.9; 64.9 57.5; 66.3 
Tyrosin ratio mean 11.4 10.7 11.3 11.0 
CI 10.3; 12.4 9.99; 11.5 10.6; 12.0 10.4; 11.6 
Tryptophan mean 52.8 49.9 41.9 45.3 
(10-6 molll) CI 48.5; 57.0 45.6; 54.2 39.1; 44.7 42.7; 47.9 
Tryptophan mean 8.9 8.6 7.5 8.0 
ratio CI 8.2; 9.6 7.8; 9.5 7.1; 7.9 7.5; 8.5 
I} Serotonin 
2) CI:::: 95% confidence interval of the mean, 
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There were no differences between the reference group and the patient group not on 
medication. The baseline levels of serotonin in the thrombocytes, plasma and in the blood 
of the clomipramine treated patients were lower than in the patients not on medication. 
The same was also true for the tryptophan levels in this group. The differences in the 
biochemical values between the patient groups with and without medication will be 
discussed in more details in chapter 10. It was investigated with discriminant analysis 
whether it was possible to distinguish between the patient group and the reference group 
on the basis of psychological and biochemical variables. The difference was adjusted for 
age and gender. 
A discriminant analysis was than performed on the SCL-90, UCL and DM! in the 
patient group and the reference group (Table 7). 
Table 7. Discriminant analyses on psychological variables at baseline; 
patients versus reference 
Canonical corr, 
0.86 
X2 
159.20 
DF 
7 
P 
0.0001 
Correlation between psychological variables and discriminant score: 
SCL-ANX 0.77 
SCL-NEU 0.75 
SCL-DEP 0.72 
SCL-IN 0.66 
UCL-D 0.65 
SCL-SLA 0.60 
SCL-SOM 0.54 
SCL-SEN 0.49 
SCL-AGO 0.40 
Cases correctly classified: 94% 
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The sensitivity, the specificity, the true positive predictivc value and the true negative 
predictive value of the discriminant analyses arc given in Table 8. 
Table 8. 
Subseale 
SCLANX 
SCLAGO 
SCLDEP 
SCLSOM 
SCLIN 
SCLSEN 
SCLHOS 
SCLSLA 
SCLNEU 
UCL-A 
UCL-P 
UCL-V 
UCL-S 
UCL-D 
UCL-E 
UCL-G 
DMITAO 
DMIPRO 
DMIINT 
DMITAS 
DMIREV 
PatientgrOUIJ compared with l'cfcl'cncegroup at baseline. 
Prediction based on discriminant analyses 
c.c.* sens l spec2 true pOS3 
(%) (%) (%) (%) 
85.9 98.2 77.0 75.7 
78.1 100.0 62.2 65.9 
88.3 98.2 81.1 79.1 
86.7 100.0 77.0 76.1 
87.5 100.0 78.4 77.2 
75.0 92.6 62.2 64.1 
76.6 94.4 63.5 65.4 
81.3 94.4 71.6 70.8 
89.8 98.2 83.8 81.5 
68.8 63.0 73.0 63.0 
53.9 66.7 51.4 46.3 
74.2 90.7 62.2 63.6 
57.0 46.3 64.9 49.0 
84.4 92.6 78.4 75.8 
59.4 44.4 70.3 52.2 
51.6 46.3 55.4 43.1 
59.2 65.4 55.4 50.8 
52.4 59.6 47.3 44.3 
63.5 65.4 62.2 54.8 
72.2 75.0 70.3 63.9 
54.0 51.9 55.4 45.9 
* c.c.~ Correctly Classified (%) 
1 sensitivity 
2 specificity 
3 True positive predictability 
4 True negative predictability 
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true neg4 
(%) 
98.3 
100.0 
98.4 
100.0 
100.0 
92.0 
94.0 
94.6 
98.4 
73.0 
62.3 
90.2 
62.3 
93.6 
63.4 
58.6 
69.5 
62.5 
71.9 
80.0 
62.1 
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Positive predicted value means these proportion of patients with positive results or 
tests, negative predictive value gives the predictive value of a negative test or post-test 
likelihood of no disease. Sensitivity indicates the percentage of patients with true positive 
test results, specificity the percentage of patients with true negative test results [Sackett. 
1983]. 
It appeared that it was possible to establish a valid distinction between the patient 
group and the reference group on the basis of psychological variables. A correct 
classification was obtained in 94% of the cases. 
The best predictors for the patient group or the reference group were not only the 
SCL-90 sub-scales, but also the coping scales Avoidance (UCL-V), Depressive reactions 
(UCL-D) and the defense scale Turning Against Self (DMI-TAS) result in a higher than 
70% hit. 
The discriminant analysis of the biochemical parameters in the reference group and 
the those at baseline in the patient group not on medication showed that the plasma 
tyrosine ratio in the patient group was lower than in the reference group. 
A conect distinction between the patients and the reference group was possible on the 
basis of the biochemical variables in 68% of the cases (Table 9). 
Table 9. Discriminant analyses on biochemical data at baseline; 
patients versus reference group 
Canonical COlT. 
0040 
X' 
9.26 
DF 
3 
P 
0.05 
Correlation between biochemical variables and discriminant score: 
Tyrosine ratio 
Tryptophane ratio 
Norharman 
Plasma serotonin 
Tyrosine 
Thrombocyt serotonin 
Tryptophane 
-.031 
-0.21 
0.16 
-0.11 
-0.04 
-0.03 
-0.01 
Cases correctly classified: 68% 
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The results of discriminant analyses after cross validation show that as far as the 
distinction between the patient population as a whole and the reference group on the 
basis of psychological parameters (SCL-90, VCL and OM!) was concerned, the model 
obtained via the discriminant analysis appeared to be stable - a correct classifIcation in 
75% of the cases: 
Discriminant analyses after cross validation on psychological values in the patient 
group and references at baseline: 
Sample' Psycho!. variables 
( n. correctly classified) 
n=27 
3 n=24 
5 n=24 
(23) 
(23) 
(19) 
Total cOlTectly classified 
111 (75%) 
2 0=25 
4 0=24 
(23) 
(23) 
I Cross-validation was performed on a changing one-t1fth of the cases 
The model on the basis of biochemical parameters was not robust - there was a drop in 
correct classification of 26% from the cases after cross-validation. 
Discriminant analyses after cross validation on biochemical values in the patient group 
versus the reference group at baseline: 
Sample' Biochem. variables 
(0. correctly classified) 
I n=lO 
3 n=13 
5 n=13 
(5) 
(5) 
(7) 
Total correctly classified: 
28 (50 %) 
2 n=ll 
4 n= 9 
(4) 
(7) 
I Cross-validation was performed on a changing onc-fifth of the cases 
84 
Chapter 6 
6.4 Discussion 
As compared with the standard group of psychiatric out-patients l Arrindell & Ettema, 
1986], the patient population investigated by us had SCL·90 scores ranging from higher 
than average to high as far as men were concerned and average as far as the women were 
concerned. 
On the basis of this findings, it can be established that in the group of patients 
investigated, one could speak of an average to severe psychiatric symptomatology as 
compared with other psychiatric ollt-patients. 
The reference group recruited by us from the hospital staff appeared to have less 
complaints on the SCL-90 than the standard group recruited from the Dutch population 
(Figure 1), This could have been due to the fact that the reference group consisted of a 
selection of working individuals, all hospital staff members and comparatively young 
(see also chapter 5), 
The complaints in the patient group were higher than those in the standard group and 
in the reference group on each SCL-90 sub-scale. 
The scores of the VeL showed that the patient group indicated a manner of coping 
which may be considered as inadequate and whereby in comparison with the reference 
group more use was made of palliation, avoidance and reaction with a depressive reaction 
pattern, whereas active problem solving was used less by the patients. Our findings agreed 
with those reported by Roy-Byrne et al [1992], who observed that patients with panic 
disorders andlor major depression reported to use coping that was less directed towards 
problem solving. 
High scores on avoidance and on depressive reaction pattern in the VCL may be inhe-
rent to the psychiatric problems of the patients. \Vhether this is hue might be derived 
from the inter-correlation between UCL and the severity of the psychiatric complaints 
(see chapter 8) and from the possible changes in coping strategies after adequate treatment 
(see chapter 12), 
On the DMI the patient group distinguished itself clearly from the reference group 
and the standard group in defense organization, whereby patients made frequenter use of 
more non-adult defense mechanisms: 
Projection and turning against self, but less use was made of the defense mechanisms 
intellectualization and turning against others (Table 4). This is in agreement with the 
findings reported by Pollack et al [1989] who investigated a group of ambulant patients 
with anxiety disorder and with those reported by Akkerman et al [1992] who investigated 
defense organization in patients suffering from major depression and with the findings of 
a previous study [Timmerman et aI, 1994]. However, in the studies by Pollack et al 
[1989] and Akkerman et al [1992] appropriate control groups were not investigated (see 
also chapter 3), In contrast with our study Andrews etal [1989] did not observed differences 
in the psychological defense organization of patients with panic disorder compared with 
a reference group. 
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Margo et aI, [1993J in her study in depressed patients using the DMI observed that 
women with depression were more likely to use externalizing defenses and depressed 
men were more likely to use internalizing defenses than their respective nondcpressed 
comparison groups for example: men had a higher tendency towards turning against self 
than the standard group in the studies reported by GIeser & Ihilevich [1986J. Margo et 
aI, r 1993] reported that the use of optimistic defense such as reversal and intellectualization 
were more frequent used in controls. Both defense mechanisms have a purpose in 
suppressing negative feelings and in creating a feeling of well-being. In our study, similar 
to Margo et aI, [1993], we also observed that men showed more lise of turning agression 
against self and less use of intel1ectualization than in the standard group. Women used 
projection more, but the use of turning agression against others by women and reversal 
by men and women was similar to that in the standard groups. 
The discriminant analysis showed that a large number of psychological factors 
contribute in distinguishing reference group from patient group. 
The highest sensitivity and specifIcity for the distinction between reference group and 
patients was observed in the SCL-90 scales. Severity of the symptomatology provided 
thus a better distinction between the two groups than differences in defense organization 
or coping strategy. Nevertheless one of our central questions: Patients with panic dis-
order andlor depression have a deviant defense organization and lise of coping strategies 
compared with a reference group was confirmed in our investigations. 
Biocllemicaimeaslires 
We found differences between tyrosine-, and tryptophan ratio of patients with panic 
disorder and/or depression and this ratio's in the reference group with lower values in the 
patient group. This is in line with the supposed function of the aminoacids ti),ptophan 
and tyrosine: Tyrosine is the precursor of (nor)adrenaline & dopamine and tryptophan is 
the precursor of serotonin. Besides the neurotransmitters noradrenaline and dopamine, 
serotonin probably also plays an important role in the etiology of depression [Green & 
Costain, 1981]. There is competition between the precursors of the neurotransmitters 
and other large amino acids for transport through the bloodlbrain barrier (see for more 
details: chapter 3). 
The distinction between the patient group and the reference group was less prominent 
on basis of biochemical parameters than 011 basis of psychological t~\ctors, especially 
after cross validation. However sixty eight percent of the patients could still be correctly 
classified on basis of the biochemical parameters (Table 9). The unstable results with 
discriminant analyses after cross validation on the biochemical variables were possibly 
caused by the small size of the medication free patient group. 
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In this distinction besides the tyrosine ratio (the ratio between tyrosine and other amino 
acids in plasma which compete for transport to the brain) the tryptophan ratio was im-
portant. This agrees with our biochemical hypotheses presented in the introduction chapter 
3 that the aminoacids tyrosine and tryptophan may playa role in the development of 
panic disorder and depression. There were no differences in the levels of norharman and 
serotonin in the plasma. thrombocytes and blood in the patient group and the reference 
group. This is similar to our findings in a pilot study in patients with panic disorder 
[Timmerman et ai, 1994]. 
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Table 4. 
DMlTAO 
DMIPRO 
DMIINT 
DMITAS 
DMIREV 
DMIREP 
UCL-A 
UCL-P 
UCL-V 
UCL-S 
UCL-D 
UCL-E 
Psychological variables in patients and referencegl'onp at baseline, 
6 and 9 months 
Baseline 6 months 9 months 
Refcrcncegroup Patients Patients Patients 
(11=54) (11=74) (11=51) (11=26) 
mean 39.6 34.2 35.2 38.0 
Cll) 37.0; 42.2 31.8; 36.6 32.4; 38.0 33.4; 42.6 
mean 38.9 38.5 37.7 37.7 
CI 37.1; 40.7 36.9; 40.1 35.7; 39.7 35.3; 40.1 
mean 48.7 44.0 45.7 45.3 
CI 47.1; 50.3 42.4; 45.6 43.7; 47.7 43.1; 47.5 
mean 35.1 43.6 39.7 36.5 
CI 33.1; 37.1 41.6; 45.6 37.7; 41.7 33.3; 39.7 
mean 37.8 39.7 41.7 42.4 
CI 35.8; 39.8 37.5; 41.9 38.9; 44.5 38.4; 46.4 
mean 8.0 11.0 14.5 12.0 
CI 1.4; 14.6 4.6; 17.4 6.5; 22.5 0.6; 23.4 
mean 18.1 14.6 14.9 16.0 
Cl 17.1; 19.1 13.8; 15.4 14.1; 15.7 14.6; 17.4 
mean 17.0 17.8 17.4 17.8 
CI 15.8; 18.2 16.8; 18.8 16.4; 18.4 16.4; 19.2 
mean 14.0 18.2 16.8 15.6 
CI 13.4; 14.6 17.2; 19.2 15.8; 17.8 14.0; 17.2 
mean 13.8 12.5 11.7 12.2 
CI 12,8; 14.8 11.5; 13.5 10.9; 12.5 11.0; 13.4 
mean 9.9 17.2 13.5 12.4 
CI 9.3; 10.5 16.2; 18.2 12.5; 14.5 11.2; 13.6 
mean 6.4 5.8 5.7 5.8 
CI 6.0; 6.8 5.2; 6.4 5.1; 6.3 5.2; 6.4 
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UCL-G 
SCLANX 
SCLAGO 
SCLDEP 
SCLSOM 
SCLIN 
SCLSEN 
SCLHOS 
SCLSLA 
SCLRES 
SCLNEU 
SCLPAN 
Appendix Chapter 6 
Psychological variables in patients and referencegl'oup at baseline, 
6 and 9 months (continued) 
Baseline 6 months 9 months 
Refercnccgroup Patients Patients Patients 
(n=54) (n=74) (n=51) (n=26) 
mean 11.6 11.2 11.7 12.1 
CI 10.8; 12.4 10.6; 11.8 10.9; 12.5 11.1; 13.1 
mean 11.3 30.0 19.3 15.5 
CI 10.7; 11.9 27.8; 32.2 17.3; 21.3 13.3; 17.7 
mean 7.1 17.2 10.9 9.4 
CI 6.1; 8.1 15.4; 19.0 9.5; 12.3 8.2; 10.6 
mean 18.9 48.7 30.6 26.8 
CI 17.7; 20.1 45.1; 52.3 30.2; 31.0 22.4; 31.2 
mean 14.1 29.9 21.0 18.6 
CI 13.3; 14.9 27.7; 32.1 18.8; 23.2 15.2; 22.0 
mean 11.2 25.7 18.9 16.2 
CI 10.6; 11.8 23.7; 27.7 16.9; 20.9 13.4; 19.0 
mean 22.8 40.0 29.6 26.5 
CI 21.4; 24.2 36.6; 43.4 26.0; 33.2 23.3; 29.7 
mean 6.8 11.0 8.5 8.7 
CI 6.4; 7.2 9.8; 12.2 7.5; 9.5 7.5; 9.9 
mean 3.6 9.7 5.5 5.0 
CI 3.2;4.0 8.7; 10.7 4.7; 6.3 4.3; 5.8 
mean 10.1 18.8 14.7 12.5 
CI 9.7; 10.5 17.2; 20.4 13.1; 16.3 10.7; 14.3 
mean 105.9 230.9 158.8 139.2 
CI 101.3; 110.5 216.7; 245.1 143.6; 174.0 12.1; 157.4 
mean 10.9 25.7 17.4 14.6 
CI 10.1; 11.7 23.9; 27.5 16.0; 18.8 12.6; 16.6 
" CI = 95% Confidence interval 89 
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CHAPTER 7. DISTINCTION BETWEEN THE PATIENT GROUPS 
WITH PANIC DISORDER AND/OR DEPRESSION ON 
PSYCHOLOGICAL AND BIOCHEMICAL VARIABLES 
7.1 Introduction 
In the study described in this chapter, the extent to which the three patient groups with 
panic disorder, depression and pank: disorder & depression could he distinguished fro111 
each other on the basis of psychological and biochemical parameters \vas investigated. 
The central question in this chapter was whether onc could speak of a unitary etiology 
in panic disorder and major depres-sion which lies in a single basic biological affliction, 
If this was the case, then it could be expected that patients with major depression and/or 
panic disorder could be distinguished from each other on the basis of symptomatology 
and possibly on the basis of defense organization and coping, but not on differences in 
biological parameters, Firstly, it was investigated whether it was possible to distinguish 
between patient groups with depression and panic disorder on the basis of characteristic 
symptomatology of panic attacks using the "panic score" that was designed by us on the 
hasis of SCL-90 items. This was done since the SCL-90 was developed in the 1970s, an 
era in which the concept of panic disorder was not yet clearly dcscribed and frequently 
went masked under the hyperventilation syndrome, Therefore the SCL-90 lacked a 
subscale for the measurement of panic disorder. The panic score of the SCL-90 (PAN) 
designed by llS consisted of the in table 10 mentioned items which arc identical to 10 of 
the 13 symptoms of a punic attack according to the DSM TII-R [Timmerman ct aI, 1995~J, 
Tahle 10. 
Items: 004 
012 
017 
039 
040 
048 
049 
059 
072 
086 
Items of the SCL-90 for the DSM [[I-R diagnosis panic disorder 
Dizziness 
Pain in chest/heart region 
Trembling 
Palpitations 
Nausea or stomach distress 
Shortness of breath 
\Vann!cold flushes 
Thought of death or dying 
Attacks of anxiety or panic 
Thoughts/images of anxicty nature 
The next step was a comparison on symptoms, defense organisation, and coping strategy 
between the three different patient groups with panic disorder, depression and panic dis-
order & depression. The last step is a comparison of the biochemical profiles between 
the three patient groups. 
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7.2 Statistical analysis 
The transformation to the standard group was conducted as described in chapter 6. 
The scores of SCL-90, VeL and DMI in the three palient groups are given as mean and 
the 95% contldence interval of the mean in Tables 11,12 and 13 and graphically in Figures 
4,5, and 6. 
The internal consistency as a measure of reliability of the panic scale designed was 
estimated with Cronbach standardized alpha. Subsequently it was examined whether the 
separate items could distinguish between patients with panic disorder and those with 
depression (diagnosis according to the DSM III-R criteria and NIDCL). [Timmerman et 
ai, 19953]. 
Using the fishers' l11utiple linear discriminant analysis, with corrections for age 
and gender. the extent to which the three patient groups 1ll1ltllal1y differed from each 
other on suh-scales of the SCL, UeL and DMI together and 011 the biochemical variables 
were investigated. The following step was a cross validation of the discriminant analysis 
to see how rohust our model is. This method of statistical analysis was described in 
chapter 6. 
7.3 Results 
Psychopathology; 
The T-scores of the sub-scales of the SCL-90 of the reference -group, patients with 
panic disorder, patients with depression and patients with panic disorder & depression 
are shO\vn in table 11. Mean and 95% confidence intervals of the mean in these groups 
transformed to the standard group orthe sub--scores and total score (NEU) orthe SCL-
90 are mentioned in this table. 
Table 11. 
SCL-
subs 
ANX 
AGO 
DEP 
Baseline values on the SCL-901) ill three patientgrollps and in 
rcfcl'cnccgronp 
Dep & pan Depression Panic Reference 
mean 95% meaa 95% mean 95% mean 95% 
CI') CI CI CI 
101.0 92.7 86.S 79.9 88.6 79.9 46.2 44.9 
10.4 93.3 97.3 47.5 
109.5 86.5 83.4 72.3 102.6 88.5 46.3 45.8 
132.4 94.5 116.7 46.9 
106.4 93.4 100.0 93.1 82.3 72.6 47.3 45.7 
119.3 106.9 92.0 48.9 
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Table 11. Baseline values on the SCL~901) in three patientgronps and in 
referencegrOll(l (continued) 
Dep & pan Depression Panic Reference 
SOM 81.5 70.9 72.5 
92.1 
IN 81.6 72.8 81.4 
90.5 
SEN 71.8 57.3 76.2 
86.3 
HOS 61.8 53.8 65.7 
69.8 
SLA 82.7 77.2 72.1 
88.3 
NEU 100.6 88.3 93.7 
112.7 
I) T-scores compared with normgroup; 
2) CI:::: 95% Confidence interval 
67.3 71.1 65.0 45.9 44.7 
77.7 77.2 47.1 
75.6 69.6 63.2 46.1 44.7 
87.3 76.1 47.4 
68.9 68.2 60.5 47.3 45.3 
83.6 75.9 49.3 
58.8 62.5 55.1 47.1 45.9 
72.5 69.9 48.3 
66.5 65.2 59.3 46.3 45.0 
77.8 71.2 47.6 
86.5 85.4 76.8 46.0 44.5 
100.8 94.0 47.6 
The scores of all sub-scales of SCL-90 in all the three patient groups were significantly 
higher than those in the reference group, whereby the group of patients with co-morbid 
major depression and panic disorder achieved the highest total score in the SCL-90 
followed by the group of patients with major depression. 
Figure 4. Transformed baseline values in the patientgroup and the referencegroup 
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The profile of the scores of the SCL-90 in all the three patient groups was highly 
similar (Figure 4) with the s<.;ores of agoraphobia in the group of patients with depression 
being lower than those in the other two patient groups, The scores of depression were 
higher than those in the patient group with panic disorder. 
In an explorative study the total score of the designed panic scale expressed as the slim 
of the scores of the different items provided a significant distinction between patients 
with depression and those with panic disorder (P<O.05). The results are given in more 
detail elsewere [Timmerman et aI, I 995-T The items 12 (pain in chest/heart region), item 
48 (shortness of breath) and item 72 (anxiety or panic attacks) significantly distinguished 
between patients with panic disorder and those with depression, 
Copil/g: 
The scores of the sub-scales of the UCL are shown in Table 12, 
Table 12. Baseline values on the UCLI) in three different patientgl'oupS 
and in referencegroup 
Dep & pan Depression Panic Reference 
UCL- mean 95% mean 
subs CF) 
UCL-A 35.8 31.4 40.1 
40.3 
UCL-P 57.9 52.9 56.7 
62.9 
UCL-V 61.1 54.5 60.9 
67.6 
UCL-S 51.1 46.0 52.6 
56.2 
UCL-D 74.4 67.5 73.2 
81.2 
UCL-E 45.7 37.4 46.8 
54.0 
UCL-G 46.9 43.7 49.1 
50.1 
I) T-scores compared with normgroup; 
2) CI = 95% Confidence interval 
95% mean 95% mean 95% 
CI CI CI 
36.8 40.2 35.7 49.0 46.4 
43.4 44.6 51.7 
53.4 56.6 51.8 54.4 51.5 
60.1 61.4 57.2 
56.2 59.9 56.2 47.8 46.2 
65.7 63.5 49.5 
47.8 60.6 55.1 59.0 56.0 
57.4 66.1 62.0 
69.1 71.9 66.1 48.0 45.9 
77.3 77.6 50.1 
41.8 50.6 45.2 51.0 48.6 
51.9 56.0 53.4 
45.9 49.5 45.8 49.8 47.1 
52.3 53.2 52.4 
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A graphic presentation of the results of the veL in the three patient groups as compared 
with the standard group is depicted in Figure 5. 
Figure 5. Transformed baseline values in the three patientgroup and the referencegroup 
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These three groups had an almost identical profile with the exception of a higher score 
on coping strategy seeking support (UCL-S) in the patient group with panic disorder. 
Defense mechanisms: 
The psychological defense organization as determined with the Defense Mechanism 
Inventory (DMI) in patients with major depression, panic disorder and panic disorder 
with major depression are shown in Table 13. 
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Table 13. Baseline yalnes on the Dl\U') in three different patientgruups 
and in rCfCI'Cllcegronp 
Dep & pan Depression Panic Rcferencegroup 
DMI- mean 95% mean 95% mean 95% mean 95% 
subs CI') CI CI CI 
TAO 46.9 41.6 48.1 45.0 50.8 45.5 54.5 51.8 
52.2 51.3 56.1 57.1 
PRO 50.0 44.2 51.9 49.1 53.2 48.8 52.7 50.3 
55.8 54.7 57.5 55.1 
INT 48.1 44.5 47.3 43.8 44.2 39.9 53.4 50.9 
51.6 50.8 48.5 55.8 
TAS 59.8 51.0 55.9 52.2 54.6 49.2 42.8 39.8 
68.6 59.7 60.0 45.8 
REV 47.6 42.4 48.7 45.3 47.5 42.S 46.2 44.1 
52.7 52.0 52.2 48.4 
I) T-scores compared with Ilormgroup 2) CI = 95% Confidence interval 
A graphic presentation of the results of the OMI in the three patient groups is depicted 
in Figure 6. The three patient groups had a very similar profile. 
Figure 6. Transformed baseline values in the patientgroup and the referencegroup 
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The high scores of the patients on the defense mechanisms turning against self (TAS) 
and the low scores of itellectua-lization (INT) were noticeable. Patients with depression 
had a )mver tendency towards turning agression to ohers (TAO) than those in the standard 
and reference group. 
The SCL-90 scores in the three patient groups transformed to the reference group are 
shown in Figure 7. 
Figure 7. Transformed baseline values in the three patientgroups *) 
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The transformed DeL and DJ\.lI scores of the three patient groups are shown in 
Figure 8. An almost identical pattern in the three patient groups was once again obvious. 
Figure 8. Transformed baseline values in the three patientgroup and the referencegroup 
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The extent to which the three patient groups differed [rom each other in the sub-scales 
of the SCL-90, UCL and DMI individually and together was investigated using multiple 
linear discriminant analysis (see table 14). 
Table 14. Discriminant analysis on psychological variables at baseline; three 
patient groups compared 
Canonical COlT. 
0.68 
X2 
49.20 
DF 
12 
P 
0.05 
Correlation between psychological variables and discriminant score 
SCL-DEP 0.39 DMI-REV -0.33 
SCL-AGO -0.27 SCL-RES 0.27 
UCL-D 0.23 UCL-V 0.22 
m'Il-PRO 0.20 SCL-HOS 0.20 
SCL-IN 0.20 UCL-E 0.19 
DMI-REP -0.18 SCL-SEN 0.18 
SCL-NEU 0.18 DMI-TAS 0.15 
SCL-ANG -0.49 
Cases correctly classified: 68% 
In Table 15 a classification scheme based on the discriminant analysis is presented. In 
this scheme, percentage correctly classified, sensitivity and true predictive value in the 
three patient groups on the basis of psychological variables are shown. 
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Table 15. Discriminant analysis on SCL-90, UCL and DMI in the three 
patientgronps at baseline 
Scales %Hit % Sensitivity % True positive 
predictive value 
Subs. DplJ D" pJ) DP D P 
SCLANX 36.5 63.6 52.8 3.7 21.9 54.3 14.3 
SCLAGO 50.0 54.6 72.2 18.5 22.2 63.4 83.3 
SCLDEP 43.2 63.6 22.2 63.0 24.1 50.0 58.6 
SCLSOM 33.8 45.5 8.3 63.0 17.Y 60.0 41.5 
SCLIN 35.1 54.6 11.1 59.3 19.4 40.0 48.5 
SCLSEN 47.3 0 50.0 63.0 0 54.6 46.0 
SCLHOS 32.4 63.6 36.1 14.8 14.9 59.1 80.0 
SCLSLA 33.8 54.6 13.9 51.9 24.0 29.4 43.8 
SCLNEU 32.4 54.6 8.3 55.6 18.8 37.5 44.1 
UCL-A 27.0 63.6 0 48.2 18.0 0 37.1 
UCL-P 27.0 63.6 0 48.2 18.4 0 36.1 
UCL-V 29.7 54.6 0 59.3 17.7 0 40.0 
UCL-S 324 45.5 8.3 59.3 15.6 30.0 50.0 
UCL-D 28.4 54.6 0 55.6 26.7 0 39.5 
UCL-E 27.0 63.6 0 48.2 17.5 0 38.2 
UCL-G 28.4 72.7 0 48.2 19.5 0 39.4 
DMITAO 28.4 45.5 5.6 51.9 15.2 50.0 37.8 
DMIPRO 33.8 54.6 11.1 55.6 20.7 66.7 38.5 
DMIINT 31.1 72.7 5.6 48.2 21.6 40.0 40.6 
DMITAS 41.9 45.5 27.8 59.3 20.8 62.5 47.1 
DMIREV 46.0 0 52.8 55.6 0 50.0 41.7 
1) DP: Depression & Panic 2) D: Depression .'J P: Panic 
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In 68% of the cases, it was possible to correctly predict the group to which the patient 
belonged to on the basis of psycho-logical variables. For the distinction, the scores of the 
SCL-90 sub-scales depression. agoraphobia. anxiety and sensitivity made significant 
contributions. The model provided by discriminant analyses provided to be moderately 
stable after cross validation: Discriminant analyses ajter CIVSS validatiof/ on psychological 
values in the three patientgroups at baseline 
Sample1 Psycho!. variables 
(n. correctly classified) 
I 11=17 (8) 2 11=15 (6) 
3 11=15 (7) 4 n=14 (6) 
5 n=14 (7) 
Total correctly classified 34 (46 %) 
1 Cross-validation was performed on a changing one-fifth of the cases 
In Table 16, the raw biochemical values at baseline in the three patient groups who 
were not on medication are given as mcan and 95% confidence interval. No differences 
between these three groups \vere obscrved except for a Imv norharman concentration in 
patients with panic disorder and a higher tyrosin concentration in the depressed patients. 
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Table 16. Baseline biochemical yalnes iUllledicationfree patient groups 
Depression & Panic Depression 
Panic 
(n=15) (n=1I) (n=5) 
Patientgroup mean 95% CI mean 95% CI mean 95%CI 
5HT' (hrombo's 3.56 2.74 3.36 0.74 3.61 1.09 
4.38 5.98 5.13 
Norharman 0.55 0 0.30 0 0.59 0 
1.61 0.84 1.41 
Tryptophane 44.40 33.12 49.64 28.22 52.00 22.44 
55.68 71.06 81.56 
Tryptophane ratio 9.48 4.04 9.39 4.09 7.74 3.76 
14.92 14.69 11.72 
Tyrosin 54.80 6.92 56.18 31.38 73.21 22.45 
102.62 92.74 123.97 
Tyrosin ratio 10.94 6.54 10.08 6.40 1l.l0 4.48 
15.34 13.86 17.72 
51-IT blood 900.72 329.19 896.71 151.23 748.27 0 
1472.15 1615.19 1571.87 
I 5HT::::: serotOl1ll1 
For the discriminant analysis of the biochemical parameters, only the values obtained 
using blood samples from patients (N:::::31) who were not on medication at cntry into the 
study were used. 
103 
The values of the different biochemical parameters who contributed significantly after 
discriminant analysis between the three patient groups are given in Table 17. 
Table 17. Discriminant analysis at basclinc: three patient groups compared 011 
biochemical variables 
Canonical COlT. 
0.64 
X, 
15.70 
DF 
6 
P 
0.02 
Correlation between biochemical factors and tliscriminantscore 
Norharman 
Tryptophan ratio 
Tryptophan 
0.45 
·0.32 
·0.1 K 
Cases correctly classified: 62% 
The levels of norharman distinguished the three patient groups from each other. In 
patients with panic disorder, the level of norharmun was lower than that in the other two 
patient groups. 
A correct classification in one of the three patient groups was possiblc in 62% of the 
cases on the basis of biochemical variables. Besides norhannan, the tryptophan ratio anti 
tryptophan also contributed in tlistinguishing between the three patient groups. 
Cross-validation of biochemical parameters provided a correct classification in 30% 
of the patients: 
Discriminant analyses aftcr cross validation on biochemical values in three patientgroups 
at baseline: 
Sample l Biochemical variables (n. correctly classified) 
n~6 
3 n~7 
5 n~8 
(3) 
(2) 
(I) 
2 n~6 
4 n~6 
(3) 
(I) 
Total correctly classified 10 (30 %) 
l Cross-validation was performed on a changing one-fifth of the cases 
The limited stability derived after cross-validation was probably caused by the small 
size of the groups. 
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7.4 Discussion 
In previous research we found that the patient groups with depression and panic dis-
order \vere clearly distinguished from each other at the level of symptoms lIsing the 
panic scale lhal was designed by us on the basis of SCL-90 items and with the SCL-90 
scales: anxiety (ANG), agoraphobia (AGO), and depression (DEP) [Timmerman et 
aI, 19953J. However, it was not possible to distinguish clearly between the three patient 
groups on the basis of defense organization or indicated use of coping strategy. Defense 
organization and coping strategy appeared not to be correlated with the three Jifferent 
types of psychiatric disorder, 
However, as was expected on the basis of the literature, patients with depression had a 
higher tendency to turn aggression to self than patients with panic disorder as measured 
with the DMI Turning Agression against Self (TAS) scale Dhelevich & GIeser, 19~6; 
Margo et aI, 1993], 
Patients with co-morbid panic disorder and depression made less use of mature 
[according to the classification by Vaillant, 1988] defense mechanisms such as Reversal 
(REV, Intellectualizalion (INT) and tcnded less towards active problem solving 
(UCL-A), 
Similar to that observed in our study. Roy-Byrne ct al [1992] also reported that there 
were no differences in the indicated use of coping strategy between patients with panic 
disorder and depression. 
However, Hoffart & .Martinsen [1993], in their investigation in 95 patients with 
depression, depression and agoraphobia and with agoraphobia only observed that patients 
with only agoraphobia and depression-. and with agoraphobia sought less social support 
and tended more towards wishful thinking than patients suffering from depression. These 
authors suggested that agoraphobia was associated with more maladaptive coping than 
was the case in patients with depression. Agoraphobia seemed to be a more severely 
disabled subgroup of patients with panic disorder. 
The number of patients correctly classified on the basis of psychological parameters 
using discriminant analysis was 68%. A table 15 shows this percentage was negatively 
influenced by the patient group with co-morbid depression and panic disorder. A correct 
classification in this group was only possible in 36% of the cases. The significant factors 
which contributed in distinguishing the groups were symptom clusters, but not the 
differences in coping strategy or defense organization. 
In discriminant analysis on the biochemical values, the patient group with panic dis-
order distinguished itself from the other two patient groups and the reference group by a 
lower cOIH.:elltration of norharman. This differed from the findings of a previous study 
[Timmerman et ai, 19941] in which there were no differences in the levels of norharman 
in patients with panic disorder and a reference group, but does fit in well with the possible 
activity of norharman as a benzodiazepine receptor agonist [Van Geldcren et aI, 1994]. 
A decrease in this agonistic function could possibly lead to an increased anxiety. However, 
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the group of patients suffering from panic disorder without medication at baseline was 
rather small (II patients) and the level of norharman in the patient group \vith co-morbid 
panic disorder and depression did not differ from that in the reference group. Investigations 
on the levels of norharman in a larger group of patients with panic disorder would, 
therefore, also be warranted. 
We observed no significant differences between the levels of serotonin in the plasma 
and thrombocytes in patients not on medication and those in the reference group. This is 
in disagreement with the findings of Hanh Le Quan-Bui et al [1984] who observed that 
the levels of serotonin in the plasm of patients with major depression were clearly reduced 
indicating that there was a dysfunctional serotonergic system in panic disorder and ma-
jor depression. It is also in contrast with the observations in our earlier investigations 
[Timmerman et ai, 19941 L where no relationship between the levels of serotonin in 
thrombocytes and anxiety was observed. (A further discussion on the inter-dependence 
between biochemical and psychological parameters is presented in chapter II). 
Similar to the discriminant analysis of the psychological parameters, the percentage of 
correctly classified patients on the basis of biochemical parameters using discriminant 
analysis was negatively influenced by the group of patients \vith comorbid panic dis-
order and depression. Sixty two percent of the cases were correctly classified whereby 
norhannan was the most important distinguishing factor. (table 17) 
It was cOIlc/uded that the model provided by discriminant analysis in which the patient 
groups and the reference groups were distinguished from each other with the help of 
psychological and biochemical differences was stable, but possibly because of their limited 
size, the three patient groups could not be distinguished clearly from each other. 
There was a lack of specificity of different defense mechanisms and coping stnttegies 
between patients with panic disorder and major depression \vhich supported the unitary 
hypothesis of the two disorders on a psychologicalleveJ [Lapierre & Hamilton, 1993}. 
This fits with the idea that co-morbidity arises as a consequence of the lack of specificity 
of different defense mechanisms for pm1icular lypes of personality and its disorders [Maser 
& Cloninger, 1990]. 
The unity between panic disorder and depression that was observed from a 
psydlOlogical point of view was not observed from the biochemical profile: The 
biochemical data suggest that the small patient group with the diagnosis panic disorder 
have a lower norhannan plasma level than the two other patient groups. It is possible that 
biological factors determine which psychiatric disorder, panic disorder or depression 
occur. This was in agreement with recent genetic studies in which panic disorder and 
depression emerged as separate illnesses [\Veissman et ai, 1994] and with the Kraepelinian 
biomedical theory in which each psychiatric disease is believed to have specific genetic 
and neurobiological antecedents. 
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CHAPTER 8. INTERDEPENDENCE OF PSYCHOLOGICAL 
CHARACTERISTICS 
8.1 Introduction 
The inter-correlation between the coping strategies and defense mechanisms, 
opcrationalized in the sub-scales of veL and DMI, were investigated in the reference 
group and in the patient group as a whole prior to commencing therapy in order to gain 
further insight into the relationship between the psychological variables. Tn addition, it 
was also examined whether there were differences in inter-correlations hetween the patient 
group and the reference group. The inter-correlations between the bioche-mical variables 
and the psychological variables were also investigated in the reference group and the 
patient group without medication. These are discussed in chapter II. 
S.2 Statistical method 
The inter-correlations of the sub-scales of Df..11 and veL in the patient group at baseline 
and in the reference group were estimated (Pearsoll product moment correlation 
coefficient) and were adjusted for age and gender. The significant inter-correlations 
with their 95 % confidence interval between the DMI and UCL scales in the patient 
group and the reference group have been determined (p < D.OS, two tailed T-test) 
8.3 Results 
Only the substantial inter-correlalions between DMI and UCL scales in the patient 
group are shown in Table 18 (appendices) and, separately for patients and reference 
group in Table 21. n:lblc 21 presents in addition the biochemical concentrations with 
their intercorrelations of the patients who \vere medication-frce at baseline) 
Sec for Table 21 chapter II 
In the Dl\U the direction of significant association in the patient group and reference 
group were similar. Between the scales of the DM! and VeL, in the patient group, positive 
associations were observed between projection and expression of emotions. Negative 
correlations were observed between intellectualization and depressive reactions and 
expression of emotions. 
No significant correlations between veL and nMI scales were noted in the reference 
group, 
Concerning the veL we observed a positive correlation between palliation (P) and 
depressive reactions (D) in the reference group but a negative association in the patient 
group. In the patient group the correlation between avoidance (A) and social support 
seeking was also negative in contrast with the reference group. Moreover, we found a 
negative association between depressive reactions (D) and reassuring thoughts (0) in the 
patient group \vhile their associations in the reference group \vere positive. 
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In the reference group, we did not observe any negative correlations mutually betvleen 
any of the VCL scales. 
8.4 Discussion 
Schreurs [1987] investigated the inter-correlations between the VeL scales in 1200 
employees of the Dutch Railways Association. Similar to that observed in our 
investigations in the reference group, he also observed a positive correlation between 
avoidance and depressive reactions, between seeking support and depressive reactions 
and positive correlations between palliation and almost aU other veL scales. Schreurs 
[1987] also observed a positive association between expression of emotions and palliation. 
This association, although not significant, was also positive in our reference group. 
Schreurs [1987] concluded that all scales apparently contained an element for the 
avoidance of the problem and for the regulation of aroused tension. 
In contrast with the reference group, the patient group, showed negative correlations 
between reassuring thoughts and depressive reactions, and between avoidance and seeking 
support. 
It appeared from table 4 (Chapter 6) that the patients used less adequate coping 
mcchanisms such as seeking support and reassuring thoughts than those in the reference 
group. The other associations between the coping strategies in the patient group and in 
the reference group were similarly directed and there were only quantitative differences 
in the degree of association. More significant associations regarding the VeL were being 
noted within the patient group. 
As far as the DI\U \vas concerned, the findings in the reference group were very similar 
to those reported for the standard group in the literature: Passehier & Verhage [19861 
reported the same inter-correlations in their investigations in Dutch controls. 
Similar to Ihilevich & Gieser [1986], we also observed a positive correlation between 
turning aggression against others and projcction in the reference group. Further, Ihilevich 
& Gieser [1986] observed a positive correlation between reversal and intellectualization. 
Reversal and inteJiectualization also correlated positively in our reference group. 
Freud had already established that these two defense mechanisms were functionally 
linked when he described the disconnection of thoughts and feelings as a form of repression 
11962]. Since the elimination of unpleasant emotions from the consciousness is common 
in both intellectualization and revcrsal, they oftcn occur together in the same individual. 
Negative correlations were observed between turning aggression against others and 
reversal, between projection and reversal and between intellectualization and turning 
aggression against others and projection. 
These negative correlations observed in the reference group also corroborated those 
reported in the standard group by Ihilevich & GIeser [19861. 
The same positive and negative correlations between the defense mechanisms as those 
in the reference group were also observed in our patient group, whereby there were only 
quantitative differences bctwecn the reference group and the patient group. In the reference 
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group, we did observe a few significant correlations between VeL and DMI scales. 
In his investigations, Schreurs r 1987 J concluded that there was no clear relationship 
between UeL and DMI and that both scales indeed measured a different construct namely 
coping and defense. However, we observed a positive correlation between intellec-
tualization and active problem solving in the patient group. Both were considered as 
adequate intra-psychological processes for solving problems (see chapter 3). We observed 
moderate negative associations between intellectualization and depressive reactions and 
expression of emotions in the patient group. It is possible that intellectualization gives 
some protection against depressive reactions. However the confidence interval is rather 
large. 
In conc/usio1l, it call be stated that there were quantitative differences in the inter-
correlations in UeL and DMI in the reference group and the patient group, but that the 
direction of the associations in these two groups was identical. 
Concerning coping these quantitative differences in correlations between the patient 
group and the reference group involved the strategies avoidance and depressive reactions 
which were possibly correlated with the symptomatology of the psychiatric disorder. If 
these coping strategies preexist to psychiatric disease we expect them to be mainly trait 
dependent and not much change in the indicated use of these coping strategies after 
therapy is likely to occur. In chapter 9 \ve will investigate whether this is the case. 
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Table 18. Suhstantial partiali) correlations between 
psychological variables, adjusted fol' 
gender and age (N=74) 
Turning agression against others (DMITAO) 
1'2) 95% CP' 
DMIPRO .62 .46 .74 
DMIINT -.63 -.75 -.50 
DMlREV -.68 -.79 -.53 
DMlREP -.91 -.94 -.86 
SCLHOS .35 .13 .54 
SCLIN .24 .01 .44 
J) Two-tailed 
2) Pearson product -moment correlation coeftlcient 
3) Confidence Interval 
Projection (DMIPRO) 
r 95% CI 
DMITAS -.40 -.58 -.19 
DMIINT -.48 -.58 -.19 
DMlREV -.70 -.80 -.56 
DMIREP -.83 -.89 -.74 
SCLHOS .24 .01 .44 
UCL-E .40 .19 .58 
UCL-P .25 .02 .45 
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Tuble 18. Substantial partial l ) correlations between 
psychological yariablcs, adjusted for 
gender and age (N=74) (continued) 
Intellectualisation (DMIINT) 
r 95% CI 
DMIREV .38 . 17 .56 
DMIREP .72 .59 .81 
UCL-A .35 .13 .54 
UCL-D -.37 -.55 -.15 
UCL-E -.31 -.50 -.09 
SCLANX -.33 -.52 -.11 
SCLIN -.37 -.55 -.15 
SCLSEN -.35 -.54 -.13 
SCLHOS -.30 -.49 -.08 
SCLNEU -.36 -.54 -.14 
SCLDEP -.25 -.45 -.02 
Turning agression against self (DMITAS) 
r 95% CI 
DMIREP .26 .03 .46 
SCLDEP .29 .07 .49 
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Table 18. Substantial pal'tial l ) correlations between 
psychological variables, adjusted for 
gender and age (N=74) (continued) 
Reversal (DMIREV) 
r 95% Cl 
DMlREP .85 .77 .90 
SCLDEP -.25 -.45 -.02 
SCLIN -.24 -.44 -.01 
Repression (DMTREP) 
r 95% CI 
SCLIN -.28 -.48 -.06 
SCLSEN -.24 -.44 -.01 
SCLHOS -.34 -.53 -.12 
SCLNEU -.24 -.44 -.01 
Palliation (UCL-P) 
r 95% CI 
UCL-E .28 .06 .48 
UCL-G .45 .25 .62 
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Table 18. Substantial partiaJll correlations between 
psychological variables, adjusted for 
gender and age (N=74) (continued) 
Active problem solving (UCL-A) 
r 95% CI 
UCL-P .27 ,04 ,47 
UCL-V -,28 -,48 -,06 
UCL-D -,32 -,51 -,10 
UCL-G ,48 ,28 ,64 
SCLANX -.31 -,50 -,09 
SCLAGO -24 -,44 -,() I 
SCLDEP -,24 -,44 -,01 
SCLIN -,36 -,54 -,14 
SCLNEU -,25 -,45 -,02 
SCLPAN -,33 -,52 -,11 
Avoidance (UCL-V) 
r 95% CI 
UCL-D ,38 ,17 ,56 
SCLDEP ,28 ,06 ,48 
SCLNEU ,28 ,06 ,48 
SCLIN ,41 ,20 ,58 
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Table 18. Substantinl partial!) correlations between 
psychological variables. adjusted for 
gender and age (N=74) (continned) 
Seeking support (UCL-S) 
r 95% C[ 
UCL-D .36 .14 .54 
UCL-E .58 .41 .71 
SCLAGO .30 .08 .49 
Depressive reactions (UCL-D) 
r 95%CI 
UCL-E .41 .20 .58 
UCL-G -.33 -.52 -.11 
SCLANX .58 .41 .71 
SCLAGO .40 .19 .58 
SCLDEP .63 .47 .75 
SCLSOM .54 .36 .68 
SCLIN .63 .47 .75 
SCLSEN .61 .44 .74 
SCLHOS .41 .20 .58 
SCLSLA .49 .29 .65 
SCLNEU .74 .62 .83 
SCLPAN .55 .37 .69 
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Table 18. SubstallUal pm'Hal1) correlations between 
psychological variables, adjusted for 
gender and age (N=74) (continued) 
Expressed emotions (UCL-E) 
r 95% CI 
SCLIN .35 .13 .54 
SCLSEN .41 .20 .58 
SCLHOS .65 .50 .76 
SCLNEU .32 .10 .51 
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CHAPTER 9. EVALUATION OF THE CHANGES IN PSYCHIATRIC 
PATIENTS AFTER THERAPY AND THREE MONTHS 
LATER 
9.1 Introduction 
In the study described in this chaptcr we investigated whether there were changes in 
the scores of SCL-90, ueL and DMI during the treatment of psychiatric patients with a 
combination of antidepressants and cognitive therapy, and if so wieh direction those 
changes had. 
Moreover, \ve also examined whether any changes persisted aftcr medkation therapy 
\vas discontinued. This was carried out by measuring the symptomatology of the patients 
with the SCL-90, and in the stability of defense organization and coping strategies by the 
scores of DMT and ueL after 6 months of therapy (the moment on wich a subgroup of 
the patients decided to stop their therapy) and at follow-up, three months later. 
\Ve expected that the SCL-90 scores \vould decline with successful therapy, but that 
scores of DMI and UCL wi11 not change considerably since we expect them to renect 
more trait than state aspects of the patients and not highly prone to changes. 
It was also examined which of the three patient groups showed the strongest effe<.::t of 
therapy as measured in SCL-90, and if there were differen<.::es between the three palient 
groups conccrning coping and defensc mechanisms after combined psychotherapeuli<.:: 
and clomipramine therapy. 
9.2 Method of statistical analysis 
The changes in the psydlOlogical sub-scales wcre expressed as mean and 95 % 
confidence interval of the mean and are shown in Table 4. (see chapter 6) 
Missing values are estimated by the method of predicted mean matching [Little, 1988). 
By estimating missing values no empty cells will be present wich is necessary condition 
for a repeated measurement design. The number of cases will not be diminished and 
consequently the power of statistical analyses will be higher and the number of cases 
wi1l be equal for all analyses!). 
Next the regression analysis was performed on all individual variables after the missing 
values had been substituted (Slaets [1994]) as follows; 
First the variables were standardized at TO and T6. Then the three pSy<.::hiatric groups 
were <.::oded by two dummy variables (codes 1 and 2). The subgroup depression became 
linear dependent and as a consequen<.::e eliminated from the analyses. 
Thc regression analysis was performed with both the dummy coded variables and the 
baseline measurements corrected for age and sexc as independent (predictive) variables. 
Finally the standardized regression coefficient (beta) and the standard error of beta for 
the baseline measurements and the psychiatric subgroups at six months were estimated 
(Table 19)", 
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1) To that aim, a regression analysis was performed for the missing value at '1'6 with T6 predicted variable and 
TO, age and gender as predictive variables. 
The derived estimated value for T6 from the analysis was cumpared with that case that had this estimated 
value or that was close to it. Subsequently, the missing vulue at T6 was substituted by the observed value 
for the la~t named case. The same method was used for the missing value at TO. 
2) The standard regression coefi1cient cun be inlerprclated .u; follows: 
TIle higher the regression coefficient oflhe predictor v,triable, the higher the association with the outcume 
variable. If the beta is negative than a high value implies that the outcome value is related negatively with 
the standerdized predictor variable. For example: A beta of .50 means that an increa~e of the predictor 
variable with one point yields an expected increase of .50 on the outcome variable measured atT=6 months. 
If beta is -.50 than the expected value un the uutcume variable will decrease with .50. 
9.3 Results 
After six months of therapy, there was still a group of 51 patients in the study, From 
this group, 26 patients wanted to discontinue their medication at that moment. This group 
of 26 patients was evaluated again three months after discontinuing their medication. 
The mean scores and their 95 % confidence interval of SCL-90, UCL and DMI in the 
two different patient groups, (those who wanted to stop their medication and those who 
wanted to continue their medication after six months of treatment), are shown in Table 4. 
In the SCL-90, scores of an sub-scales had decreased between baseline and six months 
as can be seen in the 95 % confidence interval. The highest decrease was in the SCL-90 
scales anxiety (ANX), depression (DEP), panic (PAN), sleep disorders (SLA) and psycho-
neuroticism (NEU), The mean SCL psycho-neuroticism score (NEU), a frequently used 
indicator for an overall therapeutic effect was reduced further during the period six months-
nine months from 158.82 to 139.23. 
A further analysis (not included in this thesis) revealed that there were no significant 
differences on SCL, UeLand DMI scores and biochemical values between the dropouts, 
the patient group who stopped therapy after six months and those patients who were 
included in the fonow-up investigations. We concluded that the dropouts \vere random, 
From the UeL scales avoidance (V) and depressive reactions (D) decreased the most. 
There were hardly any other changes in the UCL scales. 
In the DMI small increasements were noted in turning agression against others (TAO), 
reversal (REV) and repression (REP). Turning aggression against self (TAS) was 
decreased. 
It was noticeable that changes in psychological parameters at six months, had mostly 
taken root at the follow-up after nine months. This was especially true for the effect on 
the symptomatology. 
Regression analysis showed that the psychiatric subgroup appeared not to be an im-
portant factor in the outcome of the different coping and defense scales at six months. 
The subgroup panic disorder & depression however did have the smal-Iest therapeutic 
response as revealed by SCL-90 NEU score. 
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Table 19. 
DMITAO 
DMIPRO 
DMllNT 
DMlTAS 
DMIREV 
DMIREP 
UCL-A 
UCL-P 
UCL-V 
UCL-S 
UCL-D 
UCL-E 
UCL-G 
SCLANX 
SCLAGO 
SCLDEP 
SCLSOM 
SCLIN 
SCLSEN 
SCLHOS 
SCLSLA 
SCLRES 
SCLNEU 
SCLPAN 
Differential qualities of diagnostic catagories l 
(adjusted for age and gender), 
011 outcome after six months of treatment 
Depression and panic Panic 
Beta SE Beta Beta SE Beta 
0,14 0,21 0.57 0,21 
0,14 0,25 0,31 0,25 
0,26 0,29 0,29 0.29 
- 0,22 0,23 0,66 0,23 
0.36 0,22 0,31 0,22 
0,19 0,21 0,53 0,21 
- 0,01 0.29 0.39 0,29 
0,62 0,)3 - 0,14 0,28 
0.45 0.31 - 0.D7 0,31 
0,06 0,30 0.49 0.31 
0.20 0,28 0,16 0,29 
0,17 0.24 0.45 0,24 
0,13 0.31 0,27 0,31 
0,66 0,28 - 0,24 0,28 
0,10 0,29 0,06 (),29 
0,16 0,33 0,14 0,33 
0,69 0,22 - 0.07 0,22 
0,20 0,32 0,22 0,32 
0,55 0,23 n.()5 0,23 
0.57 0,24 0.11 0,24 
0,65 0,31 - 0,20 0,30 
0,70 0,24 - 0,14 0,24 
0,83 0,26 - 0,33 0,26 
(),53 0,25 - 0,02 0,24 
ladjusted for corresponding baseline variables 
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9.4 Discussion 
As was expected, the pattern of complaints in patients with panic disorder and/or ma-
jor depression as measured with the SCL~90 altered considerably during combined 
treatment with clomipramine and cognitive therapy. Although, the therapeutic effect in 
all three patient groups in this open trial was high, it was observed that the patient group 
with co-morbid panic disorder and major depression showed lower response to therapy 
at six months than the other diagnostic groups as measured by the SCL Psycho-neuroticism 
(NEU) which is an overall measure for psychologkal distress. 
This was in agreement with the findings by Albus & Scheibe [1992] who reported that 
palients with co-morbid panic disorder and major depression showed a poor response to 
therapy (see also chapter 3). 
Prohably consists the comorbid group of more severe ill patients. Improvement was 
rcached after six months of treatment and continued to persist at follow-up at nine months 
in the group of patients who discontinued their medication after six months. In coping 
style the most notably changes, diminishments, were in avoidance and depressive reaction 
pattern. Of the defense mechanisms only turning agression to self decreased markedly. 
Although moderately the scores of the DM!- and the DCL scales in the patients had 
changed in the direction of those in the standard groups. 
Further, it appeared that it was not relevant to which diagnostic group the patients 
helonged to for the outcome on the different scales of the DCL and DM!. 
On the basis of this, one can state that the changes in the style of coping and indicated 
defense mechanisms were not dependent on having a specific psychiatric disorder in the 
sense of panic disorder or major depression or both. The lack of specificity was in line 
with the findings by Bond & Vaillant 119861 who found that DSM III diagnosis could not 
predict defense style. 
The use of coping strategies sllch as depressive reactions and avoidance was probably 
partially related to the presence of depression and/or panic disorder symptomatology at 
baseline. A large number of our patients with panic disorder had also agoraphobia which 
implied avoidance (see also: chapter 5). On the basis of our findings of the lack of 
considerable change in ueL scores, we might concluded that coping is mainly a stable 
trait. Traditionally, coping was seen as a trait characteristic [Troop. 1994]. This is also is 
in agreement with the hypothesis by Andrews {1991] who stated that general vulnerability 
for anxiety disorders and depression was determined by a high level of trait anxiety and 
poor coping. 
On the basis of their investigations in thirty in-patients with agoraphobia and/or 
depression who were treated with psychotherapy (exposure and insight providing 
psychotherapy) for thirteen weeks, Hoffart & Martinsen [1993] observed that while the 
coping strategies active problem solving and wishful thinking behaved mainly as state 
phenomena. avoidance behaved predominantly as a trait phenomenon. Seeking social 
support had both trait and state phenomenon. The results of this study however arc tentative 
because off the small sample size. 
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In this study of Hoffart & Martinsen, a high level of seeking social support predicted 
a favorable therapeutic result. This is in agreement with the outcomes of life-stress re-
search ,vhich pointed out that the presence of social support forms a buffer against the 
occurrence and recurrence of psychological disorders [Smtees, 1980]. 
It was noticeable that of the defense mechanisms, reversal (REV) and turning agression 
against others (TAO) increased, although insignificantly and turning against self (TAS) 
decreased. This suggest that during therapy, patients tend to direct aggression less at 
themselves, but more towards others. Therefore, it can be stated that psychological defense 
probably is partly state determined, which idea is in agreement with Freud's original 
ideas [1986]. 
Since a part of the TAS question refers to depressive feelings and mood it is, however, 
possible that the TAS scores in patients form an epiphenomenon of psychopathology, 
especially depression. 
After six months of therapy (the moment of discontinuation of the medication and 
cognitive therapy), the level of repression (REP) was increased insignificantly compared 
with the baseline value, but repression diminished again at follow-up three months later. 
After therapy the patient group had changed in defense organization in the direction of 
those in the reference group. 
In disagreement with Akkerman [1992], who observed no changes after therapy in 
neurotic defense mechanisms, we observed that the use of mature defense mechanisms 
(PRN) was increased after the therapy. Projection, however, which is an immature defense 
mechanism, decreased during the therapy, wich was in accordance with the results of the 
study by Akkerman! 19921. Most of these changes were statistically not significant, so 
these conclusions aIs tentative. 
In this study we made usc of a comparatively small patient group especially at our 
follow-up investigations. Since we Jid not used a placebo control group we cannot rule 
out that the changes found in our patient group are sponteneous. However, most patients 
had their illness during quite a long time ( see chapter 5) wich makes that sponteneous 
remission seelllS unlikely. 
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CHAPTER 10. DISTINCTION BETWEEN PATIENTS ON MEDICATION 
AND THOSE NOT ON MEDICATION AT BASELINE 
10.1 Introduction 
In this study, all patients who did and who did not use antidepressants as medication at 
baseline were included. A limited number (11:::43) of patients were put on medication 
with clomipramine before the analysis of their blood samples were done. For ethical 
reasons, the clinical severity of the psychiatric condition of the patients in such cases 
received priority above the setup of the study. The Usc of medication as far as the tricyclic 
antidepressants were concerned was checked by determining the hlood levels. In the 
studies described in this chapter, it was investigated whether there were differences in 
the psychological and the biochemical parameters at baseline he tween these two groups 
of patients. 
If there were no differences between the psychological variables in the two patient 
groups, then it would be justified to study the two different patient groups combined in 
these respects. We expected that there would be differences between the biochemical 
parameters in the two patient groups because of the influence of clomipramine. 
10.2 Statistical analysis 
.Mean scores with standard deviation of sub-scales of SCL-90, DMI and DCL in the 
palients group on medication (n=43) and the patient group not on medication (n=31) at 
baseline were compared. It was investigated wether there were significant differences 
between the two patient groups with the \Vilcoxon test. 
It was also investigated whether there was a difference in the severity of the 
psychopathology between the two patient groups on the basis of the SCL-90 total score 
(NEU). The mean score with 95 % confidence interval of the biochemical variables in 
the two palient groups were also compared (table 6). 
10.3 Results 
The mean scores on the psycholgical measures with standard deviation in the group of 
patients who did and did not lise tricyclic antidepressants are given in Table 20. 
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Table 20. 
DMITAO 
DMIPRO 
DMlINT 
DMITAS 
DMlREV 
DMIREP 
UCL-A 
UCL-P 
UCL-V 
UCL-S 
UCL-D 
UCL-E 
UCL-G 
SCLANX 
SCLAGO 
SCLDEP 
SCLSOM 
SCLIN 
SCLSEN 
SCLHOS 
SCLSLA 
SCLRES 
SCLNEU 
SCLPAN 
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Comparison between patients with and without use of tricyclic 
antidepressants at baseline 
.Mcdicationrrcc Medication 
(J1~31 ) (n~43) 
Mean Sd Mean Sd 
35.4 10.7 33.4 10.3 
41.0 5.4 36.6 6.7 
42.7 7.1 44.9 6.2 
43.1 7.6 44.0 8.6 
37.9 7.8 41.1 10.1 
4.3 25.7 15.9 28.2 
14.8 3.7 14.4 3.8 
18.6 4.1 17.2 3.8 
18.5 4.5 18.0 3.8 
13.0 4.3 12.2 4.1 
17.5 4.2 17.0 3.7 
5.9 2.5 5.8 2.5 
II. 7 2.7 10.9 2.0 
30.5 9.0 29.6 9.3 
17.6 6.9 16.9 8.4 
48.0 15.9 49.2 15.3 
29.5 9.1 30.1 9.6 
26.2 8.6 25.3 8.0 
42.5 14.5 38.3 15.1 
10.7 4.1 11.2 5.3 
9.4 4.4 9.9 3.7 
18.7 6.4 18.9 6.6 
233.1 60.6 229.3 62.1 
26.1 7.4 25.4 7.4 
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There were only small nonsignificant differences between these two palient groups. 
The biochemical values in these two patient groups are shown in Table 6. (see Appendix) 
The serotonin level in thrombocytes was lower in the group of palients who used 
antidepressants. Also the tryptophan and levels of serotonin in the blood and plasma 
were decreased in these patients. 
There were no significant differences in the other biochemical parameters between the 
two patient groups. 
10.4 Discussion 
A majority of the patients were still on the tricyclic antidepressant clomipramine at the 
first blood sampling. 
Regarding the (;omplaints (SCL-90), copingstrategies (VCL) and defense mechanisms 
(DMI) scores at baseline were almost identical in the two patient groups as was expected. 
Therefore it is unnecessary to distinguish between patients who still used clomipramine 
and those who did not at entry into the study. 
It is known that antidepressants ( e.g. clomipramine) influence the level of serotonin 
in the blood, plasma and thrombocytes of the patients. The levels of serotonin in the 
blood, plasma and thromhocytes of patients who used these antidepressants were lower 
than those in patients who did not use antidepressants and than those in the reference 
group. 
This effect can be attrihuted to the fact that clomipramine has a strong influence on the 
serotonergic system by inhibiting the uptake of serotonin. Previous investigations using 
selective inhibitor of serotonin uptake, citalopram had the same effect on the levels of 
serotonin in the blood and thrombocytes (the levels of serotonin in the plasma were not 
investigated in that study) [Timmerman et ai, 1987]. 
Our findings were in contrast to the investigations reported by Hanh Le Quan-Bui et al 
119H4] who observed that treatment with tricyclic antidepressants had no effect on the 
levels of serotonin in the plasma and in the thrombocytes of patients with major depression, 
However, these authors did not mention the type of antidepressants that were used for 
treatment. It may well be that they had used antidepressants such as maprotiline which 
had either only a slight effect or no effect at all on the serotonergic system. 
Sarrias et all19871 conducted a study with clomipramine in eighteen patients with 
melancholia and observed that the level of serotonin in thrombocytes strongly decreased 
during the therapy, but that there was no change in the level of serotonin in the plasma. 
These authors concluded that there were different pools of plasma- and thrombocyte 
serotonin. Since in our study serotonin in plasma decreased as \vell, we were unable to 
confinn this conclusion. 
Besides a significant negative influence on the levels of serotonin in thrombocytes, 
blood and plasma, the use of clomipramine also appeared to be associated with a low 
level of tryptophan, a precursor of serotonin in the patients, and with a low tryptophan 
ratio, the reason for which remains unknown. 
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One could speculate that the use of clomipramine causes enzyme-induction in the 
liver with activation of tryptophan pyrrolase \vhcrcby degradation of tryptophan is 
increased. However, this explanation is less likely because low doses of antidepressants 
already inhibit this enzyme [Bradawy & Evans, 198 I]. 
Other explanations for a decrease in the level of tryptophan in the plasma is an increased 
uptake of free tryptophan by brain tissue possibly in combination with the shift of albumin-
bound tryptophan towards free ttyptophan by the tricyclic antidepressant [Thomas et ai, 
1987], or decreased absorbtion of tryptophan from the gastrointestinal tract. 
The use of clomipramine had no significant influence on the baseline levels of 
norharman and tyrosine, 
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Table 6. Baseline biochemical values in patients and reference 
Reference Medication Patients All 
free with patients 
patients medication 
(n~27) (n~3()) (n~36) (n~66) 
Serl) in mean 14.2 15.5 7.6 11.2 
plasllla CI" 7.8; 20.7 10.4 ; 20.6 5.1; 10.1 8.4 ; 14.0 
(10" mol/I) 
Scr in mean 3.6 3.5 1.1 2.9 
platelets CI 3.2; 4.0 3.1; 4.0 0.2; 2.0 2.4; 3.4 
(I0"moll 
IOE' pI) 
SCI' in bloou mean 957.7 820.5 131.4 547.7 
(10-911101/1) CI 815.9; 1099.6 682.4; 958.6 26.3; 236.5 414.2; 681.2 
Norhannun mean 0.45 0.49 0.53 0.51 
(10-12 mol/I) CI 0.37; 0.53 0.31; 0.59 0.40; 0.65 0.42; 0.60 
Tyrosin mean 67.1 63.9 60,4 61.9 
(10-6 mol/I) CI 59.0; 75.3 55,4; 72.4 55.9; 64.9 57.5; 66.3 
Tyrosin ratio mean 11.4 10.7 11.3 11.0 
CI 10.3; 12,4 9.99; 11.5 10.6; 12.0 10,4; 11.6 
Tryptophan lUean 52.8 49.9 41.9 45.3 
(10-6 molll) CI 48.5; 57.0 45.6; 54.2 39.1; 44.7 42.7; 47.9 
Tryptophan mean 8.9 8.6 7.5 8.0 
ratio CI 8.2; 9.6 7.8; 9.5 7.1; 7.9 7.5; 8.5 
I) Serotonin 
1) 95% Confidence interval of the mean. 
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CHAPTER 11. RELATIONSHIP BETWEEN PSYCHOLOGICAL AND 
BIOCHEMICAL VALUES AT BASELINE: 
AN EXPLORATION 
11.1 Introduction 
Van Praag r 1995 J states that the Kraepelinian experience in \vhich behavior disorders 
were regarded as discrete illnesses such as major depression or panic disorder yielded a 
wealth of interesting data in biological psychiatric investigations, but failed to provide a 
single noteworthy specificity for diagnosis. He stated that nosological concepts were not 
the end-point for the diagnosis, but were just a beginning. 
According to this the next step is the dismantling of the hypothetical syndrome into its 
various components including psychological (dys)ful1ctions. Van Praag [1995] expected 
that these two-tailed diagnosis would lead to a shift from a nosological to a multi-functional 
orientation, whereby psycho-pharmaceuticals directed more at the complaints instead of 
the diagnosis could be prescribed. 
In our earlier investigations into the relationship between biochemical parameters, 
presentation of psychiatric illness and psychological dysfunctions, we observed in 
agreement \vith the view of Van Praag [1995] that norharman was not correlated with a 
psychiatric illness (panic disorder), but to psychological dysfunctions in the sense of 
indicated defense organization and coping strategies ITimmerman et ai, 19941]. 
In the study described in this chapter, relationships between biochemical parameters 
and psychological parameters at baseline in patients not on medication and the reference 
group were investigated. 
The questions were whether there were any coneiations between biochemical variables 
and psychological dysfunctions and whether there was a difference between these 
correlations in the patient group and the reference group. 
11.2 Statistical method 
Partial inter-correlations of psychological and biochemical parameters that were 
estimated at baseline in patient group not on medication and in the reference group were 
adjusted for age and gender. These partial inter-correlations, were presented including a 
95% confidence interval and are shown in table 21 (see appendices) and, in summary, in 
table 21'. 
11.3 Results 
Since the psychological variables at baseline in patient group not on medication did 
not essentially differ from those in the patient group on medication (chapter 10), the 
inter- cor-relations between the psychological variables for this patient group are not 
discussed separately (see chapter 8), except for the SCL-90, uot discussed earlier. Active 
problem solving coping (UCL-A) in the UCL scale showed a negative correlation with 
the severity of symptomatology (NEU) as measured in the SCL-90. Depressive 
reactions(UCL-D) correlated positively with all SCL-90 scales. 
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Some important significant inter-correlations of biochemistry and psychology in the 
reference group and the patient group: 
DMI 
Turning aggression against others (TAO) correlated negatively with serotonin in the 
thrombocytes and plasma in the patient group and positively in the reference group. 
In the patient group, repression (REP) was correlated positively with 5-HT in 
thrombocytes and \vith tryptophan ratio. 
In the reference group, repression \vas cOlTelated negatively \'lith 5-HT in thrombocytes. 
plasma 5-HT and with tryptophan ratio but positively with tyrosine ratio and tyrosine. 
Table 21a 
DMI 
SCL 
95% c.I.2) 
DM! 
95%C! 
Confidence intervals of partial correlations between 
serotonin in thrombo's and in plasma with 
psychological variables (excerpt from table 21) 
serotonin in thrombo'sl 
Patients Reference 
TAO REP HOS TAO REP 
-.67 .09 -.68 .16 -.72 
.00 .72 -.07 .75 -.1 1 
serotonin in plasma 
Patients Reference 
TAO REP TAO REP 
-.21 -.23 .12 -.76 
-.54 .48 .73 -.20 
I) Substantial partial correlation adjusted for age and gender 
2) 95% confidence interval 
VCL 
HOS 
-.52 
.21 
From the coping mechanisms depressive reaclions (D) was correlated positively with 
tyrosine ratio in the patient group. 
However, this correlation was negative in the reference group. UCL-D also showed a 
negative correlation with 5HT in thrombocytes. 
There were other no significant correlations between coping mechanisms and 
biochemical variables in the patient group. 
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In the SCL-90, we observed positive correlations between serotonin in thrombocytes 
and anxiety (AN X), depression (DEP) and sleep disorders (SLA) in the reference group. 
The tryptophan ratio was correlated positively with anxiety. There was, however, a 
negative correlation between serotonin in plasma and depression (DEP) in the patient 
group. 
Serotonin in plasma was correlated negatively with hostility (HOS) both in the patient 
group and to a lesser extend in the reference group. 
This was also tmc for the correlations between hostility and tryptophan ratio. 
Biochemical )I(lriables 
There was a strong positive correlation between serotonin in plasma and that in blood 
in both the patient group and in the reference group. 
Moreover, in the patient group there were positive correlations between tryptophan & 
tyrosine and tryptophan ratio & tyrosine ratio. In thereferel1ce group, we observed positive 
correlations between tryptophan & tyrosine, tyrosine & tyrosine ratio and tryptophan 
ratio and serotonin in thrombocytes. 
11.4 Discussion. 
The results of this exploration into inter-correlations between biochemical and 
psychological variables described in this chapter must be interpreted with caution because 
of the small size of the groups. 
Thrombocytes have lllany similarities with serotonergic synaptosomes and have been 
used as a model for uptake of serotonin by synaptosomes [pletcher, 1981 J.1n our patients, 
serotonin in thrombocytes appeared to be negatively correlated with parameters of 
aggression and positively with levels of repression and denial. The negative correlation 
between serotonin in thrombocytes and turning aggression against others, depression 
(DEP) and hostility (HOS) and between serotonin in plasma and tryptophan with HOS in 
our patient group supported the suggested coupling between aggression and depression 
with a low func:.:tioning serotonergic system I Brown et aI, 1979; r..1uch-Seler et ai, 1983; 
Van Praag, 1991]. The correlations between biochemical variables with symptoms as 
hostility snpport the hypothesis by Van Praag 1199 I] in which he stated that biochemical 
parameters werc not correlated with the presentations of psychiatric illnesses, but were 
correlated with behavior. The patient group differed highly from the reference group in 
the coupling of these serotonergic parameters with psychological parameters which pleads 
for a relationship between these biological parameters and psychological dysfunctions. 
In our previolIs study [Timmerman et aI, 1994] we observed negative correlations 
between norharman and intellectualization (TNT) and repression (REP) and positive 
correlations between norharman and palliation (UeL-p). In this present study however, 
wc observed no significant correlations bet\veen norhannull and defense organization or 
coping mechanisms in the patient group. On the basis of these results it is unlikely that 
norharman reflects intra-psychological processes such as defense and coping. 
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In the patient group, we observed that repression (REP) and reversal (REV) were 
negatively correlated with the amino acid tyrosine and with the ratios of tyrosine and 
tryptophan as compared with other large neutral amino acids. 
OUf findings are compatible with a function of tyrosine, since tyrosine, the precursor 
of dopamine, is a neurotransmitter which has a possible positive correlation with novelty 
seeking and impulsiveness [reviewed by Glas, 1991l 
\Ve suggest that patients with high novelty seeking and impulsiveness seem to be less 
likely to make frequent use of repression and reversal. 
Problem solving coping (UeL-A) showed a (nonsignificant) negative correlation with 
the severity of symptomatology (NEU) as measureu in the SCL-90 in the patient group. 
Depressive reactions correlated positively with all SCL-90 scales. 
This was in agreement \vith the findings reported by Roy-Byrne et al [19921 who 
observed that level of "distress" in patients with panic disorder and/or depression was a 
strong predictor for the use of less problem solving but more emotionally directed coping. 
Though our patient sample was rather small and the ranges in the confidence intervals 
large a tentative conclusion of in this chapter may be, that though we did not found a 
correlalion between H specific psychiatric disorder and a biochemical substrate (see chapter 
7), we did found (negative) corrrelations between various agression parameters and 
serotonin in thrombo<.::ytes. 
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Table 21. SlIbstalltiaP) partial correlations between psychological- and 
biochemical variahles adjusted for age and gender in 
referencegroup and in at baseline mcdicationfl'ce patients 
Turning agression against others (DMITAO) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n=49) (n=31) 
COlT 95%CI COlT 95% CI 
DMIPRO .48 .23 .67 DMIPRO .52 .21 .74 
DMIINT -.68 -.80 -.49 DMIINT ,.60 ,.79 ,.31 
DMITAS ,.36 ,.58 ,.09 DMITAS ,.54 ,.75 ,.23 
DMIREV ,.75 ,.85 ,.59 DMlREV ,.62 ,.80 ,.34 
DMIREP ,.90 ,.94 ,.83 DMIREP ,.88 ,.94 ,.77 
HTp 2) 
.51 .16 .75 HTP ,.38 ,.67 .004 
HPP3) 
.48 .12 .73 HPP ,.21 ,.54 .16 
I) two tailed 2) serotonin in platelets; 3) serotonin in plasma. 
Projection (DMIPRO) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(1l=49) (n=31) 
COlT 95% CI COlT 95% CI 
DMIlNT ,.49 ,.68 ,.24 DMIINT '.50 ,.73 ,.18 
DMITAS ,.46 ,.66 ,.21 DMITAS ,.22 ,.53 .15 
DMIREV ,.58 ,.74 ,.36 DMlREV ,.73 ,.86 ,.50 
DMIREP ,.73 ,.84 ,.57 DMlREP ,.80 ,.90 ,.61 
UCL,S .10 ,.19 .40 UCL,S .47 .13 .70 
UCL,E 0 ,.28 .28 UCL,E .51 .19 .73 
TPR 4) .53 .19 .76 TPR ,.42 ,.68 ,JJ7 
TYR" ,.36 ,.65 .03 TYR .47 .13 .71 
..) tryptophan ratio; 5) tyrosin 
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Table 21. Substantial" partial correlations between psychological. and 
biochemical variables adjusted for age and gender in 
refcl'cncegronp and in at baseline medicationfree patients 
(continued) 
Intellectualisation (DlvIIINT) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(11=49) (11=31 ) 
COlT 95% CI COlT 95% CI 
DMIREV .56 .33 .73 DlvIlREV 040 .05 .66 
DMlREP .81 .69 .89 DlvIIREP .75 .54 .87 
UCL-A .08 -.20 .36 UCL-A .51 .19 .73 
UCL-D -.33 -.56 -.OS UCL-D -.36 -.62 .02 
SCLRES .04 -.24 .32 SCLRES -.38 -.65 -.03 
TPR -045 -.71 -.09 TPR .06 -.31 Al 
TYR 044 .07 .700 TYR -.33 -.62 .04 
HPP -.47 -.72 -.11 HPP .13 -.24 .47 
Turning agressiol1 against self (DlvIITAS) 
REFERENCEGROUP lvIEDICATIONFREE PATIENTS 
(n=49) (n=31) 
COlT 95% CI COlT 95% CI 
UCL-A -.32 -.55 -.04 UCL-A -.47 -.70 -.13 
UCL-V .37 .\0 .59 UCL-V .10 -.27 .44 
SCLDEP .31 .03 .54 SCLDEP .26 -.11 .56 
SCLSOlvl .32 .04 .55 SCLSOM -.0 I -.36 .35 
135 
Table 21. Substantial" pal·tial correlations betweenpsychological-, and 
biochemical variables adjusted for age and gender in 
l'cferencegroup and in at baseline mcdicationfree patients 
(continued) 
Reversal (DMIREV) 
REFERENCEGROUP MEDICATION FREE PATIENTS 
(n=49) (n=31) 
corr 95% CI COlT 95% CI 
DMIREP .88 .79 .93 DMIREP .84 .68 .92 
HTP -.45 -.71 -.09 HTP .56 .24 .79 
TPR -.33 -.63 .05 TPR .37 .02 .65 
TYR .09 -.05 .63 TYR -.63 -.81 -.34 
TRR'" -.32 -.30 .46 TRR -.39 -.65 -.03 
HPP -.57 -.78 -.24 HPP .10 -.27 .44 
(,) Tyrision ratio 
Repression (DMIREP) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n=49) (n=31) 
COlT 95%CI COlT 95% CI 
HTP -.47 -.72 -.ll HTP .46 .09 .72 
TPR -.43 -.69 -.05 TPR .32 - .OS .61 
TYR .41 .04 .68 TYR -.54 -.75 -.22 
TRR .24 -.16 .57 TRR -.39 -.65 -.03 
HPP -.54 -.76 -.20 HPP .14 -.23 .48 
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Table 21. Substautial11 partial correlations between psychological·, and 
biochemical variables adjusted for age and gender in 
rcfcl'cncegl'onp and in at baseline medicationfree patients 
(continued) 
Active problem solving (UCL·A) 
REFERENCEGROUP MEDICATION FREE PATIENTS 
(n=49) (n=31) 
COlT 95% CI COlT 95% CI 
UCL-P .25 -.03 .49 UCL-P .39 .04 .65 
UCL-E .08 -.20 .35 UCL-E .37 .02 .64 
UCL-G .26 -.02 .50 UCL-G .44 .11 .69 
Palliation (UCL-P) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n=49) (n=31) 
COlT 95%CI corr 95% CI 
UCL-S .50 .26 .69 UCL-S .07 -.30 .41 
UCL-D .46 .21 .66 UCL-D -.04 -.39 .32 
UCL-G .53 .29 .70 UCL-G .53 .22 .75 
SCLNEU .29 .01 .53 SCLNEU -.06 -.40 .30 
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Table 21. Substantial" partial correlations between psychological-, and 
biochemical variabl~s adjusted for age and gender in 
reference group and in at baseline medicationfl'cc patients 
(continued) 
Avoidance (UCL-V) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n=49) (n=31) 
COlT 95% CI COlT 95% CI 
UCL-S ,37 ,10 ,59 UCL-S -,24 -,55 ,12 
UCL-D ,53 .29 ,70 UCL-D ,39 ,04 ,65 
SCLANX ,29 ,01 ,53 SCLANX .29 -,07 ,59 
SCLSOM .36 ,0 ,58 SCLSOM ,28 -,08 ,58 
SCLIN ,21 -,08 A6 SCLIN ,53 ,22 ,74 
SCLll.ES .38 ,II ,60 SCLRES ,57 .27 ,80 
SCLNEU ,26 -,02 .50 SCLNEU A4 ,10 ,69 
NHP -,45 -,71 -,08 NHP -,33 -,63 Jl6 
Seeking support (UCL-S) 
REFERENCEGROUP MEDlCATlONFREE PATIENTS 
(11=49) (11=31) 
COlT 95% Cl corr 95% CI 
UCL-D ,40 ,14 ,61 UCL-D Al ,07 ,67 
UCL-E .35 ,08 ,57 UCL-E ,71 ,47 ,85 
SCLHOS .36 ,09 ,58 SCLHOS ,20 -,17 ,52 
TRR -,44 -,70 -.07 TRR ,35 -,01 ,63 
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Table 21. Substantial I) partial correlations between psychological-, and 
biochemical variables adjusted for age and gender in 
referencegronp and in at baseline I11cdicationfree patients 
(continued) 
Depressive reactions (UCL-D) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n~49) (n~31) 
COlT 95% CI corr 95% CI 
UCL-E .30 .02 .53 UCL-E .15 -.22 .48 
UCL-G .48 .23 .67 UCL-G -.49 -.72 -.16 
SCLANX .56 .34 .73 SCLANX .39 .04 .66 
SCLDEP .48 .24 .67 SCLDEP .49 .16 .72 
SCLSOM .45 .20 .64 SCLSOM .51 .19 .73 
SCLIN .36 .09 .58 SCLIN .49 .16 .72 
SCLSEN .41 .16 .62 SCLSEN .62 .34 .80 
SCLSLA .24 -.04 .48 SCLSLA .41 .06 .66 
SCLRES .49 .24 .67 SCLRES .57 .27 .77 
SCLNEU .53 .30 .70 SCLNEU .62 .34 .80 
SCLPAN .30 -.09 .61 SCLPAN .40 .05 .66 
NHP7) 
-.64 -.82 -.35 NHP -.29 -.60 .10 
TRR -.25 -.50 .24 TRR .40 .05 .67 
HPP .43 .06 .70 HPP -.43 -.69 -.08 
Expressed emotions (UCL-E) 
REFERENCEGROUP MEDlCATIONFREE PATIENTS 
(n~49) (n~3 I) 
COlT 95%CI COlT 95% CI 
SCLANX -.04 -.31 .24 SCLANX -.43 -.69 -.05 
SCLHOS .04 -.24 .31 SCLHOS .42 .07 .67 
139 
Table 21. Substantial!) llarUal correlations behvecn psychological-, and 
biochemical variables adjusted for age and gender in 
refercncegl'oup and in at baselinc medicationfree patients 
(continued) 
Comforting thoughts (UCL-G) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n=49) (n=31) 
COlT 95% Cl COlT 95% C[ 
SCLHOS .36 .09 .58 SCLHOS .20 -.17 .51 
TRR -.44 -.70 .-07 TRR .35 -.01 .63 
Anxiety (SCLANX) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n=49) (n=31) 
corr 95% CI COlT 95%CI 
SCLAGO .71 .54 .82 SCLAGO .46 .13 .70 
SCLDEP .77 .63 .86 SCLDEP .70 .46 .84 
SCLSOM .66 .47 .79 SCLSOM .58 .28 .78 
SCLIN .65 .46 .78 SCLIN .44 .10 .69 
SCLSEN .68 .50 .80 SCLSEN .41 .07 .67 
SCLHOS .41 .15 .62 SCLHOS .13 -.24 .46 
SCLSLA .26 -.02 .50 SCLSLA .77 .57 .88 
SCLRES .72 .55 .83 SCLRES .46 .13 .70 
SCLNEU .86 .77 .92 SCLNEU .74 .52 .87 
SCLPAN .78 .57 .89 SCLPAN .85 .71 .93 
TPR .40 .02 .68 TPR .22 -.15 .54 
HPP .54 .20 .76 HPP -.32 -.61 .05 
7) norharman 
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Table 21. SuhstantiaPl partial correlations between psychological-, and 
biochemical variables adjusted for age and gender ill 
referenccgroup and in at baseline mcdicationfree patients 
(continlled) 
Agoraphobia (SCLAGO) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n~49) (n~31) 
COlT 95% CI COlT 95% Cl 
SCLDEP .55 .32 .72 SCLDEP .60 .31 .79 
SCLSOM .48 .24 .67 SCLSOM .57 .27 .77 
SCLIN .47 .22 .66 SCLIN .44 .10 .69 
SCLSEN .48 .24 .67 SCLSEN .57 .27 .77 
SCLRES .60 .39 .75 SCLRES .51 .19 .73 
SCLNEU .60 .39 .75 SCLNEU .71 .48 .85 
SCLPAN .91 .81 .96 SCLPAN .54 .23 .75 
Depression (SCLDEP) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n~49) (n~31 ) 
COlT 95% CI corr 95% CI 
SCLSOM .64 .44 .78 SCLSOM .66 .40 .82 
SCLIN .63 .43 .77 SCLIN .74 .52 .87 
SCLSEN .72 .55 .83 SCLSEN .55 .24 .76 
SCLHOS .43 .18 .63 SCLHOS .42 .08 .67 
SCLSLA .21 -.07 .46 SCLSLA .57 .27 .77 
SCLRES .66 .47 .79 SCLRES .58 .28 .78 
SCLNEU .88 .80 .93 SCLNEU .89 .78 .95 
SCLPAN .62 .31 .81 SCLPAN .69 .44 .84 
HPP .49 .13 .73 HPP -.39 -.66 -.03 
141 
Table 21. SubstantiaPl partial cOlTelations betwecn psychological~, and 
biochemical variables adjusted for age and gender in 
rcrcrencegroup and in at baseline mcdicatiollfree patients 
( continlled) 
Somatisation (SCLSOM) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n=49) (n=31) 
corr 95% CI COlT 95%CI 
SCLIN .60 .39 .75 SCLIN .59 .30 .78 
SCLSEN .65 .46 .79 SCLSEN .56 .26 .76 
SCLHOS .46 .21 .65 SCLHOS .46 .13 .70 
SCLSLA .08 -.20 .35 SCLSLA .53 .22 .74 
SCLRES .75 .60 .85 SCLRES .53 .22 .74 
SCLNEU .81 .69 .89 SCLNEU .81 .64 .90 
SCLPAN .72 .47 .86 SCLPAN .81 .64 .90 
Insufficiency (SCLIN) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n=49) (n=31) 
corr 95% CI COlT 95%CI 
SCLSEN .62 .42 .76 SCLSEN .69 .44 .84 
SCLHOS .27 -.01 .51 SCLHOS .55 .24 .76 
SCLRES .47 .22 .66 SCLRES .65 .38 .82 
SCLNEU .75 .60 .85 SCLNEU .82 .66 .91 
SCLPAN .74 .50 .87 SCLPAN .46 .13 .70 
TYR .13 -.26 .49 TYR .39 .03 .66 
HPP .17 -.22 .52 HPP -.51 -.74 -.18 
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Table 21. SubstulltiaPl partial correlations between psychological~, and 
biochemical variables adjusted for age and gender in 
referencegrouJ> and in at baseline mcdicatiollfree patients 
(continued) 
Sensitivity (SCLSEN) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n=49) (n=3I) 
COlT 95%CI COlT 95% CI 
SCLHOS .67 .48 .80 SCLHOS .46 .13 .70 
SCLRES .79 .66 .88 SCLRES .77 .57 .88 
SCLNEU .91 .85 .95 SCLNEU .81 .64 .90 
SCLPAN .65 .36 .83 SCLPAN .40 .05 .66 
HPP .20 ,.19 .54 HPP ,.39 ,.66 ,.03 
Hostility (SCLHOS) 
REFERENCEGROUP MEDlCATlONFREE PATIENTS 
(11=49) (11=31 ) 
COlT 95% CI corr 95% CI 
SCLRES .60 .39 .75 SCLRES .28 ,.08 .58 
SCLNEU .61 .40 .76 SCLNEU .52 .20 .74 
HTP ,.18 ,.52 .21 HTP ,.39 ,.68 ,.003 
TPR ,.02 ,.40 .36 TPR ,.42 ,.68 ,.07 
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Table 21. SubstantiaPl partial cOl'l'elations between psychological-, and 
biochemical vadables adjusted for age and gtmdel' in 
reference group and in at baseline medicationfree patients 
(continued) 
Sleeping problems (SCLSLA) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(11=49) (n=31) 
COlT 95% CI corr 95% CI 
SCLRES .04 -.24 .31 SCLRES 040 .05 .66 
SCLNEU .24 -.04 048 SCLNEU .61 .33 .79 
SCLPAN .06 -.33 043 SCLPAN .71 048 .85 
TPR .19 -.20 .53 TPR .39 .03 .66 
HPP 047 .11 .72 HPP -.28 -.58 .09 
Rest items (SCLRES) 
REFERENCEGROUP MEDlCATJONFREE PATIENTS 
(11=49) (n=31) 
COlT 95% CI COlT 95% CI 
SCLNEU .85 .75 .91 SCLNEU .77 .57 .88 
SCLPAN .64 .34 .82 SCLPAN .47 .14 .71 
TYR 0 -.38 .38 TYR AI .06 .67 
HPP .24 -.15 .57 HPP -.45 -.70 -.11 
Total score (SCLNEU) 
REFERENCEGROUP MEDlCATIONFREE PATIENTS 
(n=49) (11=31) 
corr 95%CI COlT 95% CI 
SCLPAN .76 .53 .88 SCLPAN .76 .56 .88 
HPP .36 -.02 .65 HPP -.48 -.72 -.14 
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Table 21. Substantia}!) partial correlations behvcen psychological M , and 
biochemical variables adjusted for age and gender in 
referencegroup and in at baseline mcdicatiollfree patients 
(continued) 
Serotonin in platelets (HTP) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n=49) (n=31) 
COlT 95%CI COlT 95% CI 
HTW" .85 
.69 I .93 HTW .86 .71 I .94 
S} Serotonin in blood 
Tryptophan (TRP) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n=49) (n=31) 
COlT 95% CI corr 95% Cl 
TPR .28 -.11 .60 TPR .45 .11 .70 
TYR .50 .15 .74 TYR .65 .38 .82 
TRR -.02 -.40 .36 TRR .43 .08 .68 
Tryptophan ratio (TPR) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n=49) (n=31) 
COlT 95% CI corr 95% CI 
TYR -.49 -.73 -.14 TYR -.28 -.58 .09 
HPP .46 .10 .72 TRR .07 -.30 .43 
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Table 21. SubstantiaJl) partial correlations between psychological-, and 
biochemical variables adjusted for age and gender in 
referencegroup and in at baseline medicatiollfree patients 
(continued) 
Tyrosin (TYR) 
REFERENCEGROUP MEDICATION FREE PATIENTS 
(n~49) (n~31) 
corr 95%CI COlT 95%CI 
TRR ,64 
.34 I ,82 TRR ,71 .47 I ,85 
Tyrosin ratio (TRR) 
REFERENCEGROUP MEDICATIONFREE PATIENTS 
(n~49) (n~3 I) 
COlT 95% CI COlT 95%CI 
HPP -,28 -,60 I ,II HPP -.46 -,71 I -,II 
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CHAPTER 12. COURSE AFTER SIX MONTHS OF TREATi\IENT AND ON 
FOLLOW UP IN THE PATIENT GROUP 
NOT ON MEDICATION AT BASELINE 
12.1 Introduction 
The group of patients not on medication at baseline was followed separately in order 
to obtain additional insight into the changes in the biochemical parameters during 
combined treatment with clomipramine and cognitive therapy. \Vc expected that the 
defense organisation of the patients will he stahle, trait dependent, while coping strategies 
of the patients might change because of cognitive therapy. After sliccessful treatment the 
SCL-90 score's are presumed to decline. Clomipramine is expected to decrease the 
serotonin in blood and thrombocytes. 
The changes in the psychological and biochemical values throughout the investigation 
period in Ihis patient group were therefore measured. 
12.2 Statistical method 
In addition to mean and confidence interval, the results of changes in defense 
organisation, coping style, symptoms and biochemical variahles were also measured as 
percentage change in T6-TO and T9-TO. Extreme values can playa very substantial role 
in groups of small sizes, wherehy chance plays an important role. Therefore, in order to 
eliminate the influence of extreme values as much as possible, a 5% trim \vas applied 
whereby the extreme values were excluded from the analysis (Table 22). 
The 95 % confidence interval 011 the biochemical values in the reference group and in 
the medication free patients at baseline,after six months and after nine months is presented 
in table 23. 
12.3 Results 
The mean and the 95 % confidence interval of the mean of the results for 6 and 9 
months are presented in Table 4. 
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Table 4. 
DMITAO 
DMIPRO 
DMIINT 
DMITAS 
DMIREY 
DMIREP 
UCL·A 
UCL·P 
UCL·Y 
UCL·S 
UCL·D 
UCL·E 
Chapter 12 
Psychological variables in patients and refercncegl'oup at baseline, 
6 and 9 months 
Baseline 6 months 9 months 
Referencegroup Patients Patients Patients 
(n~54) (n~74) (n~51) (n~26) 
mean 39.6 34.2 35.2 38.0 
CI') 37.0; 42.2 31.8; 36.6 32.4; 38.0 33.4; 42.6 
mean 38.9 38.5 37.7 37.7 
CI 37.1; 40.7 36.9; 40.1 35.7; 39.7 35.3; 40.1 
mean 48.7 44.0 45.7 45.3 
C1 47.1; 50.3 42.4; 45.6 43.7; 47.7 43.1; 47.5 
mean 35.1 43.6 39.7 36.5 
CI 33.1; 37.1 41.6; 45.6 37.7; 41.7 33.3; 39.7 
mean 37.8 39.7 41.7 42.4 
CI 35.8; 39.8 37.5; 41.9 38.9; 44.5 38.4; 46.4 
mean 8.0 11.0 14.5 12.0 
CI 1.4; 14.6 4.6; 17.4 6.5; 22.5 0.6; 23.4 
mean 18.1 14.6 14.9 16.0 
CI 17.1; 19.1 13.8; 15.4 14. I; 15.7 14.6; 17.4 
mcan 17.0 17.8 17.4 17.8 
CI 15.8; 18.2 16.8; 18.8 16.4; 18.4 16.4; 19.2 
mean 14.0 18.2 16.8 15.6 
CI 13.4; 14.6 17.2; 19.2 15.8; 17.8· 14.0; 17.2 
mean 13.8 12.5 11.7 12.2 
CI 12,8; 14.8 11.5; 13.5 10.9; 12.5 11.0; 13.4 
mean 9.9 17.2 13.5 12.4 
CI 9.3; 10.5 16.2; 18.2 12.5; 14.5 11.2; 13.6 
mean 6.4 5.8 5.7 5.8 
CI 6.0; 6.8 5.2; 6.4 5.1; 6.3 5.2; 6.4 
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UCL-G 
SCLANX 
SCLAGO 
SCLDEP 
SCLSOM 
SCLIN 
SCLSEN 
SCLHOS 
SCLSLA 
SCLRES 
SCLNEU 
SCLPAN 
Psychological variables in patients and l'cfcl'cncegl'onp at baseline, 
6 and 9 monlhs (continued) 
Bw.:;eline 6 months 9 months 
Refercm:cgroup Patients Patients Patients 
(11=54) (11=74) (n=51) (n=26) 
mean 11.6 11.2 11.7 12.1 
CI 10.8; 12.4 10.6; 1I.8 10.9; 12.5 11.1; 13.1 
mean 11.3 30.0 19.3 15.5 
CI 10.7; 11.9 27.8; 32.2 17.3; 21.3 13.3; 17.7 
mean 7.1 17.2 10.9 9.4 
C[ 6.1; 8.1 15.4; 19.0 9.5; 12.3 8.2; 10.6 
mean 18.9 48.7 30.6 26.8 
C[ 17.7; 20.1 45.1; 52.3 30.2; 31.0 22.4; 31.2 
mean 14.1 29.9 21.0 18.6 
CI 13.3; 14.9 27.7; 32.1 IS.8; 23.2 15.2; 22.0 
mean 11.2 25.7 IS.9 16.2 
C[ 10.6; 11.8 23.7; 27.7 16.9; 20.9 13.4; IY.O 
mean 22.8 40.0 29.6 26.5 
CI 21.4; 24.2 36.6; 43.4 26.0; 33.2 23.3; 29.7 
mean 6.8 11.0 S.5 8.7 
CI 6.4; 7.2 9.8; 12.2 7.5; 9.5 7.5; 9.9 
mean 3.6 9.7 5.5 5.0 
CI 3.2;4.0 8.7; 10.7 4.7; 6.3 4.3; 5.8 
mean 10.1 IS.8 14.7 12.5 
C[ 9.7; 10.5 17.2; 20.4 13.1; 16.3 10.7; 14.3 
mean 105.9 230.9 15S.8 139.2 
C[ 101.3; 110.5 216.7; 245.1 143.6; 174.0 12.1; 157.4 
mean 10.9 25.7 17.4 14.6 
CI 10.1;11.7 23.9; 27.5 16.0; 18.8 12.6; 16.6 
I) CI = 95% Confidence interval 
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Table 22 shows that application of the 5% trim did not have any major influence 011 the 
majority of the pcrcentages of changes. 
Table 22. 
TAO 
PRO 
INT 
TAS 
REV 
REP 
UCLA 
UCLP 
UCLV 
UCLS 
UCLD 
UCLE 
UCLG 
ANG 
AGO 
DEP 
SOM 
IN 
Folluwup on at baseline medicationfree patients: 
psychological and biochemical variables 
Percentage change TO-T6 Percentage change TO-T9 
n mean scml tri m1 n mean sem trim 
20 10.04 7.04 9.32 14 20.01 12.51 17.72 
20 -.278 3.23 -3.02 14 -9.15 4.18 -9.01 
20 4.32 3.16 3.44 14 4.29 5.13 2.88 
20 -7.42 4.65 -5.95 14 -13.10 5.47 -12.1 
20 10.3 7.06 5.78 14 IS.07 11.94 12.36 
19 -43.10 36.64 -59.80 14 -91.28 38.62 -85.65 
20 8.95 10.88 2.41 14 8.76 8.02 8.90 
20 1.33 7.01 -2.76 14 -1.03 5.32 -.66 
20 -S.81 4.80 -8.58 14 -9.10 5.08 -8.52 
20 4.16 8.04 2.64 14 -1.78 10.77 -3.69 
20 -18.69 4.66 -17.72 13 -25.82 4.37 -25.91 
20 11.27 9.91 7.58 14 -6.07 8.93 -5.26 
20 -2.94 7.18 -6.55 14 1.02 7.16 -1.05 
20 -39.59 4.00 -39.41 14 -44.78 6.11 -46.17 
20 -39.08 5.44 -39.13 14 -36.84 6.02 -36.52 
20 -35.94 5.25 -36.56 14 -40.02 7.59 -41.45 
20 -31.38 3.69 -31.03 14 -37.47 4.49 -37.8 
20 -32.18 4.28 -32.05 14 -37.46 5.87 -38.2 
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IN 
SEN 
HOS 
SLA 
RES 
NEU 
PAN 
NHPP 
TRP 
TRPR 
TYR 
TYRR 
HTPR 
HTW 
HPP 
PAN: 
NHPP: 
TRP: 
TRPR: 
Followup on at baseline medicationfree patients: 
Psychological and biochemical variables (continued) 
Percentage change TO-T6 
n mean sem 
20 -32.IR 4.28 
20 -30.69 4.63 
20 -21.31 4.00 
20 -26.82 8.53 
20 -2 l.l 2 4.86 
20 -34.93 3.82 
20 -33.65 4.13 
17 19.93 14.71 
20 -4.67 
20 2.49 
20 2.39 
20 7.43 
6 -94.81 
6 -94.49 
20 -49.31 
SCL "Panic St::alc"; 
Norharman; 
Tryptophan; 
Tryptophan ratio; 
5.14 
6.61 
9.96 
8.24 
1.84 
1.92 
9.77 
trim 
-32.05 
-30.27 
-21.14 
-27.38 
-21.06 
-33.98 
-33.41 
18.80 
-6.58 
-.89 
-3.77 
2.30 
-95.17 
-94.84 
-52.44 
TYR: 
TYRR: 
HTPR: 
HTW: 
HPP: 
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Percentage change TO-T9 
n 
14 
14 
14 
14 
14 
14 
14 
12 
10 
10 
10 
10 
7 
9 
13 
mean sem trim 
-37.46 5.87 -38.28 
-2R.OO 5.61 -27.26 
-9.23 9.0() -9.30 
-25.77 9.33 -28.49 
-25.34 5.28 -24.99 
-36.99 5.24 -37.13 
-42.90 4.61 -44.02 
6.20 22.00 .80 
-7.04 11.02 -10.47 
3.64 11.44 .33 
.37 12.00 -1.00 
8.95 8.07 8.20 
-20.35 17.86 -19.82 
255.45 192.11 199.0 
10.29 27.58 3.10 
Tyrosin; 
Tyrosin ratio; 
serotonin in platelets; 
serotonin in blood; 
serotonin in plasma. 
Chapler 12 
At baseline, 31 of the patients did not use antidepressants. Twenty of these 31 patients 
still participated in the study after six months (see also chapter 5). Fifteen of these 20 
patients discontinued their medication ancr six months. 
One patient was lost to follow-up, sO that biochemical values at follow-up \vere available 
in 14 patients who were not on medication at baseline. 
The course of the scores of the psychological sub-scale showed a decrease in all scales 
of the SCL-90 (Table 22). There was a modest decrease in the scales hostility (HOS: 21 
%) and sleep disorders (SLA: 27 %) after six months. There was a decrease of 30% or 
more in the other scales of the SCL-90. 
For the group who \vas measured aftcr 9 months the changes were persistent after nine 
months with the exception of hostility. Its score increased again after stopping therapy. 
The most impressive change in the DMI scores was a decrease in repression (REP), a 
composite scale. 
From the coping strategies Depressive reactions (UCL-D) declined. The remainder of 
the coping scales stayed rather stable though there was a small increase in the use of 
adequate coping strategies as active problem solving (UCL-A) and expression of emotions 
(UCL-E). 
The course of the biochemkal values in the patient subgroup not on medication are 
given as raw values at baseline, at six months and at nine months together with those in 
the reference group in Table 23. 
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Table 23. 
Scr I) in 
plasma 
(10-' molll) 
Sei'in 
platelets 
(lO-'moll 
lOB' pI) 
Ser in blood 
(10-9 molll) 
Norharman 
IVlean scores and their 95% confidence interval (CI) on 
biochemical variables in rcfcl'cnccgl'OUll 
and in at bHseline medicationfree patients 
Baseline Six months Nine months 
Reference Medication Medication Medication 
free free free 
patients patients patients 
(n=27) (n=30) (n=21) (n= 13) 
mean 14.20 15.50 4.41 10.61 
CI 7.79; 20.61 10.44 ; 20.60 2.51 ; 6.31 7.02; 14.20 
mean 3.57 3.50 .12 3.18 
CI 3.15; 3.99 3.05; 3.99 0.08; 0.16 1.86; 4.50 
mean 957.72 820.47 31.27 905.38 
CI 815.86; 1099.58 682.35; 958.59 20.85; 41.69 541.84; 1268.92 
mean 0.45 0.49 0.49 0.36 
(10-12 mol/I) CT 0.37; 0.53 0.31; 0.59 0.31; 0.66 0.28; 0.43 
Tyrosin mean 67.11 63.90 61.38 54.70 
(10-6 mol/I) CT 58.98; 75.25 55.42; 72.38 52.30; 70.46 44.60; 64.80 
Tyrosin ratio mean 11.36 10.70 1l.35 1l.36 
C[ 10.33; 12.39 9.86; 11.54 9.99; 12.71 9.77; 12.95 
Tryptophan Illean 52.78 49.87 41.81 37.90 
(10-(' molll) CI 48.52; 57.04 45.56; 54.18 38.71; 44.91 34.87; 40.93 
Tryptophan lllean 8.89 8.64 7.71 7.77 
ratio CI 8.22; 9.56 7.77; 9.51 7.02; 8.40 7.00; 8.54 
I) Serotollm 
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During the therapy, there was a decrease of more than 50% in serotonin in thrombocytes 
and in blood. This was due to a depletion of serotonin caused by clomipramine that was 
used by the patients. At nine months, an increase followed which approached the initial 
values. Tryptophan decreased during the therapy and in contrast to the levels of serotonin 
in thrombo-cytes and in blood, continued to decline for up till nine months, 
12.4 Discussion 
After therapy for six months and at follow-up after nine months, the psychological 
variables in the group of patients who did not use clomipramine at baseline were not 
different than those in the patient group as a whole as described in chapter 9. The first 
group, though small, showed a very substantial therapeutic effect as measured in the 
SCL-90. 
In the defense organization, after six months of therapy, there were small decreases in 
intra-punitive mechanisms such as turning aggression against self (TAS) and an increase 
in turning aggression against others (TAO) and reversal (REV), The difference between 
acting out defence mechanisms and those defense mechanisms which are internally 
directed is expressed by repression (REP), By far, the biggest changes were observed in 
these composite scale repression (REP) which decreased by 43% during therapy for six 
months and by 91 % after nine months, Our patient population showed more lise of acting 
out defense mechanisms after the cognitive-, and psychopharmacological therapy. This 
is noteworthy since according to Juni & Yanishefsky 119831 this repression scale ret1ects 
"trait" quality more than the individual D~1I scales and was determined less by situational 
stress, 
The tendency of changes within this patient group continued for up to nine months 
after commencing therapy which seemed to imply a certain amollnt of permanence, 
However, longer follow-up studies are necessary before any definite finn statements 
can be made, 
The coping strategy depressive reactions (UCL-D) decreased six months after starting 
the therapy, This was probably related to the parallel changes in the symptomatology of 
the patients, Active problem solving (UCL-A) increased and so did the expression of 
emotions (UCL-E), Expression of emotions and active problem solving \vere regarded 
as adequate means of coping, 
In the period six to nine months aner the start of the therapy, the scores in the veL 
scales with the exception of depressive reactions (UCL-D) and expression of emotions 
(UCL-E) showed hardly any changes. 
The therapeutic effect as measured on the UCL scale depressive reactions and the 
course of SCL-90 scores increased further, The use of expression of emotions decreased 
after stopping therapy. 
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Though the number of patients is rather small the results of the investigations indicated 
that after treatment with cognitive therapy and domipramine, the patients indicated a 
more problem directed coping. The changes in the scales palliative coping (UCL-P), 
seeking support (UCL-S) and reassuring thoughts (UCL-G) were very small. It is possible 
that these coping strategies retlect more trait than state characteristics. Historically, the 
indicated coping strategy was also seen mainly as a trait character [Troop, 1994]. 
The serotonergic antidepressant (clomipraminc) had a deal' effect on the concentrations 
of serotonin in the blood, plasma & thrombocylcs. Clomipramine caused a depletion of 
serotonin. It was noticed very clearly that after stopping clomipramine at six months, the 
concentrations of serotonin in the blood, plasma & thrombocytes increased, but thc lcvel 
the serotonin precursor tryptophan did not. The finding that during treatmcnt with tricyclic 
antidepressant the level of tryptophan in the plasma decreased was in agreement with 
that reported by Thomas et al11987] in a study in patients with depression. 
As stated before the cause of this low level of tryptophan after therapy for six and at 
follow up remains unknown. 
The low amount of tryptophan probably leads to a reduction in the synthesis of serotonin 
in the brain which may lead to changes in mood and behavior as e.g. depression. 
In a recent study, it appeared that reduction oftryptophall in the diet of volunteers with 
a positive family history of I11<Uor depression could lead to depressive mood [Benkelfat 
et aI, 1994]. Tryptophan depletion via diet restrictions also significantly increased 
depressive complaints in patients with obsessive-compulsive disorder as compared with 
controls [Barr et aI, 19941. In our patient group, there was a considerable percentage of 
recurrence in psychiatric complaints in the long term, more than 20% of the patients 
showed a relapse [Timmerman et al 19952]. 
One can speculate that the low level of tryptophan, and to a lesser extent, the low 
tryptophan ratio also after stopping clomipramine possibly constitute a risk for the 
recurrence of psychopathology. 
Prior to commencing therapy, the tyrosine ratio in the patient group as compared with 
that in the reference group was decreased. It is possible that the increase in the level of 
tyrosine in the patients reflected their recovery. 
Table 23 shows that norhannan increased during the therapy for six months. This 
increase is likely to be related to the medication therapy. \Vhile the effect of therapy 
between six and nine months still increased, the level of norhannan decreased again. 
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CHAPTER 13. CONCLUDING REMARKS 
The basis of this thesis is the clinical observation that patients at the out-patient 
department of psychiatly of a general hospital sometimes present with a psychiatric profile 
which satisfies the criteria of panic disorder either with or withollt agoraphobia according 
to the DSM-TTT-R criteria, whereas at the same time, a considerable percentage of these 
patients also satisfy the criteria for major depression according to the same classification 
system. Not only did it appear that in these ambulant patients onc could speak of a 
simultaneolls presence of two clusters of psychiatric symptoms, but it also appeared that 
patients who initially presented for treatment in connection with a circumscribed panic 
disorder, at a later stage or during a new episode, no longer satisfied the t:riteria for panic 
disorder, but suffered from major depression or vice versa. 
Bnsed on these dinical observations, a search for a theoretical model to explain this 
so-called co-morbidity of panic disorder and Imuor depression was undertaken. A number 
of theories concerning this were worked-out and are presented in chapter 3 of this thesis. 
In this investigation, based on these theories, it wns postulated as a hypothesis that the 
nemo-biological substrnte in patients with panic disorder and/or depression is identical 
and whereby a non-specit1c vulnerability for panic disorder and major depression develops. 
The psychological defense organizalion and used coping strategies were assumed to 
be specific for the individuals and according to this hypothesis determine which 
symptomatology would arise in patients. 
Initially, it was investigated whether the distinction of the patients suffering from panic 
disorder and those suffering from major depression was valid on the ground of 
symptomatology. In a number of studies with different set-ups, panic disorder appeared 
to show a very characteristic symptomatology whereby besides psychologically 
experienced anxiety in the sense of paroxysmal anxiety: fear of going crazy, fear of 
dying and depersonalization signs, also somatic symptoms such as dizziness, dyspnea, 
tachycardia, increased sweating and tremors were characteristic. The results of this part 
of our investigations were published elsewhere [Timmerman et aI, 1995 1]. It appeared 
that not only did pank disorder have a characteristic symptomatology, but that a valid 
distinction between patients suffering from pank disorder and those suffering from ma-
jor depression on the basis of symptomatology as measured in the Symptom Check List-
90 (SCL-90) was also possible [Timmerman ct al. 1995']. 
In the subsequent investigation (chapter 6), the extent to which defense organization 
and indicated coping strategies in the groups of patients differed from that in the patients 
in the reference- and the control groups was examined. It became clear from this 
investigation that the indicated defense -mechanisms in the patient group ,vas less adult 
and the coping was less adequate than that in the reference- and the control groups. 
However, this did not answer the question whether non-adult defense organization and 
less effective coping stra-tcgies indicated the vulnerability for the development of 
psychopathology or that (a period of) psychopathology induces the use of non-adult 
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defense - mechanisms and less effective coping strategies. Prospective investigation into 
the course of defense organization and indicated coping strategies was necessary in order 
to answer this queslion, We attempted to answer this question partially in the second part 
of the study in which the proportions of the defense organization and coping strategies in 
patients before treatment were compared with those aftcr recuperation, 
The important result that emerged from our study was that patients with major 
depression, panic disorder or panic disorder & major depression could not be distinguished 
from each other on the basis of indicated coping strategies and defense mechanisms (see 
chapter 7), This implied that there was no support for the hypothesis that there \vere 
distinct defense mechanisms and coping strategies which determined or modeled the 
psychiatric presentation, 
In biochemical investigations, we observed some differences between the three groups 
of patients as compared with the reference group, The concentration of tyrosine and the 
tyrosine-index (the proportion of the amino acid tyrosine as compared with those of the 
other large neutral amino acids in the plasma) in the plasma of the group of patients was 
lower than that in the reference group, However, for the rest, in this investigation of 
limited set-up, there was insufficient evidence for the existence of a biological substrate 
for these psychiatric disorders, However, the patient group that qualified for further 
investigation was rather small because a number of patients were already on medication 
before first blood samples could be taken for biochemical analyses, 
Within the three groups of patients, it appeared that the B-carboline norharman provided 
the best distinction towards psychiatric group, 
It was noteworthy hereby that the concentration of norharman in the plasma of patients 
with panic disorder was lower than that in patients with depression, depression & panic 
disonJer and the reference group, Norhannan is an aromatic alkaloid. In the brain of rats 
there were specific binding sites found with a very high affinity for norhanllan. Norharman 
and namely harman also shows a reasonably high affinity for the benzodiazepine receptor 
,reviewed by Van Gc1deren et ai, 19941, Recent investigations showed that norharman 
had a strong sedative effect in rats; moreover, the norhannan concentrations in the human 
plasma showed a circadian-rhythm, The concentration of norharman in the plasma 
decreases during the day, 
The affinity of (nor)hannan for benzodiazepine receptors and the sedative effect in 
rats indicated an endogenolls anxiolytic activity and are certainly not in contrast to the 
finding that the concentration of norharman was low in patients with panic disorder. 
However, further investigations are necessary, especially because we did not observe 
any abnormalities in the concentration of norharman in the group of patients suffering 
from panic disorder & major depression, 
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In the mean time, although investigations into the biological effects of norharman in 
the rat have been undertaken, to date, no studies have been conducted into the biological 
effect of norharman and harman in humans. Longitudinal prospective studies on the 
concentrations of norhanllan and harman in the plasma of healthy volunteers and 
(sub)groups of psychiatric patients are therefore warranted. 
In the second part of this study, possible changes in defense mechanisms and coping 
were investigated after combined treatment with antidepressants and cognitive therapy. 
The results of this part of the investigations must be interpreted with the necessary caution 
because of the relative small size of the patient group. 
An important outcome was that defense organization measured with the Defense 
Mechanism Inventory (DMI) under the intluence of the combined treatment changed. In 
particular there was a decrease in the lise of the defense mechanism "turning aggression 
against self' in the direction of the reference group. This is in agreement with the initial 
ideas of S. Freud [1986] concerning defense mechanisms. 
The indicated coping strategies measured with the Utrechtse Coping List (UeL) 
appeared to be more stable than defense -organization; this is in agreement with the ideas 
of Troop [1994], who saw coping chietly as a personality trait (trait determined character). 
Although, the combination of medicament and cognitive therapy administered by liS 
appeared to he successful in a large number of patients with regards to the reduction in 
the number of symptoms [Timmerman et ai, 1994J, the therapy, other then that was 
expected and hoped, led to no other fundamental changes in the coping strategies of the 
patients. Prospective long-term studies are necessary, and are being performed, in order 
to examine the stability of defense organization and indicated coping strategies in groups 
of patients and control groups. 
The investigation into the relationship between the psychological and biochemical 
variables showed that there was a negative correlation between the concentration of 
serotonin in thrombocytes & plasma and aggression parameters and confirmed the 
previously suggested link between aggression and depression on the one hand and a low 
fUllctioning serotonergic system on the other hand [Van Praag, 1991]. Treatment with 
clomipramine caused a depletion of serotonin in thrombocytes and prolonged treatment 
resulted in the lowering of its concentration in the plasma. The concentration ofttyptophan 
in the plasma decreased during treatment \vith clomipramine. In contrast to the 
concentration serotonin in thrombocytes and plasma, the concentration of tryptophan in 
the plasma remained low at follow-up. 
It is possible that the low concentration of tryptophan in the plasma can lead to a 
reduction in the synthesis of serotonin which may lead to changes in mood and behavior 
which can cause depression. In our view, further investigations into the relationship bet-
ween the concentrations of tryptophan and possibly of tyrosine in the plasma with recurrent 
psychopathology are warranted. 
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The results of QUI' investigations did not support the postulated unitmy hypothesis for 
the development of panic disorder, depression and panic disorder & depression. There 
was some biochemical evidence for the heterogeneity between the groups of patients. In 
addition, there was 110 difference in defense and coping between the groups of patients, 
but there was a real noticeable evenness irrespecti ve of the diagnosis. However, it should 
be noted that only a limited number of biochemical parameters in a relatively small 
group of patients not on any medication were investigated so that finn conclusions can 
not be drawn. 
In addition, our findings of similar defense mechanisms and coping strategies in patients 
with panic disorder and/of depression als lend support to the hypothesis by Tyrer [1992] 
who postulated 'General Neurotic Syndrome', In doing so, Tyrer considered a mixture 
of anxiety and depressive complaints with personality traits such as excessive timidity, 
low self confidence, avoiding anxiety-provocing situations and dependence on others, 
but it remains unclear what determined the sympto-matology that \vas in the foreground. 
In QUI' study, we noted a mixture of anxiety and depressive complaints in the 
symptomatology of the patients using the SCL-90. In our three groups of patients velY 
high scores as compared with those in standardized group were observed in amongst 
others for the scales anxiety and depression, \Ve also observed (using the UeL) high 
scores in the scale for avoidance. The scale seeking social support (also in the UCL) was 
only moderately increased in our groups of patients as compared with those in the 
standardized- and reference groups. 
However, it seems likcly that seeking social support, a directed active process, is dif-
fel-ent than dependence on others as meant by Tyrcr. 
On the basis of defense, coping and limited biochemical investigations, we were unable 
to find any explanatory model which could clarify as to \vhy one patient develops panic 
disorder, whereas a second patient develops depression and a third patient develops both 
disorders. 
As an explanation hypothesis, we postulate that besides a non-specific vulnerability, 
precipitating factors sHch as Life Events determine which form of psychopathology would 
arise. 
Thus, the development of panic disorder is probably linked to separation conflicts (see 
chapter D, whereas depression is probably induced by pO\verlessness and demoralization. 
Further prospectivc investigations are imperative to test this hypothesis. 
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HOOFDSTUK 14. CONCLUSIES EN AANBEVELINGEN 
Ten grondslag aan dit procfschrift ligt de klinische observatie dat patienten van cen 
polikliniek Psychiatric van cen algcmcen ziekenhuis zich SOI11S presenteren met cen 
psychiatrisch beeld dat valdoet aan de criteria voor paniekstoornis al dan niet met 
agorafobie volgens DSM-lll-R criteria, lerwijl deze patienten tevens in cen aanzicnlijk 
percentage voldoen aan de criteria yoor cen dcprcssic in cngcrc zin volgens hetzelfde 
c1assificatie systeem. Niet alleen blijkt er bij deze ambulante palicntcn zin sprake te zijn 
van gelijktijdig voorkol11cn van twee psychiatrische symptoomclusters; ook blijkt dat 
patienten zich aanvankeIijk onder behandeling stellell in verband met cen drclIl11scripte 
paniekstoornis tenvijl zij in een later stadium ofbij een nieuwe ziekteperiode, niet langeI' 
voldoen aall de criteria voor paniekstoornis maar lijden aall een depressie in engere zin 
of omgekeerd. 
Op basis van deze klinische observaties werd gezocht naareen theoretisch verklarings-
model om deze zo geheten comorbiditeit van paniekstoornis en depressie in engere zin te 
verklaren. 
Een aantal theorieen hieromtrent wordt uitgewerkt in hoofdstuk drie van dit proef-
schrift. Vit deze theorieen wordt in dit onderzoek als hypothese gefonnuleerd dat bij 
patienten met een paniekstoornis en/of depressie, het neuro-biologisch substraat voor 
deze aandoeningen identiek is en waarbij er een non-specifieke vulnerabiliteit ontstaat 
voor paniekstoornis en depressie in engere zin. 
De psychologische afweerorganisatie en gebruikte copingstrategieen worden als spe-
citlek voor de be ide patientgroepen verondersteld en bepalen volgens deze hypothese 
welke symptomatologie er bij patienten ontstaat. 
Als ccrstc wordt onderzocht of op grond van symptomatologie het onderscheid tussen 
patienten die lijden aan een paniekstoornis en een depressie in engere zin valide is. 
Panickstoornis blijkt in een aantal, qua opzet uiteenlopende, studies een zeer karaktc-
ristieke symptomatologie te vertollen waarbij naast psychologisch ervaren angst in de 
zin van paroxysm ale angst -angst 0111 gek te worden, angst am dood te gaan-en deperso-
nalisatie verschijnselen ook sOl11atische symptomen als duizeligheid, dyspnoe, tachycar-
die, vcrhoogdc transpiratie en tremoren karakteristiek zijn. De resuitaten van dit deel van 
ons onderzoek zijn tevens elders gepubliceerd [Timmerman et ai, 19951], Niet aileen 
blijkt paniekstoornis een kenmerkende symptomatologie te hebben, ook is een valide 
onderscheid op basis van symptomatologie, zoals gemeten op de Symptom Check List-
90 (SCL-90) tussen patienten met een paniekstoornis en patienten met een depressie in 
engere zin 1l10gelijk [zie ook Tinllnerman et ai, 19953 1. 
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In het onderzoek wordt vervolgens (beschreven in hoofdstuk zes) nagegaan in hoeverre 
afweerorganisatie en gehallteerde copingstrategieen in OIlze patientengroepen vcrs<.::hi1len 
vall een referentiegroep en controlegroepen. Daarbij wordt duidelijk clat de gehanteerde 
afweermcchanismcn in de patientcngroep minder rijp zijn en de coping minder adequaat 
is dan in een referentiegroep en controlegroepen. Hiermec wordt cehter geen antwoord 
gegeven op de vraag of onrijpe afweerorganisatie en matige copingstrategieen de 
vulllerabiliteit voor het ontstaan van psychopathologic geven, of clat (een periode van) 
psychopathologic het gebruik van onrijpe afweermechanismen en minder effectieve 
copingstratcgiccn induceert. Teneinde deze vraag te kunnen beantwoorden is prospcctief 
onderzock over het beloop van afweerorganisatie en gehanteerde copingstrategicen nood-
zakelijk. Wij trachten dezc vraag, gcdeeltelijk, te beantwoorden in het tweede dee I van 
het onderzoek waarbij is nagegaan hoe de afweerorganisatie en copingstrategieen bij 
herstelde patienten zich verhouden tot die van voor de behandeling. 
Als helangrijk resultaat in OilS onderzoek komt naar voren dat patienten met een de-
pressie in engere zin. paniekstoornis of paniekstoornis en depressie in engere zin zich op 
basis van gehanteerde copingstrategieen en afwcermcchanismen niet van elkaar laten 
onderscheiden (zie hoofdstuk 7). Dit implkcert dat wij geen steun vinden voor de hypo-
these dat er sprake is van onderscheidell afwccnllcchanismen en copingstrategieen die 
het psychiatrisch heeld bepalcn of vormgeven. 
Bij biochemisch onderzoek vinden wij enig verschil in de drie patientengroepen ten 
opzichte van de rcferelltiegroep: de concentratie in plasma tyrosine en de tyrosine-index 
(de vcrhouding van hct aminozuur tyrosine ten opzichte van de andere grote neutrale 
aminozuren in plasma) is in de patientengroep ten opzichte van de referelltiegroep ver-
laagd maar voor het overige zijn er in deze beperkte opzet onvoldoende aanwijzin-gen 
voor het al dan niet bestaan van een biologisch suhstraat van deze psychiatrische stoor-
nissen. De onderzochte patienten-groep welke in aanmerking kWHm voor nadere 
biochemische analyse was echter klein, daar eell aantal patientcll reeds v66rdat bloed 
kon worden afgenomen voor biochemische analyses ingesteld werd op psychofarmaca. 
Binnen de dde paW::ntengroepen blijkt het f)-carboline norharman het beste naar psy-
chiatrische groep te differentieren. 
Het vaIt hierbij op dat patienten met een paniekstoornis een lager plasma norharman 
gehaIte hebben dan patienten lllet een depressie. depressie en paniekstoornis dan de 
referentiegroep. Norharman is cen aromatische stikstofverbinding die behoort tot de groep 
van de B-carbolines ofharmanalkoloi'den. Inrattehersenen zijn specifieke bindingsplaatsen 
voor norhannan aangetoond mct cen zcer hoge affiniteit. 
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Norhannan en met name harman vertonen ook een redelijk grote affiniteit VOOl' de 
henzodiazepinen receptor (zie voor een overzicht Van Gelderen et ai, 1994). Uit recent 
onderzoek blijkt norharman bij ratten een sterk scdatief effect te hebben; voorts vertonen 
de Norharman concentraties in het plasma bij menseH een circadiaanritme, de plasma 
concentratic norhannan daalt gedurendc de Jag. 
De affiniteit vall (nor)hannan voor benzodiazepinen receploren en het sedatief effect 
bij ratten suggereert een elldogeen anxiolytische werking en zijn bepaald niet strijdig 
mct de hevinding dat norharman bij patienten met paniekstoornis verJaagd is. Nader 
onderzoek is echter noodzakclijk, te meer daar wij in de palielltengroep lijdend aan een 
paniekstoornis plus cell depressie in engere zin cen Iliet afwijkend norhannangehalte 
vinden. 
Hoe\vel er inmiddels onderzoek is verricht naar de biologische effecten van norhannan 
bij de rat, is er nog gccn studie verricht naar hct biologisch effect van norharman en 
harman bij de mens. Ook dient er longitudinaal prospectief onderzoek naal' dc Ilorharman 
en harman concentratic in plasma bij gezondc vrijwilligers en (sub)groepen psychiatri-
sche patienten vcrricht te worden. 
Tn het tweede dcel van deze studie zijn mogelijke veranderingen in afweermechanis-
men en coping onderzocht Ila een gecombineerde hehandeling mel antidepressiva en 
cognitieve therapie. Dc uitkomsten van dit dee I van het onderzoek dienen met de nodige 
voorzichtigheid te worden gei'nterpreteerd daar het om een relatief kleine groep patienten 
gaat. 
Een belangrijkc uitkomst is dat afwccrorganisatie gemeten voIgcns de Defense 
Mechanism Inventory (D!vII) onder invloed vantlc gecombineerde behandeling venmdert. 
Met name vindt een afname plaats in het gebruik van het afweer mechanismc " turning 
against self', waardoor dit meer or het niveau van de referentie groep kom te liggen. Dit 
is in Dvereenstenulling met de oorspronkelijke idceell van S. Freud (1986) betrcffende 
afwcermechanismen. 
De gehanteerde copingslralegieen gemelen mel de Ulrechtse Coping Lijsl (UCL) blij-
ken stabieler dan afweerorganisatie; dit komt overeen met de ideeen van 11'oop (1994), 
die coping ziet als voornamclijk een persoonlijkhcids trek (trait bep<lalde eigcnschap). 
Hoewel de door OilS toegepaste gccombineerde medicamenteuze en cognitieve therapie 
in een groot aalltal patienten succesvol voor \Vat betreft s),mptoomreductie blijkt [Tim-
merman e1 aI, 1994], geef( de bchandeling andel'S dan verwacht en gehoopt geen funda-
mentele veranderingen in de coping strategieen van de patienten. Prospecticf lange ter-
mijn onderzoek is nodig en wordt Illomenteel uitgevoerd, ten einde de stabiliteit van 
afwcerorganisatie en gehanteerde copingstrategieen na te gaan bij contro1egroepen en 
paticntengroepen. 
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Het onderzoek naal' de samcnhung tussell dc psychologischc en biochemische varia-
belen laal zicn Jat cr eell negatieve correlatie is tussell de concentratie van serotonine in 
trombocytcn en plasma ell agressie parameters. Dit bevestigt de eerder gesllggereerde 
koppeling tussell enerzijds agressie en depressiviteit en andcrzijds een laag fUl1ctione-
rend serotonincrg systecm anclcrzijds (Van Praag, 1991), Clomipramine bchandcling 
veroorzaakt een depletie van seroloninc in thrombocyten en bij 1angere behandelduur 
een vcrIaging van het serotonincgchaite in plasma. Oak het plasma tryptofaan gehaltc 
c1aalt geclurcnde de bchandeling met clomipramine. In tegenstelling tot de serotonine in 
thrombocyten en plasma blcef het plasma tryptofaan ook bij follow up laag. 
Hel is mugeJijk dat de lage concentratie aan plasma tryptofaan tot een reductie in de 
synthcse van scrotonine lijdt, hetgeen veranderingen in stemming en gedrag, zoals 
bijvoorbccld depressie kan veroorzaken. Nader onderzoek Haal' de correlatie tussen plasma 
tryptof~tan cn mogelijk ook plasma tyrosine met recidief psychopathologie is ons inziens 
ge'lndiceerd. 
OilS onderzoek geeft geen steun aan de gefol111uleerde unitaire hypothese vaal' het 
ontstaan vall palliekstoornis, depressie, en paniekstoornis met depressie. Biochemisch 
zijn er enige aanwijzingen voor heterogeniteit tussen de patientengroepen; en bovendien 
is er geen onderscheid in at\veer en coping tussen de patienten groepen lllaar juist een 
opvallende gelijkvorIlligheid ongeacht de diagnose. Hierbij dient te worden opgemerkt 
dat wij slechts een beperkt aantal biochemische parameters onderzochten in relatief kleine 
medicatievrije groepen patienten, zodat wij geen harde conclusies lllogen trekken. 
Onze bevindingen van overeenkomstige afweermechanismen en copingstrategieen bij 
patienten met een paniekstoornis en/of een depressie geven dnn ook steun nan de hypothese 
van Tyrcr (1992) die een 'General Neurotic Syndrome' postuleert. Tyrer gnat hierhij uit 
van een mengeling van angst en depressieve klnchten met persoonlijkheidskenmerken 
als cxccssicvc limiditeit, Iaag zelfvertrouwen, vermijden vall angstprovocerende situaties 
en atlmllkclijkheid vall anderen, waarbij onduidelijk blijft \vat de op de voorgrond staande 
symptomatologic bepaalt. 
Dc gcmengde angst en depressieve klachten vinden wij bij OilS onderzoek Ilaar de 
symptomatologic van de patienten door middel van de SCL-90. Tn ollze drie patienten-
groepen worden ten opzichte van nonngroepen sterk verhoogde scores gevonden op 
ondcr anderc dc schalen angst en depressiviteit. Ook vinden wij (op de DCL) hoge scores 
op de schaal voor vermijding. De schaal sociale steun zoeken (eveneens van de DeL) is 
in onze patielltengroepen slechts matig verhoogd ten opzichte van normgroepen en 
ret'erentiegroep. 
Het lijkt echter waarschijnlijk dat socia Ie steun zoeken, een gericht actief proces, andel's 
is dan atlmnkelijkheid van anderen zoals bedoeld door Tyrer. 
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Op basis van afweer, coping en beperkte biochemische onderzoe-kingen vinden wij 
geen model waarom de ene patient een paniekstoornis ontwikkeIt, cen andere patient een 
depressie, en eell volgende patient beide, Als verklarings hypothese postuleren wij dat 
naast een aspccifieke vulnerabiliteit, precipiterende factoren (zoals bijvoorbeeld Life 
Events) bepalen welke vonn van psychopathologie ontstaat. Zo hangt het ontstaan van 
eell paniekstoornis lllogeJijk samen met separatiecont1icten (zie hoofdstuk 0, terwijl 
dcpressie l110geJijk wordt geinduceerd door machteloosheid en demoralisatie. 
Ten einde deze hypothese te toetsen is verdeI' prospectief ol1derzoek noodzakelijk. 
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SUMMARY 
Chapter 1 
In this ehaptcr" Panic disorder, an update", following a historical description on the 
development of the concept 'panic disorder' , an inventory of the characteristic symptoma-
tology of panic attacks and a review of the epidemiological data on panic disorders are 
presented. There is considerable agreement 011 the prevalence (0.5-1.5%) of panic disorder 
from various centers spread all around the world. 
It is was also noteworthy that women suffered more frequently from panic disorder 
than men. The difference between men and women varied in variolls studies from 
50% to 200%. 
The genetic aspects of panic disorder are discussed. The conclusion was that panic 
disorder had a sped fie genetic entity \vhich was not associated with a broad spedrum of 
anxiety or other psychiatric disorders with the possible exception of social phobia. 
Besides genetic factors, Life Events also played an important role in the development 
of panic disorder. In particular, the presence of separation problems appeared to he of 
great imporlance. 
It appeared that for the treatment of panic disorder, both psycho-phannaceuticals 
(benzodiazepincs, inhibitors of serotonin uptake, tricyclic antidepressants and inhibitors 
of monoamine oxidase) and psychotherapy (cognitive behavior therapy) were effective. 
However, the prognosis for patients who suffer from panic disorder is not un-dividedly 
favorable. In a considerable proportion of the patients, the amiction follows a chronic 
course. It may be possible to improve the long-term prognosis by continuing medication 
for a prolonged period and/or by a combination of medication & psychothcrapy. 
Chapter 2 
The results of a survey and critical evaluation of the literaturc on biologic/psychiatric 
aspects of panic disorder arc presented in this chapter. The following arc discussed: 
serotonergic hypothescs, noradrenergic hypotheses, the GABA hypothesis, the roles of 
the /J-carboline norhannan and cholecystokinin. Subsequently, neum-anatomical theories 
concerning panic disorder and the importance of the septo-hippocampal system in 
particular are briefly presented. A total of ten biological theories explaining the origin of 
panic disorder are discussed. The conclusion was that none of these biologi-cal theories 
provide a unifying explanation for the origin of (or one of the?) panic disorder. 
It \vas postulated that a single inter-active model of biopsychosocial causality would 
qualify as the most important explanation model for the origin of panic disorder. 
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SUl1Il1IalY 
Chapter 3 
A survey of the literature on the co-morbidity between panic disorder and major 
depression relevant to the set-up of the present study is presented in this chapter. Several 
factors appeared to be important in the etiology of the co-morbidity between panic dis-
order and depression: the gender of the patient, the duration of the psychiatric aftliction, 
genetic load and co-morbidity of panic disorder with other psychiatric afflictions such as 
social phobia and generalized anxiety disorder. 
Six theoretical models are discussed in order to explain the simultaneolls occurrence 
of panic disorder and major depression. 
1. A model in which the starting point is a common pathogenesis of panic disorder and 
depression (unitary hypothesis). 
2. A model in which it is postulated that two separate and well circumscribed syndromes 
occur together (by chance?). 
3. A predisposition model in which one affliction etiologically, chronologically or 
psychopathologically leads to another affliction. 
4. A model in which the starting point is an artificial overlap between two different 
afflictions because of the manner in which they are defined. 
5. A combined model: 'general neurotic syndrome' ill \vhich a combination of anxiety, 
depression and a dependent personality disorder are assumed. 
6. A model in which the simultaneous development ofll1ultiple psychopathology whereby 
the development of panic disorder generally precedes the development of depression 
is proposed as a hypothesis. 
An introduction to our own studies is presented in the second half of this chapter. The 
importance of psychological defense mechanisms and coping strategy in patients with 
panic disorder and depression as compared with patients with another psychiatric dis-
order and in control groups are briefly discussed. Tn addition, based on the data in the 
literature, it was investigated if it was possible to establish whether psychological 
functions, defense and coping were trait or state determined. 
The possible meaning of serotonin in the etiology of depression and panic disorder are 
discussed and presented together with those of amino acids tyrosine & tryptophan and 
the a-carboline norhannan. It was postulated on the basis of previolls investigations that 
plasma norharman probably retlected the intra-psychological processes. 
As a central investigational hypothesis, it was established that one could speak of 
unitmy etiology in panic dL"order and mltior depression and that this etiology may lie in 
a biological substrate whereby psychological characteristics such as defense organization 
and/or coping strategies determine which psychiatric disorder would develop. 
lSI 
On the basis of this hypothesis, it was expected that it would be possible to distinguish 
patients with panic..: disorder or major depression from each other on the basis of 
symptomatology, defense organization and coping strategies, but not on the grounds of 
their biochemical profile. 
Chllpter 4 
The set-up of the investigation, inclusion & exclusion criteria for the patients, methods 
including the treatment of the patients according to protocol and the used questionnaires 
such as Symptom Check List-90 (SCL-90), Utrechtse Coping List (UCL), Defense 
Mechanism Iuveutory (DMI) aud Munich Diagnostic Check List (MDCL) are discussed 
in this chapter. 
Chapter 5 
In Chapter 5, the population that was investigated, biographic- and psychopathological 
particulars of the patients and the drop-outs whic..:h occurred during the period of 
investigation are described. The cO-lllorbidity between panic disorder and major depression 
in our study was lower (15%) than that (25-40%) cited in the literature. The drop-out 
percentage during the treatment for 6 months was 31 %. This percentage \vas lower than 
that observed under the same treatment setting in an earlier study in patients with 
depression and wns also lower than the percentage reported in other studies involving 
comparable groups of patients. It was speculated that this was because of the open nature 
of the treatment protocol \vhich reduced the uncertainty for the patients and because of 
the combined treatment with medication & psychotherapy. 
Chapter 6 
In the studies described in this chapter, the extent to which the groups of patients as a 
whole differed from a reference group and standardized groups with regards to 
psychological variables such as complaints. coping strategies and defense organization 
\vas evaluated. Tn addition, it was also investigated whether there were any differences 
between the groups of patients and the reference group with regards to the biochemical 
parameters such as the concentration of serotonin in the blood, plasma & thrombocytes, 
the concentrations of tyrosine & tryptophan and their index in relation to other amino 
acids and the concentration of g-carboline norharmall. 
On the basis of SCL-90 scores, it appeared that in the investigated group of patients, 
one could speak of a moderately severe to severe symptomatology as compared with 
other psychiatric out-patients in the Netherlands. The scores of the VCL clearly showed 
that the group of patients indicated inadequate coping whereby more use was mude of 
palliation, avoidance and depressive reactions as compared with the reference group. 
The patients also tended to show a lower active problem solving than that in the reference 
group. 
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Summary 
As far as defense organization was concerned, the group of patients tended to make 
more use of non-adult defense mechanisms such as projection as compared with the 
reference group. The male patients also tended to use turning aggression against self 
more as compared with those in the standardized-and reference groups. 
On the basis of psychological variables in discriminant analysis, it appeared that a 
very reliable distinction could be made between the reference group and the group of 
patients. A correct classification was possible in 94% of the cases. 
The SCL-90 sub-scales provided the best distinction followed by the coping strategies 
avoidance and depressive reactions both of which were used more by the patients than 
those in the reference group. The defense mechanism turning aggression against self was 
indicated more in the group of patients than those in the reference group. 
A reliable distinction between the group of patients and the reference was also ohtained 
upon discriminant analysis on the basis of biochemical parameters. However, the 
distinction based on biochemical parameters was evidently less clear-cut than that obtained 
on the basis of psychological variables. 
Of the biochemical panllneters, the tyrosine ratio (tyrosine compared with other large 
neutral amino acids) weighed the heaviest in discriminant analysis. Tyrosine is an amino 
acid which serves as the precursor for the synthesis noradrenalin and dopamine in the 
brain. Besides serotonin, these neurotransmitters probably play an important role in the 
etiology of depression and panic disorder. 
Chapter 7 
The extent to which the three groups of patients with panic disorder, major depression 
and panic disorder & major depression respectively could be distinguished from each 
other on the basis of psychological and biochemical parameters \vas examined in the 
studies described in this chapter. It appeared that the three groups could be clearly 
distinguished from each other at the level of symptoms (SCL-90 scales) among other 
using the panic score developed by us on the basis of the SCL-90. 
However, a reliable distinction between the three groups of patients appeared not to be 
possible on the basis of psychological defense organization or indicated coping strategies. 
Biochemically, patients with panic disorder could be distinguished from the other two 
groups of patients because they had a low concentration of the 3-carboline norharman. 
This finding fits in with the possible function of nor han nan as benzodiazepine agonist. 
Patients with panic disorder probably have a high level of anxiety because of low 
concentration of norharman, However, there is no explanation for the normal concentration 
of norhanllan in patients with co-morbid panic disorder and depression. 
In discriminant analysis, it appeared that 62.1 % of the patients could be classified in 
one of the three groups on the basis of biochemical variables. 
Besides norhannan, tryptophan and tryptophan ratio, the concentration of serotonin in 
the blood also contributed the most towards discrimination. 
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The findings of this investigation provided some evidence for the hypothesis of 
biological heterogeneity of panic disorder and major depression whereby every psychiatric 
disorder has its own specific genetic and neurobiological origin. \Ve also found no support 
for the "unitary" hypothesis of the two disorders because there were no differences in the 
psychological characteristics such as defense and coping between the patients with panic 
disorder andlor depression. 
Chapter 8 
The inter-dependence of the psychological variables prior to treatment are discussed 
in this chapter. 
\Vitllin the coping sub-scales of the UCL, in the group of patients, there was a positive 
correlation between avoidance and depressive reactions; expression of emotions and 
palliation; depressive reactions and expression of emotions and between seeking support 
and expression of emotions. Differences in the relationship between coping style as 
compared with standardized- and reference groups are also presented. 
In the defense mechanisms, a positive correlation was observed between turning 
aggression against others and projection. Negative correlations were observed between 
turning aggression against others and repression, avoidance and intellectualization. 
Projection also correlated negatively with repression, denial, intellectualization and 
turning aggression against self. In the reference group, the lise of defense mechanisms 
measured using the DMJ did not differ from that in the control groups as reported in the 
literature. The differences in the indicated defense mechanisms between the group of 
patients and the reference group were only quantitative. 
No important significant correlations between coping strategies and defense 
mechanisms were noted in the reference group. However, in the group of patients, there 
was a positive correlation between intellectualization and active problem solving and 
there were negative associations between intellectualization, depressive reactions and 
expression of emotions. Use of intellectualization as defense mechanism probably offered 
protection against depressive reactions. 
Chapter 9 
The changes in the measurements using the SCL-90, UCL, DMI and biochemical 
parameters six and nine months after the start of the treatment are presented in this chapter. 
The pattern of complaints by the patients with panic disorder andlor major depression as 
measured using the SCL-90 scale changed favorably during treatment with a combination 
of clomipramine and cognitive therapy. The group of patients with co-morbid major 
depression and panic.: disorder showed a lower therapeutic response than the other two 
diagnostic groups. 
It appeared from the measurements at the follow-up that in the group of patients in 
whom clomipramine had been withdrawn after six months of treatment, the observed 
improvement that had been achieved appeared to have set in three months later. 
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Summary 
Changes in the style of coping and indicated defense mechanisms did not depend on 
the diagnostic group to which the patients belonged, Indicated coping strategy changed 
during the treatment. Hmvever, the changes were unclear except for the scores of the 
scales avoidance and depressive reactions which decreased during treatment. The defense 
organization as measured using the DMI changed during the treatment: during the 
combined treatment with medication and cognitive therapy, the use of the defense 
mechanisms turning aggression against others increased, whereas turning aggression 
against self decreased, 
Although during treatment changes occurred in the psychological defense and to a 
lesser extent, in indicated coping strategy, it appeared upon regression analysis that the 
initial values in the scales used for evaluating defense and coping, the DMI and the VCL 
were of utmost importance in determining the outcome six and nine months after the 
start of the treatment, 
Chaplers /0, 11 al/{/12 
Additional discussions on the patients who were not on any medication at baseline are 
presented in these three chapters, 
In the studies described in Chapter 10, it \vas examined whether there were differences 
between the SCL-90, VCL and Dt<.1I scores of patients who were on clomipramine and 
those not 011 any medication at the beginning of treatment when the blood samples were 
first taken, It appeared that the scores at this level of psychological functions in the t\VO 
groups were almost identicaL Therefore, the patient population could be regarded as one 
for the purposes of discussion on the psychological variables, 
Clomipramine appeared to have a very strong effect on the concentrations of serotonin 
in the blood, plasma and in thrombocytes of the patients, The concentration of serotonin 
in the patients on clomipramine was much lower than that in the patients in the reference 
group and in the patients who did not use antidepressant at the time blood samples were 
first taken, The concentration of tryptophan in patients on clomipramine was much lowcr 
than that in the group not on any medication, 
It can he speculated that the use of clomipramine induced the activation of the enzyme 
tryptophan pyrrolase in the liver which resulted in an increased degradation of tryptophan, 
Alternative hypotheses for the low level of tryptophan in the group of patients on 
clomipramine are also presented for example: a shift from protein-bound to free tryptophan 
under the influence of the antidepressant or a reduced absorption of tryptophan in the 
gnt. 
In Chapter 11, the inter-dependence of psychological and hiochemical values is 
described, The inter· correlations between SCL·90, D1vlI & VCL and the biochemical 
parameters, as far as significant, are given for the group of patients and thc reference 
group, 
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In the group of patients as a whole, negative correlation were ohserved between the 
concentration of serotonin in thrombo<.:ytes & depression and hostility & turning 
aggression against others. Serotonin in plasma and tryptophan correlated negatively with 
hostility. These findings supported the suggested link between aggression and depression 
with a low funclioning serotonergic system. In contrast to previous observations, in the 
present study, there were no correlations between norhannan and intra-psychological 
mechanisms such as defense organization or coping strategies. 
The changes in the group of patients not on any medication at haseline after treatment 
for six and nine months are described in Chapter 12. As far as the therapeutic effect and 
the results are concerned, this group did not appear to behave any differently from the 
patient group as a whole as mentioned in Chapter 8. 
After six months of treatment \vith clomipramine and cognitive therapy, there \vas a 
decrease in the intra-punitive mechanism turning aggression against self and an increase 
in turning aggression against others and reversaL 
These changes in the o:rvII increased further in the period from six to nine months 
during which the treatment was withdrawn. The biggest change occurred in the compiled 
scale repression: a decrease 01'91 % was noted nine months after the start of the treatment. 
On the basis of this, it can be postulated that indkated defense mcduUlisms for an 
important part depends Oil the actual psychiatric affliction in the patients. 
However, this hypothesis should be viewed with the necessary caution because the 
repression scale of the DMJ is compiled 011 the basis of different scores (see chapter 4). 
Relatively small changes in the score of the compiled scales may lead to large changes in 
the repression scale. 
From the coping strategies, depressive rea<.:tiolls and avoidance had changed (negatively) 
the most. Depressive rea<.:tions decreased by 26% and avoidance by 9% nine months 
after the start of the treatment. It can be remarked that change in the coping strategy 
depressive reactions is probably state determined and was strongly influen<.:ed by the 
therapeutic effect. The remaining coping strategies appeared to be more trait dependent 
and changed little (less than lO%) during the combined treatment with antidepressant 
and cognitive therapy. 
The biggest changes in the biochemkal variables were noted in the concentrations of 
serotonin in the blood, plasma and thrombocytes. The concentration of serotonin increased 
again when clomipramine was withdrawn after 6 months of treatment. It was noteworthy 
that the cOIl<.:entration of tryptophan, the precursor of serotonin, remained low even after 
clomipramine had been withdrawn. The cause of this low concentration of tryptophan 
after six and nine months of treatment remains unknown. One can speCUlate that the low 
concentration of tryptophan and to a lesser extent, the low tryptophan ratio which were 
still observed three months after the withdrawal of clomipramine formed a risk for a 
re<.:urrence of psychopathology via derangement of the serotonergic system. 
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Summal), 
The concentration of norharman in the plasma appeared to be highly increased during 
the treatment with clomipramine. This increase appeared to be linked to the treatment 
with clomipramine: whereas the therapeutic effect in this group of patients still increased 
between six and nine months, the concentration of norharman in the plasma decreased 
again. 
Chapters 13 alld 14 
Concluding remarks in English and Dutch are presented in chapters 13 and 14 
respectively. On the basis of defense, coping and limited biochemical investigations, we 
were unable to find any explanatory model which could clarify as to why one patient 
develops panic disorder, whereas a second patient develops depression and a third patient 
develops both disorders. As an explanation hypothesis, we postulate that besides a non-
specifIc vulnerability, precipitating factors such as Life Events determine which form of 
psychopathology would arise. 
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SAMENYATTING 
Hoofdslllk 1 
Dit hoofdstuk " Panic disorder, an update", geeft nn cen historische beschrijving van 
de ontwikkcling van het bcgrip paniekstoornis cen inventarisatie van de kenmerkcnde 
symptomatologic van panickaanvallen en cen overzicht van de epidcmio-logische 
gegevens van p<lniekstoornis. Paniekstoornis blijkt in uitccniopclldc centra verspreid over 
de gehele wereld cell grate mate van overeenkomst in prevalcntic (0.5-1.5 %) Ie vertonen. 
Het valt hierbij op dat vrouwen veel frequenter dan Illannen aan cen panickstoornis 
Iijden. Het verschil tussen mallncn en vrouwen varieert in uiteenlopcnde studies van 50 
tot 200%. 
De genetische aspectcn van paniekstoornis worden besproken. Geconcludeerd wordt 
dat paniekstoornis een specifieke genetische entiteit heeft welke niet geassocieerd is met 
een breed spectrum van diverse angst-, of andere psychiatrische stoornissen uitgezon-
derd mogelijk sociale tobie. 
Naast genetische factoren spelen ook life events een belangrijke rol in het ontstaan 
van een paniekstoornis .. Met name het bestaan van separatieproblematiek blijkt vall groat 
belang. 
Bij de behandeling van panieksloornis blijkt clat zowel behandeling met psychofannaca 
(benzodiazepines, serotonine heropname remmers, tricyclische antidepressiva en mono-
amine-oxydase remmel's) als met psychotherapie (cognitieve gedragstherapie) eft'ectief 
kan zijn. De prognose voor patienten die aan een paniekstoornis lijden is echter niet 
onverdeeld gunstig. Een aanmerkelijk percentage van de patienten blijkt een chronisch 
ziektebeioop te vertonen . .rvlogelijk is de lange termijn prognose te verbeteren door het 
langeI' voortzetten van de farmacotherapeutische behandeling en/of een combinatie van 
fannacotherapie met psychotherapie. 
Hoofdslllk 2 
In hoofdstuk twee worden de resultaten weergegeven van een kritisch literatuur 011-
derzoek naal' de biologisch-psychiatrische aspecten van paniekstoornis. Hierhij worden 
besproken: seroloninerge hypothesen, noradrenerge hypothesen, de GABA hypothese, 
de 1'01 van het J3 carboline norharman en van cholecystokinine. Vervolgens worden 
neuroanatomische theorieen belreffcndc panickstoornis, met name het belang van het 
seplo-hippocampaJe systecm kort wccrgcgcvcn. In hel totaal komen tien biologische 
vcrklaringstheorieen voor het ontstaan van paniekstoornis tel' sprakc. Gcconcludeerd wordt 
dat gccn van deze biologische theorieen eenduidig een vcrklaring kan geven vaal' het 
ontstaan van de (of een?) paniekstoornis. 
Gepostuleerd wordt dat een interactief model van biopsychosociale callsa1iteit als 
belangrijkste verklaringsmodei voor het ontstaan van paniekstoornis in aanl1lerking komt. 
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Somcnvofting 
Hooids/uk 3 
In hoofdstuk drie wordt een literatuuroverzicht betreffende comorbiditeit tussell paniek-
stoornis en depressie in engere zin gegeven voor zover relevant in de opzel van de hui-
dige studie. In de etiologie van de comorbiditeit tussen paniekstoornis en depressic blij-
ken ecn aantal facloren van belang: het geslacht van de patient, de tijdsduur gedurcndc 
welke de psychiatrische stoornis bestaat, genetisehe belasting en comorbiditeit van paniek-
stoornis met andere psychiatrischc stournissen zoals sociale fobie en gegeneraliseerde 
angststoornis. 
Er worden zes theoretische modellen besproken van waaruit het gelijktijdig voorko-
men van paniekstoornis en depressie in engere zin kan worden verklaard. 
1. Een model waarbij uitgegaan wordt van een gemeenschappelijk pathogenese van 
paniekstoornis en depressiviteit (unitary hypothese). 
2. Een model welke postuleert dat t\vee separate, goed afgegrensde, syndromen (bij 
toeval?) samengaan. 
3. Een predispositie model, waarbij de ene stoornis etiologiseh, ehronologisch of 
psychopathologisch lijdt tot cen andere stoornis. 
4. Een model dat uitgaat van een artificiele overlap door de \vijze van definiering van 
twee verschillendc aandoeningcn. 
5. Een gecumbincerd model: 'general neurotic syndrome', dat een combinatie van angst, 
depress ie, en een afhankclijke pcrsoonlijkheidsstoornis veronderstelt. 
6. Een model dat aIs hypothese de geIeidelijke ontwikkeling van multiple psycho-
pathologie stelt en waarbij het ontstaan van cen paniekstoornis in het algemeen voor 
afgaat aan het ontstaan van cell depressie. 
Het twcede dccl van hoofdstuk drie betreft een inleiding op het eigen onderzoek. Er 
wordt kort ingegaan op het beIang van psyehologisehe afweenlleehanismen en 
copingstrategiecn bij paniekstoornis en depressie in vergelijking tot patienten met een 
andere psychiatrische stuornis en in controIegroepen. Tevens wordt nagegaan of er op 
basis van de literatllurgegevens cen lIitspraak kan worden gedaan of deze psychologi-
sehe functies, afweer en coping, trait of state bepaald zijn. 
De mogelijkc betekcnis van serotonine in de etiologie van depressie en paniekstoornis 
wordt besproken, evenals die van de aminozuren tyrosine en tryptofaan en het 
betacarholine norharman. Op basis van eerder onderzoek wordt gepostuleerd dat plasma 
norhanllan mogelijk intrapsyehische processen weerspiegelt. 
Ais centrale onderzoebhypothese wordt gesteld dat er sprake is van unitaire etiologie 
bij paniekstoornis en depressie in engere zin, en dat deze etiologie gelcgen kan zijn in 
eell biologisch substraat waarbij psychologische kenmerkcn in de zin van afweer-
organisatie en/of copingstrategieen bepalen \velke psychiatrische stoornis ontstaat. 
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Op basis van deze hypothese wordt verwacht dat patienten met een paniekstoornis of 
depressie in engere zin weI op basis van symptomatologie, afwccrorganisatie en coping 
strategicen van elkaar te onderscheiden zijn, maar niet op grond van hun biochemisch 
profiel. 
Hoojds/uk 4 
In hoofdstuk vicr worden onderzoeksopzet, in-, en exclusie criteria, mcthoden, waar-
onder protocollaire behandeling van de patienten en de gehantcerde vragenlijsten -
Symptom Check List -90 (SCL-90), Utrechtse Coping Lijst (UCL), Defense Mechanism 
Inventory (DMI) en Munich Diagnostic Check List (MDCL)- besproken. 
Hoojds/uk 5 
Hoofdstuk vijf geeft een beschrijving van de onderzoekspopulatie, biografische en 
psychopathologische gegevens en beschrijft de drop-outs die gedurende de onderzoeks-
periode optreden. Het comorbiditeitspercentage tussen paniekstoornis en depressie in 
engere zin ligt in onze studie lager (15%) dan in de Iiteratuur wordt aangegeven 
(25% - 40%). Het drop-out percentage gedurende de totale hehandelduur van zes maan-
den bedroeg 31 %. Dit percentage ligt onder dat van eell eerder onderzoek bij depressieve 
patienten in dezelfde behandelsetting en onder het percentage dat andere onderzoekers 
in vergelijkbare patientengroepen vonden. Er wordt gespeculeerd dat dit kumt door het 
open karakter van de behandeIing, hetgeen mindel' onzekerheid voor de patienten met 
zich meebrengt en door de combinatie van mcdicamenteuze therapie met psychothe-
rapie. 
Hoojds/uk 6 
In hoofdstuk zes wordt onderzocht in hoeverre de patientengroep als gehcel vcrschiIt 
van eell referentiegroep en normgroepen op psychologische variabelen: klachten, 
copingstrategieen en afweerorganisatie. Tevens wordt onderzocht of er verschi11en Zijll 
tussell de patientengroep en de referentiegroep betreffende een aantal biochemische 
parameters: Serotonine in bloed, bloedplaatjes en plasl11a~ tyrosine en tryptofaan en hun 
index ten opzichte van andere aminozuren; het fi carboline norhanllan. 
Bij de onderzoeksgroep bleek op basis van SCL-90-scores sprake van gemiddeld 
ernstige tot ernstige symptomatologie in vergelijking tot andere poliklinischc psychiatri-
sche patienten in Ncderland. De scores op de veL maken duidelijk dat de patienten-
groep een in vergelijking tot de referentiegrocp inadequate coping hantcert waarbij meer 
gebruik gemaakt wordt van palliatie, vermijden en met een depressief reactiepatroon 
reageren. Ook neigcn de patienten minder dan in de referentiegroep ertoe problemen 
actief aan te pakken. 
Qua afweerorganisatie maakt de patientengroep in vergelijking tot de refercntie groep 
meer gebruik van onvolwassen afweermechanismen als projectie. terwiji de mannelijkc 
patienten cr meer dan in de norm-, en referentiegroep toe ncigen agressie op zichzelf te 
richtcn. 
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Salnellwlltil1g 
Bij discriminant analyse op basis van psydlOlogische variabelen blijkt dat er zeer 
betrouwbaar een onderscheid gemaakt kan worden tussen referentiegroep en patienten-
graep, in 94 % van de gevallen v.indt er een correcte c1assificatie plaats, 
Het best discrimineren de SCL-90 subschalen, gevolgd door de coping strategieen 
vermijden en depressief reageren waarvan de patienten meer gebruik maken dan de 
referentiegraep, en het afwecrmechanisme turning agression against self, Dit afwecr-
mechanimc wordt in de patiCntengroep meer dan in de referentie-groep gehanteerd. 
Ook bij discriminantanalyse op basis van biochemische paramemeters komt het tot 
een betrouwbaar onderscheid tussen patienten en refercntiegroep, maar in dllidelijk 
mindere mate clan op basis van psychologische variabclen het geval is. 
Van de biochemische parameters gccft de ratio van het aminozuur tyros inc ten opzichte 
van de andere grote neutraie aminozuren het mecste gewicht bij discriminantanaiyse. 
Tyrosine is een aminozuur dat in de hersenen als precursor voor de noradrenaline en 
dopamine synthese fungeert. Deze neurotransmitters spelen naast serotonine mogelijk 
eell helangrijke rol in de etiologic vall depressie cn paniekstoornis. 
Hoofds/lIk 7 
In hoofdstuk zeven wordt nagegaan in hoevcrre de drie patientcngroepen met respec-
tievelijk paniekstoornis, depressie in engere zin en paniekstoornis + depressie in ellgere 
zin van elkaar te onderscheiden zijn op basis van psychologischc en biochemische para-
meters. Het blijkt dat de drie patienten groepen zich op symptoo1l1niveau (SCL-90-schalen) 
goed latcn onderscheiden, onder andere middels eell door ons op basis van de SCL-90 
oI1tworpen paniekscore. 
Betrouwbaar onderscheid tussen de drie patientengroepen op basis van psychologische 
afweerarganisatie of gehanteerde copingstrategiecn blijkt echter nlet mogclijk. 
In biochcmisch opzicht ollderscheiden paticnten met een paniekstoornis zich ten 
opzichte van de twee andere patientengroepen door cen laag gehalte van het B carboline 
norhannan. Deze bevinding past bij de 1l10gelijke funetie van norharman als 
benzodiazepine-agonist. Patientcn met eell paniekstoornis zouden 1l10gcIijk een hoog 
angstniveall kUllnen hebben door <lit lage norharman gehalte, onverklaard blijft dan echter 
het nonnale norhannan gehalte bij patientenmet comorbiditeit paniekstoornis en dcpressie. 
Bij discrill1inantanalyse blijkt op basis van biochemische variabelen in 62.1 % vall de 
gevallen cen correcte indeling in een van de drie patientengroepen mogclijk. 
Naast norharlllan dragen het meest bij nan de discrmininatie: tryptofaan ratio, plasma 
tryptofaan en serotonine gchaJte in het bioed. 
De onderzoeksbevindingen geven enige aanwijzingen voor de hypothese van 
biologische heterogeniteit van paniekstoornis en depressie in engere zin in, waarbij iedere 
psychiatrische stoornis zijn eigen specifieke genetische en neurobiologische oorsprong 
hecft. \Vij vinden geen steun, mede door het ontbreken van verschiI in psychologische 
kenmerken als afweer en coping tussen patienten met ecn paniekstoornis enl of depressic, 
voor de "unitary" hypothese van de twee ziekten. 
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HooJdsllIk 8 
In hoofdstuk aeht wordt de interdependcntic van de psychologische variabelen v66r 
behancieling besprokcn. 
Binncn de coping subschalen van de ueL blijkcn cr in de patienten groep positieve 
correlatic le zijn tussen vennijden en Jepressief reagcren; emoties uitcn en pal1iatie; 
ciepressief rcageren en emoties uitcn en tussell stcun zoekcn en emoties uitcn. Verschil-
len in verhanden tussen coping stijl ten op-zichtc van 110rl11-, en referentie groep worden 
weergegevcn. 
Bij de afweermcchanismen wordt cen positicve corrclatie gcvonden tussell agressie 
op anderen richten en projectie; en negatieve correlatics tussell tussell agressie op anderen 
rkhlen met verciringing, ontkcnning en illtellectualisatie. 
Projectie correleert eveneens negatief met verdringing, olltkenning en intellectualisatie 
en tevens met agressie op het zelf richten. Het gebruik van afweermechallismcn zoals 
geilleten met de DMI vcrschilt ill de rererentie groep niet van de controle groepen zoals 
gegeven in de literatuur. De verschillen in het hanteren van at\veennechanismen tllssen 
patienten groep en referentie groep zijn slcchts kwantitatief. 
Tussen de copingstrategieen en afweermechanismen worden geen belangrijke signifi-
cante correlaties gevonden in de referentic groep. In de patientengroep vinden wij echter 
eell positieve correlatie tussen intellectualisatie en actief problemen oplossen en negatieve 
associaties tllssell intellectualisatie met depressief reageren en emoties uiten. 
Gebruikmaken van intellectualisatie als afweermed1l1isme geeft mogelijk bescher-
ming tegen depressieve rcactievormen. 
HooJd"llIk 9 
In hoofdstuk negen worden de veranderingsll1etingen op de SCL, VeL, Dt\1I en 
biochemische parameters zes en negen ll1aanden na aanvang van de behandeling 
beschreven. Het kluchtenpatroon van de patienten met cen paniekstoornis en/of tiepressie 
in engere zin, zoals gemcten op de SCL-90-schaul verandert gedurende een gecombi-
neerde behandeling met clomipramine en cognitieve therapie in gunstigc zin. De patienten-
groep mct comorbiditeit van depressie in engere zin met paniekstoornis heeft een minder 
goede therapierespons dan de andere twee diagnostische groepen, 
De verbetering bereikt na zes maanden behandeling blijkt zich, in de patientengroep 
die op vcrzoek de clomipramine medicatie stopt na zes maanden behancieling, bij eell 
follow-up meting drie maanden later te hebben voortgezet. 
Veranderingen in copingstijl en gehanteerde af\veennel:hanismen zijn niet athallkelijk 
van de diagnostische groep waartoe patientcn behoren. Gehanteerde copingstratcgie 
verandelt tijdcns de behandcling, afgezien van de scores op de schalen vennijden en 
dcpressief reageren die gedurendc de behandeling afnemen, niet duidelijk. De afwecr-
organisatie zoals gemeten met dc OMI verandert gedllrende dc behandeling: gedurendc 
de gccombineerde medicamenteuse cn cognitieve therapie neemt het gebruik van het 
afweermechanisme agrcssie naar huitcn richten toe en van agressie op het zelf rich ten af. 
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Sll11leJlwittilig 
Hoewel er in de psychoIogische afweer en, in mindere mate, in gehanteerde 
copingstrategie tijdens de behandeling veranderingen optreden, blijkt na regressie analyse 
de uitgangswaarden op de betreffende D!vll- en UCL-schalen, het meest bepaIend voor 
de uitkomsten na zes en negen maanden na aanvang van de behandeling. 
Hoofds/llk 10, 11 ell 12 
Hoofdstuk tien, elf en twaaIf geven een nadere beschouwing van die patientengrocp 
wclke op baseline geen psychofannaca gebruikte. 
In hoojdstuk tiell wordt nagegaan of er verschillen zijn in SCL-90-scores en de VCL 
en DMI scores tussen patienten die bij aanvang van het bloedonderzoek reeds 
clomipramine gebruikt en zij die dit niet deden. 
Het hlijkt dat de scores up deze matcH van psychisch functioneren in de twee groepen 
vrijwel gelijk zijn, zodat voor een heschouwing van de psychologische variabelen de 
patielltengroep als cen geheel kan worden heschouwd. 
Clomipramine blijkt een zeer sterke invloed te hebben op het scrotonine gehaltc in 
bloed, plasma en in tromhocyten van de patienten. Het serotoninc gehaltc van de 
clomipramine gebruikende patienten ligt veellager dan in de rererentie groep en dan bij 
patienten die geen anti-depressiva gebruiken ten tijde van de eerste blocdafname. Ook 
het tryptoraangehalte van de clomipramine gebruikende paticnten blijkt verlaagd ten 
opzichte van dat in de medicatievrije groep. 
Gespeculcerd wordt dat er door cIomipraminegebruik enzyminductie in de lever 
optreedt met activatie van het enzym tryptofaanpyrrolase waardoor de albraak van 
tryptofaan toencemt. 
Ook alternatieve verklarillgshypothesen voor het lage tryptofaan gehalte in de 
clomipramine gcbruikende patientengroep worden gegeven waaronderecn verschuivillg 
van eiwit gebonden naar vrij tryptofaan onder invIoed van het antidepressivlllll en 
vennillderde absorptie van tryptofaan uit de darm. 
Hoofdstllk elf beschrijft de interdependentie van psychologische en biochemische 
waarden. 
De intercorrclaties tussell SCL-90, Di\H en VCL met de biochemische parameters 
worden, voor zover significant, gegeven voor de patielltellgroep en de referentiegroep. 
Er worden negatieve correIaties gevonden in de patientengrocp als gehcel tussen 
serotonine gchalte in trombocyten met depressiviteit, hostiliteit cn agressie op anderen 
gcricht. 
Serotonine in plasma en tryptot~1an correlerennegatier met hostiliteit. Dcze bevindingen 
ondersteunen de gesuggereerde koppeling tllssen agressiviteit en depressiviteit met cen 
laag functionerelld serotonerg systeem. In tegenstelling (ot in eerder onderzoek vinden 
wij geen correlaties tlissen norhannan en intrapsychische mechanismen als afweer-
organisatie of copingstratcgiccn. 
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Hooftlstllk twaalj'beschrljft de veranderingen na zes en negen maanden behandeling 
in de op baseline medicatievrije patientengroep. Deze groep blijkt zich qua behandel-
resuitaat en effect niet wczenIijk andel's te gedragen dan de patientengroep als geheel 
zoals beschreven in hoofdstuk acht. 
Na zes maanden behandeling met clomipraminc cn cognitieve therapie treedt er een 
afname op van het intrapunitieve ll1echanisme turning aggression against self en toe-
name van LUrning aggression against others en reversal. 
Deze veranderingen op de DMI blijken in de perlode van zes tot negen maanden, 
waarin de hehandeling gestaakt is, verdeI' toe te nemen. De graotstc verandering treedt 
or in de samengestelde schaal repression: Een en negentig procent afname negen maan-
den na aanvang van de behandeling. 
Op basis hiervan wordt gepostuleerd dat gehallteerde afweermechanisll1en voor een 
belangrijk deel afhankeJijk zijn van de actuele psychiatrische stoornis van patienten. 
Voorzichtigheid bij deze hypothese is echter op zijn plaats daar de repression schaal 
van de DMI eell samengestelde schaal is op basis van verschil scores (zie hoofdstuk 
vier). 
Relatiefkleine veranderingen qua score in de samenstellende schalen kUllnell tot grate 
veranderingen in de repression schaal leiden. Van de copingstrategieen blijken 
depressief reageren en vennijden het meest (negatief) aan verandering onderhevig. 
Depressief rcageren neemt met 26% af, negen maanden na start van de behandeling, 
venllijden met 9%. Opgemerkt wordt dat verandering in de copingstrategie depressief 
reageren mogelijk state bepaald is en sterk wordt beinvloed door therapie effect. De 
overige copingstrategieen hlijken meer trait afhankelijk en veranderen weinig ( mindel' 
dan tien procent) gcdurende de gecombineerde bchandeling met antidepressiva en 
cognitieve therapie. 
In de biochell1ische variabelen treden de grootste veranderingen op in seratonine in 
bloed, plasma en trombm.:yten. Na het staken van de clomipramine na zes maanden 
hehandeling nel11en de serotonine concentraties weer toe, opvallend genoeg blijft het 
tryptot'aangehalte, de precursor van serotonine, ook na het staken van de clomipramine 
laag. De oorzaak van dit luge tryptot'aangehalte na zes en negen maanden behandeling is 
onbekend. Men ZOll kunnen speculeren dat het lage tryptofaangehalte en in mindere mate 
ook de lage tryptofaanratio welke nag gevonden wordt dde maanden na het staken van 
clomipraminemedicatie een risico voor een reciclief optreden van psychopathologie 
vormen door een ontregeling van het seratoninerge systeem. Het plasma norharman blijkt 
gedurende de behandeling met clomipramine sterk toe te nemen. Deze stijging Iijkt in 
verband te staan met de clomipraminebehandeling. Terwiji het therapie-effect in deze 
patientengroep tussen zes en negen ll1aanden nog toeneemt, daalt het plasma 
norhannangehalte weer. 
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Samel1vattillg 
HoofdSlllk 13 ell 14 
Hoofdstuk dertien en veertien geven de concluding remarks in cen respectievelijk 
engelse en nederlandse versie. 
Op basis van afweer, coping en beperktc biochemische onderzoeken wordt OBS 
verklaringsmodel waarom de ene patient een depressie ontwikkelt, een andere patient 
een paniekstoornis en een derde patient beide, niet ondersteund. 
Ais aHernatieve verklaringshypothese postuleren wij dat naast een aspecifieke 
vulnerabiliteit precipiterende factorcn zoals Life Events bepalen welke vorm van 
psychopathologie ontstaat. 
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VERANTWOORDING 
De in dit procfschrift beschrevcn studies, werden verricht op de afdeling Psychiatric 
van het Drechtstcdenzickenhuis, lokatie Refaja te Dordrccht en cloor de wcrkgrocp 
Pathofysiologie vall Gedrag van de Eraslllusuniversiteit Rotterdam (hoofd: Prof, dr. 
L. Pepplillkhuizcn). Op deze plaats wiI ik graag die personen bcdanken die betrokkcn 
waren bij de totstandkoming en uitvoering van het onderzoek. 
Tn de cerste plants gaat mijn dank uit naal' mijn promotorcn Lolke Pepplinkhuizcn en 
Jan Passchicr die mij gestimuleerd hebhen lot het opzettcn en uitvoeren van elit onder-
zock en die vclc constructieve opmerkingen plaatstcn bij het vervaardigen van dit proef-
schrift. 
Zonder de medcwcrkers van het Drechtstedcnziekenhuis lokatie Rcfaja: de psychiaters 
Arthur Van Gool en Hans Kamp, de medewerkers van het klinisch chemisch laboratoriutTI 
(hoofd: Dr. R.B. Dinkelaar) en de administmtieve ondersteuning van Betty Noorlander 
en Jolallda Vermeulen, was elil onderzoek niet mogelijk gewcest. 
De methodologische kant van de verwerking vall de onderzoeksresultaten was in 
handen van Hugo Duivenvoorden (afdeling Jvledische Psychologic Erasmllsuniversiteit 
Rotterdam) ell de statistische be werking geschiedde door Dick Stronks (Researchbureau 
Stronks Gouda). Hugo en Dick verrichtten zeer veel werk, waarvan slechts een beperkt 
deel in dit poefschrift zichtbaar wordt. 
De biochemische bepalingen werden uitgevoerd door het laboratorium vall de 
\verkgroep Pathofysiologic van Gedrag (hoofd: Durk Fekkes). Het samenwerken met 
Durk was steeds een genoegen en zal zeker worden voortgezet. 
Judica Berkelaaren Ria Keulemans ben ik erkentelijk voorde sccretariele ondersteuning 
bij het totstandkomen van de definitieve versie van dit procfschrift en de vormgeving 
ervan. 
Finallciccl werd dit onderzoeksproject gesteund door de werkgroep Pathofysiologie 
van Gedrag, dc slichting Nederlandse Associatie Neuropsychiatric, Ciba Geigy Nederland, 
Nouryphanna, Smithkline Beecham, en Delta Psychiatrisch Ziekenhuis. 
De engelsc vcrtaling geschiedde door Dr. D. Tank. Tot slot dank ik de patiellten en 
vrijwilligers die berekl waren in de studies te participcrcn. Zonder hun gemotiveerdc 
inzet en medewerking was dit onderzoek absoluut olll1logeJijk. 
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